diff --git "a/dev.jsonl" "b/dev.jsonl" --- "a/dev.jsonl" +++ "b/dev.jsonl" @@ -1,200 +1,200 @@ -{"answer": "B", "question": "\u4e0b\u5217\u4f55\u7a2e\u7dad\u751f\u7d20\u53ef\u7531\u8eab\u9ad4\u81ea\u884c\u5408\u6210\uff1f \nA. carotenoids\n \nB. retinoids\n \nC. cholecalciferol\n \nD. tocopherols", "year": 1081, "prof": "\u71df\u990a\u5e2b", "subject": "\u71df\u990a\u5b78"} -{"answer": "C", "question": "\u6709\u95dc\u9ad4\u5167\u526f\u7532\uf9fa\u817a\u8377\u723e\u8499\uff08PTH\uff09\u5c0d\u9aa8\u9abc\u7684\u5f71\u97ff\u4e4b\u6558\u8ff0\uff0c\u4e0b\uf99c\u4f55\u8005\u932f\u8aa4\uff1f \nA. \u589e\u52a0\u8178\u9053\u5c0d\u9223\u8cea\u7684\u5438\u6536 \nB. \u4f7f\u7dad\u751f\u7d20 D \u8f49\u63db\u6210\u6d3b\u5316\u578b \nC. \u4fc3\u9032\u9aa8\u9223\u5f62\u6210 \n \nD. \u589e\u52a0\u814e\u81df\u5c0d\u9223\u7684\u518d\u5438\u6536", "year": 1002, "prof": "\u71df\u990a\u5e2b", "subject": "\u81b3\u98df\u7642\u990a\u5b78"} -{"answer": "B", "question": "\u4e0b\uf99c\u4f55\u8005\u6709\u52a9\u65bc\u589e\u52a0\u9223\u8cea\u7684\u5438\u6536\uff1f \nA. Phytic acid \nB. Lactose \nC. Tannin \nD. Oxalic acid", "year": 1001, "prof": "\u71df\u990a\u5e2b", "subject": "\u71df\u990a\u5b78"} -{"answer": "C", "question": "\u5f9e\u521d\u59cb\u7cbe\u7d30\u80de\uff08primary spermatocyte\uff09\u81f3\u7cbe\u5b50\uff08sperm\uff09\u751f\u6210\u7684\u6574\u500b\u904e\u7a0b\uff0c\u7d04\u9808\u8cbb\u6642\u591a\u4e45\uff1f \nA. 64 \u5206\u9418 \nB. 64 \u5c0f\u6642 \nC. 64 \u5929 \nD. 6 \u500b\u6708\u53c8 4 \u5929", "year": 1012, "prof": "\u71df\u990a\u5e2b", "subject": "\u751f\u7406\u5b78\u8207\u751f\u7269\u5316\u5b78"} -{"answer": "B", "question": "\u73fe\u4eca\u83dc\u55ae\u8a2d\u8a08\u6642\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u71df\u990a\u7d20\u651d\u53d6\u91cf\u4e4b\u4f9d\u64da\uff1f \nA. BMI \nB. DRIs \nC. RDA \nD. RDNA", "year": 1062, "prof": "\u71df\u990a\u5e2b", "subject": "\u5718\u9ad4\u81b3\u98df\u8a2d\u8a08\u8207\u7ba1\u7406"} -{"answer": "D", "question": "\u9ec3\u8c46\u7c89\u5e38\u88ab\u52a0\u5165\u9eb5\u7cf0\u4e2d\u4f5c\u70ba\u5929\u7136\u4e4b\u6f02\u767d\u5291\uff0c\u662f\u56e0\u70ba\uff1a \nA. \u9ec3\u8c46\u4e2d\u542b\u6709 lipase \n \nB. \u9ec3\u8c46\u4e2d\u542b\u6709 lipoxygenase \nC. \u9ec3\u8c46\u4e2d\u542b\u6709 carboxyl esterase \nD. \u9ec3\u8c46\u4e2d\u542b\u6709 carboxypeptidase", "year": 1052, "prof": "\u71df\u990a\u5e2b", "subject": "\u71df\u990a\u5b78"} -{"answer": "C", "question": "\u4e09\u9178\u7518\u6cb9\u916f\u5f9e\u6d88\u5316\u7cfb\u7d71\u9032\u5165\uf9f5\u5df4\u7cfb\u7d71\u5f8c\uff0c\u4fc2\u900f\u904e\u4e0b\uf99c\u4f55\u8005\u904b\u9001\u81f3\u809d\u81df\uff1f \nA. \u6975\u4f4e\u5bc6\ufa01\u8102\u86cb\u767d\uff08very low density lipoprotein\uff09 \nB. \u4f4e\u5bc6\ufa01\u8102\u86cb\u767d\uff08low density lipoprotein\uff09 \nC. \u4e73\u7cdc\u5fae\uf9f9\uff08chylomicrons\uff09 \nD. \u5fae\u8102\uf9f9\uff08liposomes\uff09", "year": 1012, "prof": "\u71df\u990a\u5e2b", "subject": "\u751f\u7406\u5b78\u8207\u751f\u7269\u5316\u5b78"} -{"answer": "D", "question": "\u8001\u5e74\u4eba\u53ef\u85c9\u7531\u651d\u53d6\u4e0b\u5217\u4f55\u7a2e\u7269\u8cea\u4f86\u6539\u5584\u6d88\u5316\u9053\u7684\u8815\u52d5\uff1f \nA. proline \nB. pectin \nC. phytate \nD. pantothenic acid", "year": 1062, "prof": "\u71df\u990a\u5e2b", "subject": "\u71df\u990a\u5b78"} -{"answer": "B", "question": "\u98df\u54c1\u6240\u542b\u6709\u7684\u5929\u7136\u6297\u83cc\u7269\u8cea\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u8513\u8d8a\u8393\uff08cranberry\uff09\uff1a\u82ef\u7532\u9178\uff08benzoic acid\uff09\nB. \u745e\u58eb\u4e7e\u916a\uff1a\u4e19\u9178\uff08propionic acid\uff09\nC. \u5375\u767d\uff1a\u5375\u78f7\u8102\uff08lecithin\uff09\nD. \u9bae\u4e73\uff1a\u4e73\u7d20\uff08lactenins\uff09", "year": 1092, "prof": "\u71df\u990a\u5e2b", "subject": "\u98df\u54c1\u885b\u751f\u8207\u5b89\u5168"} -{"answer": "D", "question": "\u8840\u6db2\u4e2d\u7684 CO2 \u5927\u90e8\u5206\u4ee5\u4e0b\u5217\u4f55\u7a2e\u578b\u614b\u5b58\u5728\uff1f \nA. \u6eb6\u89e3\u614b CO2 \n \nB. \u91cd\u78b3\u9178\u6839\u96e2\u5b50\uff08bicarbonate\uff09 \nC. \u78b3\u91af\u80fa\u57fa\u8840\u7d05\u7d20\uff08carbaminohemoglobin\uff09 \nD. \u4e00\u6c27\u5316\u78b3\u8840\u7d05\u7d20\uff08carboxyhemoglobin\uff09", "year": 1081, "prof": "\u71df\u990a\u5e2b", "subject": "\u751f\u7406\u5b78\u8207\u751f\u7269\u5316\u5b78"} -{"answer": "C", "question": "\u4e0b\uf99c\u5c0d\u65bc\u8aee\u5546\u95dc\u4fc2\u6838\u5fc3\u689d\u4ef6\uff08core condition\uff09\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f \nA. \u8aee\u5546\u5e2b\u61c9\u5177\uf9ba\u89e3\u3001\u6f84\u6e05\u8207\u53cd\u6620\u6848\u4e3b\u96b1\u85cf\u672a\uf96f\u60c5\u7dd2\u7684\u80fd\uf98a \nB. \u300c\u5c0a\u91cd\u8207\u7a4d\u6975\u95dc\u6ce8\u300d\u5373\u5728\u50b3\u905e\u8aee\u5546\u5e2b\u76f8\u4fe1\u6848\u4e3b\u6709\u80fd\uf98a\u70ba\u81ea\u5df1\u8ca0\u8cac\u7684\u4fe1\uf9a3 \nC. \u57fa\u65bc\u5c0d\u6848\u4e3b\u7684\u5c0a\u91cd\uff0c\u8aee\u5546\u5e2b\u61c9\u5c0f\u5fc3\u8b39\u614e\u5730\u53ea\u626e\u6f14\u52a9\u4eba\u8005\u7684\u89d2\u8272 \nD. \u4e00\u4f4d\u8aa0\u6470\u7684\u8aee\u5546\u5e2b\u5fc5\u9808\u8868\u73fe\u51fa\u4e00\u4e9b\u5c0d\u6848\u4e3b\u6709\u610f\u7fa9\u8207\u76f8\u95dc\uf997\u7684\u6fc0\uf97f\ufa08\u70ba", "year": 1012, "prof": "\u8aee\u5546\u5fc3\u7406\u5e2b", "subject": "\u8aee\u5546\u8207\u5fc3\u7406\u6cbb\u7642\u7406\u8ad6"} -{"answer": "D", "question": "\u95dc\u65bc\u6709\u6548\u80fd\u7684\u5718\u9ad4\u9818\u5c0e\u8005\u7279\u8cea\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u6709\u6642\u9700\u8981\u5766\u8aa0\u544a\u77e5\u6210\u54e1\u4ed6\u4e0d\u60f3\u770b\u898b\u7684\u90e8\u5206\uff0c\u4e26\u505a\u9078\u64c7\u6027\u7684\u81ea\u6211\u63ed\u9732\nB. \u9075\u5b88\u5718\u9ad4\u6b77\u7a0b\u53ca\u898f\u7bc4\uff0c\u5728\u5718\u9ad4\u9032\u884c\u4e2d\u5118\u53ef\u80fd\u4e0d\u52a0\u5165\u9818\u5c0e\u8005\u7684\u5275\u610f\nC. \u80fd\u5bdf\u89ba\u81ea\u5df1\u7684\u5167\u5728\u885d\u7a81\u8207\u554f\u984c\nD. \u6709\u610f\u9858\u8207\u6210\u54e1\u4e92\u52d5", "year": 1092, "prof": "\u8aee\u5546\u5fc3\u7406\u5e2b", "subject": "\u5718\u9ad4\u8aee\u5546\u8207\u5fc3\u7406\u6cbb\u7642"} -{"answer": "D", "question": "\u5018\u82e5\u4e00\u500b\u5bb6\u5ead\u5177\u6709\u300c\u9752\u5c11\u5e74\u4e0d\u53ef\u4ee5\u6311\u6230\u7236\u6bcd\u300d\u6216\u300c\u7236\u6bcd\u53ef\u4ee5\u5168\u6b0a\u6c7a\u5b9a\u9752\u5c11\u5e74\u8a72\u505a\u4ec0\u9ebc\u300d\u9019\u6a23\u7684\u898f\u5247\uff0c\u4e0b\u5217\u90a3\u500b\u5bb6\u5ead\u6cbb\u7642\u89c0\u9ede\u53ef\u6982\u5ff5\u5316\u9019\u500b\u73fe\u8c61\uff1f\nA. \u4e16\u4ee3\u50b3\u627f\u6a21\u5f0f\nB. \u50f5\u5316\u7684\u754c\u7dda\nC. \u4e09\u89d2\u95dc\u4fc2\nD. \u96d9\u91cd\u675f\u7e1b", "year": 1091, "prof": "\u8aee\u5546\u5fc3\u7406\u5e2b", "subject": "\u8aee\u5546\u8207\u5fc3\u7406\u6cbb\u7642\u7406\u8ad6"} -{"answer": "A", "question": "Horney \u8a8d\u70ba\u4e0b\u5217\u4f55\u8005\u662f\u5f8c\u4f86\u767c\u5c55\u51fa\u7cbe\u795e\u5b98\u80fd\u75c7\u7684\u57fa\u790e\uff1f\nA. \u6200\u6bcd\u60c5\u7d50\uff08Oedipus complex\uff09\nB. \u5b50\u5bae\u5992\u7fa8\uff08womb envy\uff09\nC. \u81ea\u5351\u60c5\u7d50\uff08inferiority complex\uff09\nD. \u57fa\u672c\u7126\u616e\uff08basic anxiety\uff09", "year": 1092, "prof": "\u8aee\u5546\u5fc3\u7406\u5e2b", "subject": "\u8aee\u5546\u7684\u5fc3\u7406\u5b78\u57fa\u790e"} -{"answer": "C", "question": "\u6797\u5fc3\u7406\u5e2b\u60f3\u8981\u4e86\u89e3\u5176\u6848\u4e3b\u7684\u554f\u984c\u662f\u5426\u5df2\u7d93\u89e3\u6c7a\uff0c\u4ed6\u91cd\u65b0\u5be6\u65bd\u6848\u4e3b\u4e00\u5e74\u524d\u525b\u5230\u8aee\u5546\u4e2d\u5fc3\u6240\u505a\u904e\u7684\u5fc3\u7406\u6e2c\u9a57\u3002\u6797\u5fc3\u7406\u5e2b\u7684\u505a\u6cd5\u5c6c\u65bc\u90a3\u4e00\u7a2e\u5fc3\u7406\u8a55\u91cf\u7684\u76ee\u7684\uff1f \nA. \u754c\u5b9a\u554f\u984c \nB. \u9078\u64c7\u53ef\u80fd\u7684\u8f14\u5c0e\u65b9\u6848 \nC. \u9a57\u8b49 \nD. \u6c7a\u7b56", "year": 1071, "prof": "\u8aee\u5546\u5fc3\u7406\u5e2b", "subject": "\u500b\u6848\u8a55\u4f30\u8207\u5fc3\u7406\u8861\u9451"} -{"answer": "A", "question": "\u4f9d\u64da\u5152\u7ae5\u53ca\u5c11\uf98e\u4fdd\u8b77\u901a\u5831\u53ca\u8655\uf9e4\u8fa6\u6cd5\uff0c\u57f7\ufa08\u5152\u7ae5\u53ca\u5c11\uf98e\u798f\uf9dd\u696d\u52d9\u4eba\u54e1\uff0c\u77e5\u6089\u6709\u61c9\u4fdd\u8b77\u4e4b\u5152\u7ae5\u53ca\u5c11\uf98e\u6642\uff0c\u6700\u9072\u61c9\u65bc\u591a\u4e45\u4e4b\u5167\u901a\u5831\uff1f \nA. 24 \u5c0f\u6642 \nB. 36 \u5c0f\u6642 \nC. 48 \u5c0f\u6642 \nD. 72 \u5c0f\u6642", "year": 1011, "prof": "\u8aee\u5546\u5fc3\u7406\u5e2b", "subject": "\u8aee\u5546\u8207\u5fc3\u7406\u6cbb\u7642\u5be6\u52d9"} -{"answer": "C", "question": "\u4e0b\uf99c\u6709\u95dc\ufa08\u70ba\u6cbb\uf9c1\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f \nA. \u5be6\u52d9\u805a\u7126\u65bc\u53ef\u89c0\u5bdf\u7684\ufa08\u70ba\u3001\u7576\u524d\ufa08\u70ba\u7684\u6c7a\u5b9a\u56e0\u5b50\u53ca\u4fc3\u9032\u6539\u8b8a\u7684\u5b78\u7fd2\u7d93\u9a57\u7b49 \nB. \u89c0\u5bdf\u5b78\u7fd2\u5c07\u53e4\u5178\u3001\u64cd\u4f5c\u5236\u7d04\uf978\u8005\u7d50\u5408\uff0c\u4e26\u5c07\u8a8d\u77e5\u7684\u6982\uf9a3\u5e36\u5165\u6b63\u7d71\ufa08\u70ba\u6cbb\uf9c1\u7684\u6838\u5fc3 \nC. \u64cd\u4f5c\u5236\u7d04\u53c8\u7a31\u70ba\u53cd\u61c9\u5236\u7d04 \nD. \u73fe\u4ee3\u7684\ufa08\u70ba\u5b78\u6d3e\u53ef\u4ee5\u4f9d\u7167\u56db\u500b\u767c\u5c55\uf9b4\u57df\uf92d\u52a0\u4ee5\u8a8d\uf9fc\uff1a\u53e4\u5178\u5236\u7d04\u3001\u64cd\u4f5c\u5236\u7d04\u3001\u793e\u6703\u5b78\u7fd2\uf9e4\uf941\u3001\u8a8d\u77e5\ufa08\u70ba", "year": 1021, "prof": "\u8aee\u5546\u5fc3\u7406\u5e2b", "subject": "\u8aee\u5546\u8207\u5fc3\u7406\u6cbb\u7642\u7406\u8ad6"} -{"answer": "C", "question": "\u5b58\u5728\u4e3b\u7fa9\u8aee\u5546\u5fc3\u7406\u5e2b\u5354\u52a9\u7576\u4e8b\u4eba\u5c0b\u627e\u751f\u547d\u610f\u7fa9\u7684\u65b9\u6cd5\uff0c\u4e0b\u5217\u4f55\u8005\u6b63\u78ba\uff1f \nA. \u6aa2\u8996\u904e\u53bb\u7684\u751f\u547d\u7d93\u9a57\uff0c\u7531\u5176\u4e2d\u627e\u5230\u751f\u547d\u610f\u7fa9 \nB. \u544a\u77e5\u7576\u4e8b\u4eba\uff0c\u751f\u547d\u610f\u7fa9\u70ba\u4f55 \nC. \u7406\u89e3\u751f\u547d\u610f\u7fa9\u662f\u6574\u500b\u4eba\u751f\u4e2d\u6301\u7e8c\u4e0d\u65b7\u5730\u6399\u624e\u8ffd\u5c0b\u7684\u904e\u7a0b \nD. \u5efa\u69cb\u4e0d\u540c\u7684\u751f\u6d3b\u9858\u666f\uff0c\u4ee5\u8ffd\u5c0b\u6c38\u6046\u7684\u751f\u547d\u610f\u7fa9", "year": 1071, "prof": "\u8aee\u5546\u5fc3\u7406\u5e2b", "subject": "\u8aee\u5546\u8207\u5fc3\u7406\u6cbb\u7642\u7406\u8ad6"} -{"answer": "D", "question": "\u5bb6\u5ead\u7cfb\u7d71\u6cbb\uf9c1\u5e2b\u5f37\u8abf\u5bb6\u5ead\u624d\u662f\u554f\u984c\u89e3\u6c7a\u7684\u5c08\u5bb6\uff0c\u56e0\u800c\u63a1\u53d6\u5408\u4f5c\u3001\u597d\u5947\u8207\u52a0\u5165\u7684\u614b\ufa01\u9032\ufa08\u5bb6\u65cf\u6703\u8ac7\uff0c\u6b64\u4e43\u5c6c\u65bc\u90a3\u4e00\u9805\uff1f \nA. \u7b2c\u4e00\u5e8f\u6539\u8b8a \nB. \u7b2c\u4e8c\u5e8f\u6539\u8b8a \nC. \u7b2c\u4e00\u5e8f\u63a7\u5236\uf941 \nD. \u7b2c\u4e8c\u5e8f\u63a7\u5236\uf941", "year": 1022, "prof": "\u8aee\u5546\u5fc3\u7406\u5e2b", "subject": "\u8aee\u5546\u8207\u5fc3\u7406\u6cbb\u7642\u7406\u8ad6"} -{"answer": "A", "question": "\u4e0b\u5217\u5c0d\u65bc\u7126\u9ede\u89e3\u6c7a\u77ed\u671f\u6cbb\u7642\u7684\u63cf\u8ff0\uff0c\u4f55\u8005\u6700\u6b63\u78ba\uff1f \nA. \u4e0d\u6703\u5c08\u6ce8\u65bc\u5fae\u5c0f\u7684\u6b63\u5411\u6539\u8b8a \nB. \u76f8\u4fe1\u7576\u4e8b\u4eba\u7f3a\u4e4f\u80fd\u529b\u89e3\u6c7a\u5176\u554f\u984c \nC. \u6cbb\u7642\u76ee\u6a19\u61c9\u7531\u8aee\u5546\u5fc3\u7406\u5e2b\u8207\u7576\u4e8b\u4eba\u5171\u540c\u5efa\u69cb \nD. \u6cbb\u7642\u76ee\u6a19\u61c9\u7531\u7576\u4e8b\u4eba\u81ea\u5df1\u5efa\u69cb\uff0c\u8aee\u5546\u5fc3\u7406\u5e2b\u53ea\u662f\u5e6b\u52a9\u7576\u4e8b\u4eba\u5275\u9020\u51fa\u66f4\u6e05\u695a\u7684\u76ee\u6a19", "year": 1061, "prof": "\u8aee\u5546\u5fc3\u7406\u5e2b", "subject": "\u8aee\u5546\u8207\u5fc3\u7406\u6cbb\u7642\u7406\u8ad6"} -{"answer": "C", "question": "\u4f9d\u4e2d\u83ef\u85e5\u5178\u898f\u5b9a\uff0c\u6ce8\u5c04\u5291\u8caf\u5b58\u65bc\u591a\u5291\u91cf\u5bb9\u5668\u4e2d\uff0c\u9664\u53e6\u6709\u898f\u5b9a\u5916\uff0c\u5fc5\u9808\u52a0\u5165\u4e0b\u5217\u4f55\u7a2e\u6210\u5206\uff1f \nA.\u6297\u6c27\u5316\u5291\nB.\u7de9\u885d\u5291\nC.\u6291\u83cc\u5291\nD.\u7b49\u5f35\u5291", "year": 1112, "prof": "\u85e5\u5e2b", "subject": "\u85e5\u5291\u5b78\u8207\u751f\u7269\u85e5\u5291\u5b78"} -{"answer": "D", "question": "\u4e0b\u5217\u4f55\u8005\u975e\u4e3b\u6210\u5206\u542b\u91cf\u6e2c\u5b9a\u9808\u9032\u884c\u7684\u78ba\u6548\u9805\u76ee\uff1f \nA.\u6e96\u78ba\u5ea6\uff08Accuracy\uff09 \nB.\u7cbe\u5bc6\u5ea6\uff08Precision\uff09 \nC.\u9078\u64c7\u6027\uff08Selectivity\uff09 \nD.\u5075\u6e2c\u6975\u9650\uff08Limit of detection\uff09", "year": 1051, "prof": "\u85e5\u5e2b", "subject": "\u85e5\u5291\u5b78\u8207\u751f\u7269\u85e5\u5291\u5b78"} -{"answer": "C", "question": "\u4e0b\u5217\u4f55\u8005\u6700\u4e0d\u53ef\u80fd\u662f\u5b89\u975e\u4ed6\u547d\u985e\u85e5\u54c1\u5f15\u8d77\u7684\u8eab\u5fc3\u75c7\u72c0\uff1f \nA.\u591a\u7591\u8207\u88ab\u5bb3\u5984\u60f3\nB.\u5e7b\u89ba\nC.\u6027\u617e\u964d\u4f4e\nD.\u5f37\u8feb\u6216\u91cd\u8907\u6027\u884c\u70ba", "year": 1101, "prof": "\u85e5\u5e2b", "subject": "\u85e5\u7269\u6cbb\u7642\u5b78"} -{"answer": "A", "question": "\u4f7f\u75281.5 g NaCl\u53ef\u4ee5\u8abf\u88fd\u591a\u5c11mL\u751f\u7406\u98df\u9e7d\u6c34\uff1f \nA.166.7 \nB.150 \nC.200 \nD.1,667", "year": 1061, "prof": "\u85e5\u5e2b", "subject": "\u8abf\u5291\u5b78\u8207\u81e8\u5e8a\u85e5\u5b78"} -{"answer": "D", "question": "\u6709\u95dc\u71b1\u539f\uff08pyrogens\uff09\u53ca\u71b1\u539f\u8a66\u9a57\u4e4b\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f \nA.\u71b1\u539f\u4e3b\u8981\u4fc2\u7531\u9769\u862d\u6c0f\u9670\u6027\u83cc\u4e4b\u7d30\u80de\u58c1\u5167\u8102\u591a\u91a3\u800c\u4f86\nB.\u71b1\u539f\u8a66\u9a57\u4e4b\u76ee\u7684\u70ba\u6e2c\u8a66\u85e5\u54c1\u65bc\u6ce8\u5c04\u5f8c\u4f7f\u75c5\u4eba\u767c\u71b1\u4e4b\u7a0b\u5ea6\uff0c\u4ee5\u4e0d\u8d85\u904e\u898f\u5b9a\u6700\u4f4e\u9650\u5ea6\u70ba\u6e96\u5247\nC.\u71b1\u539f\u8a66\u9a57\u4e2d\u6240\u4f7f\u7528\u4e4b\u6ce8\u5c04\u5668\u3001\u91dd\u982d\u53ca\u5176\u4ed6\u73bb\u7483\u5668\u76bf\u7b49\u53ef\u7f6e\u65bc250\u2103\u4e2d\u4e7e\u71b130\u5206\u9418\u4ee5\u53bb\u9664\u71b1\u539f\nD.\u4f9d\u4e2d\u83ef\u85e5\u5178\u898f\u5b9a\uff0c\u71b1\u539f\u8a66\u9a57\u9700\u4ee5\u4e0d\u8d85\u904e1 mL/kg \u7684\u7528\u91cf\uff0c\u65bc10\u5206\u9418\u5167\u7d93\u5154\u5b50\u8033\u975c\u8108\u6ce8\u5165", "year": 1102, "prof": "\u85e5\u5e2b", "subject": "\u85e5\u5291\u5b78\u8207\u751f\u7269\u85e5\u5291\u5b78"} -{"answer": "B", "question": "\u4e0b\u5217\u90a3\u4e00\u79d1\u5225\u4e4b\u690d\u7269\u7684\u7cbe\u6cb9\u4e3b\u8981\u85cf\u65bcglandular hair\u4e2d\uff1f \nA.Apiaceae \nB.Lamiaceae \nC.Leguminosae \nD.Pinaceae", "year": 1051, "prof": "\u85e5\u5e2b", "subject": "\u85e5\u5291\u5b78\u8207\u751f\u7269\u85e5\u5291\u5b78"} -{"answer": "B", "question": "\u4e0b\uf99c\u91ab\u9662\u85e5\u5e2b\u548c\u4e00\u4f4d\ufa03\uf9bd\u75c5\u4eba\u7684\u5c0d\u8a71\u4e2d\uff0c\u4f55\u9805\u5c6c\u65bc\u958b\u653e\u6027\u554f\u984c\uff1f \nA. \uf9f4\uf934\u4f2f\u60a8\u4eca\u5929\u7684\u6c23\u8272\u771f\uf967\u932f\u5594\uff01 \nB. \u60a8\u4f4f\u9662\u524d\u662f\u5982\u4f55\u4f7f\u7528\u80f0\u5cf6\u7d20\u9019\u500b\u85e5\u54c1\uff1f \nC. \u60a8\u6709\u89aa\u4eba\u5e6b\u60a8\u6ce8\u5c04\u80f0\u5cf6\u7d20\u85e5\u54c1\u55ce\uff1f \nD. \u60a8\u5728\u5bb6\u4f7f\u7528\u80f0\u5cf6\u7d20\u662f\u5426\u66fe\u767c\u751f\u4f4e\u8840\ufa03\u73fe\u8c61\uff1f", "year": 1011, "prof": "\u85e5\u5e2b", "subject": "\u8abf\u5291\u5b78\u8207\u81e8\u5e8a\u85e5\u5b78"} -{"answer": "B", "question": "\u4e0b\u5217\u975e\u56fa\u9187\u985e\u6297\u767c\u708e\u85e5 (NSAID)\uff0c\u4f55\u8005\u662foxicam\u4e4b\u884d\u751f\u7269\uff1f \nA.aspirin\nB.piroxicam\nC.diclofenac\nD.indomethacin", "year": 1121, "prof": "\u85e5\u5e2b", "subject": "\u85e5\u7406\u5b78\u8207\u85e5\u7269\u5316\u5b78"} -{"answer": "D", "question": "\u4e0b\u5217\u4f55\u8005\u6703\u589e\u52a0theophylline\u7684\u6e05\u9664\u7387\uff08clearance\uff09\uff1f \nA.Left ventricular failure \nB.Liver dysfunction \nC.Pneumonia \nD.Smoking", "year": 1021, "prof": "\u85e5\u5e2b", "subject": "\u85e5\u7269\u6cbb\u7642\u5b78"} -{"answer": "A", "question": "\u5728\u6e2c\u91cf\u916e\u542b\u91cf\u6642\u5efa\u8b70\u540c\u6642\u4f7f\u7528\u4e0b\u5217\u4f55\u7a2e\u8a66\u5291\uff0c\u4ee5\u4fbf\u5728\u6ef4\u5b9a\u7d42\u9ede\u7121\u984f\u8272\u5448\u73fe\u6642\uff0c\u53ef\u4ee5\u5728\u915a\u915e\u8a66\u5291\u5b58\u5728\u4e0b\u52a0\u71b1\u800c\u5448\u8272\uff1f\nA.\u4e9e\u786b\u9178\u6c2b\u9209\uff08sodium bisulfite\uff09\nB.\u6c2b\u6c27\u5316\u9209\nC.\u4e59\u9187\nD.\u7fa5\u80fa\uff08hydroxylamine\uff09", "year": 1091, "prof": "\u85e5\u5e2b", "subject": "\u85e5\u5291\u5b78\u8207\u751f\u7269\u85e5\u5291\u5b78"} -{"answer": "B", "question": "\u738b\u592a\u592a 58 \u6b72\uff0c\u7528\u529b\u54b3\u55fd\u6216\u8005\u5927\u7b11\u6642\u5c31\u6703\u51fa\u73fe\u6ef2\u5c3f\uff0c\u5fc3\u60c5\u53d7\u5f71\u97ff\u60c5\u7dd2\u4f4e\u843d\uff0c\u4e0b\u5217\u4f55\u9805\u8b77\u7406\u63aa\u65bd\u4e0d\u5408\u9069\uff1f\nA. \u544a\u8a34\u75c5\u4eba\u9019\u662f\u4e2d\u5e74\u5a66\u5973\u6b63\u5e38\u73fe\u8c61\uff0c\u4e0d\u8981\u592a\u5728\u610f\nB. \u8a55\u4f30\u662f\u5426\u6709\u58d3\u529b\u6027\u5c3f\u5931\u7981\u76f8\u95dc\u56e0\u5b50\uff0c\u4f8b\u5982\uff1a\u505c\u7d93\u3001\u80a5\u80d6\nC. \u6559\u5c0e\u52ff\u63d0\u91cd\u7269\u3001\u7a81\u7136\u5927\u7b11\u7b49\u589e\u52a0\u8179\u5167\u58d3\u4e4b\u52d5\u4f5c\nD. \u6559\u5c0e\u9aa8\u76c6\u5e95\u808c\u8089\u904b\u52d5\u8a13\u7df4\uff0c\u589e\u52a0\u5c3f\u9053\u62ec\u7d04\u808c\u5f35\u529b", "year": 1091, "prof": "\u8b77\u7406\u5e2b", "subject": "\u57fa\u672c\u8b77\u7406\u5b78"} -{"answer": "A", "question": "\u6709\u95dc\u5ddd\u5d0e\u6c0f\u75c5\uff08Kawasaki disease\uff09\u4e4b\u6558\u8ff0\uff0c\u4e0b\uf99c\u4f55\u8005\u932f\u8aa4\uff1f \nA. \u7531 A \u7fa4\u03b2-\u6eb6\u8840\u6027\u93c8\u7403\u83cc\u611f\u67d3\u6240\u5f15\u8d77\u4e4b\u5168\u8eab\u6027\u76ae\u819a\u75c5 \nB. \u8840\u6db2\u6aa2\u67e5\u986f\u793a\u767d\u8840\u7403\u3001\u7d05\u8840\u7403\u6c89\ufa09\uf961\u53ca\u8840\u5c0f\u677f\u5747\u589e\u591a \nC. \u4ee5 Aspirin\u3001\uf9d0\u56fa\u9187\u6216\u975c\u8108\u6ce8\u5c04\u03b3\u514d\u75ab\u7403\u86cb\u767d\u6cbb\uf9c1 \nD. \u53ef\u80fd\u6703\u5f15\u8d77\u5fc3\u81df\u8840\u7ba1\u65b9\u9762\u7684\u75c5\u8b8a\uff0c\u5982\u51a0\uf9fa\u52d5\u8108\u7624", "year": 1001, "prof": "\u8b77\u7406\u5e2b", "subject": "\u7522\u5152\u79d1\u3001\u7cbe\u795e\u79d1\u8207\u793e\u5340"} -{"answer": "C", "question": "\u6709\u95dc\u7532\uf9fa\u817a\ufa00\u9664\u8853\u4e4b\u8853\u5f8c\u8b77\uf9e4\u6d3b\u52d5\uff0c\u4e0b\uf99c\u4f55\u8005\u932f\u8aa4\uff1f \nA. \u6bcf\u5c0f\u6642\u8207\u75c5\u4eba\uf96f\u8a71\uff0c\u8a55\u4f30\u8072\u97f3\u662f\u5426\u6c99\u555e \nB. \u75c5\u5e8a\u908a\u61c9\u5099\u6709 calcium gluconate\uff0c\u4f9b\u7dca\u6025\u6642\u4f7f\u7528 \nC. \u9f13\uf97f\u75c5\u4eba\u5728\u9ebb\u9189\u6e05\u9192\u5f8c\uff0c\u5373\u53ef\u57f7\ufa08\u9838\u90e8\u7684 ROM \nD. \u8853\u5f8c\u7b2c 2 \u5929\u5373\u53ef\u9032\u98df\u51b0\u6dbc\u7684\u6db2\u9ad4\u6216\u8edf\u8cea\u98df\u7269", "year": 1002, "prof": "\u8b77\u7406\u5e2b", "subject": "\u5167\u5916\u79d1\u8b77\u7406\u5b78"} -{"answer": "C", "question": "\u6709\u95dc\u6d88\u5316\u9053\u808c\u8089\u5c64\u7684\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u9664\u53e3\u8154\u3001\u54bd\u90e8\u5916\uff0c\u6240\u6709\u6d88\u5316\u9053\u7684\u808c\u8089\u5c64\u7686\u7531\u5e73\u6ed1\u808c\u69cb\u6210\nB. \u9664\u53e3\u8154\u3001\u54bd\u90e8\u5916\uff0c\u6240\u6709\u6d88\u5316\u9053\u7684\u808c\u8089\u5c64\u7686\u5206\u70ba\u5167\u5c64\u74b0\u5411\u3001\u5916\u5c64\u7e31\u5411\nC. \u54bd\u90e8\u4e3b\u8981\u7531\u9aa8\u9abc\u808c\u6240\u69cb\u6210\nD. \u53e3\u8154\u7684\u786c\u816d\u662f\u9aa8\u9abc\u808c\u69cb\u6210\uff0c\u800c\u8edf\u816d\u662f\u5e73\u6ed1\u808c\u6240\u69cb\u6210", "year": 1102, "prof": "\u8b77\u7406\u5e2b", "subject": "\u57fa\u790e\u91ab\u5b78"} -{"answer": "C", "question": "\u6709\u95dc\u6025\u6027\u5fc3\u808c\u6897\u585e\u75c5\u4eba\u63a1\u9650\u9209\u98f2\u98df\u4e4b\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u6b63\u78ba\uff1f \nA. \u53ef\u6539\u5584\u73fe\u5b58\u6c34\u816b\u554f\u984c\uff0c\u4e26\u63d0\u9ad8\u5fc3\u81df\u6548\u80fd \nB. \u53ef\u9810\u9632\u56e0\u7d44\u7e54\u6c34\u816b\u6240\u5c0e\u81f4\u7684\u8840\u58d3\u5347\u9ad8 \nC. \u53ef\u907f\u514d\u6c34\u5206\u6eef\u7559\uff0c\u4ee5\u6e1b\u5c11\u5fc3\u81df\u5de5\u4f5c\u8ca0\u8377 \nD. \u53ef\u7522\u751f\u5229\u5c3f\u6548\u679c\uff0c\u4e26\u6e1b\u5c11\u5faa\u74b0\u8840\u91cf", "year": 1082, "prof": "\u8b77\u7406\u5e2b", "subject": "\u5167\u5916\u79d1\u8b77\u7406\u5b78"} -{"answer": "C", "question": "\u56e0\u6ce8\u5c04\u9752\u9ef4\u7d20\u5f15\u8d77\u904e\u654f\u6027\u53cd\u61c9\uff0c\u6700\u53ef\u80fd\u662f\u7531\u4e0b\u5217\u4f55\u7a2e\u6a5f\u5236\u6240\u9020\u6210\uff1f\nA. \u6297\u9ad4\u8207\u6297\u539f\u7d50\u5408\u7684\u514d\u75ab\u8907\u5408\u9ad4\u6c88\u7a4d\nB. \u6297\u9ad4\u8207\u7d30\u80de\u8868\u9762\u6297\u539f\u7d50\u5408\u5f8c\uff0c\u4f7f\u7d30\u80de\u88ab\u7834\u58de\nC. \u514d\u75ab\u7403\u86cb\u767d E \u8207\u6297\u539f\u7d50\u5408\u5f8c\uff0c\u9020\u6210\u80a5\u80d6\u7d30\u80de\u7684\u53bb\u9846\u7c92\u5316\u4f5c\u7528\nD. T\u7d30\u80de\u8207\u6297\u539f\u63a5\u89f8\u5206\u6ccc\u6dcb\u5df4\u6fc0\u7d20\uff0c\u5f15\u8d77\u8089\u82bd\u816b\u53cd\u61c9", "year": 1042, "prof": "\u8b77\u7406\u5e2b", "subject": "\u57fa\u790e\u91ab\u5b78"} -{"answer": "D", "question": "\u4e0b\u5217\u4f55\u8005\u4e0d\u662f\u6642\u9593\u7ba1\u7406\u5e38\u72af\u7684\u8ff7\u601d\u6216\u504f\u5dee\uff1f \nA. \u4e8b\u5fc5\u8eac\u89aa \nB. \u5145\u5206\u6388\u6b0a \nC. \u80fd\u8005\u591a\u52de \nD. \u6548\u7387\u639b\u5e25", "year": 1041, "prof": "\u8b77\u7406\u5e2b", "subject": "\u57fa\u672c\u8b77\u7406\u5b78"} -{"answer": "D", "question": "\u4e0b\u5217\u4f55\u8005\u662f\u6ffe\u6ce1\u6027\u6dcb\u5df4\u7624\uff08follicular lymphoma\uff09\u6700\u5e38\u898b\u5230\u7684\u67d3\u8272\u9ad4\u8b8a\u5316\uff1f \nA. t\uff0814,18\uff09 \nB. t\uff0815,17\uff09 \nC. t\uff0811,22\uff09 \nD. t\uff084,11\uff09", "year": 1082, "prof": "\u8b77\u7406\u5e2b", "subject": "\u57fa\u790e\u91ab\u5b78"} -{"answer": "B", "question": "\u4e0b\u5217\u4f55\u9805\u6bd4\u8f03\u4e0d\u6703\u5f71\u97ff\u5433\u592a\u592a\u7761\u7720\u72c0\u6cc1\uff1f \nA. \u5e74\u9f61 \nB. \u75bc\u75db \nC. \u6297\u751f\u7d20 \nD. \u03b2 \u963b\u65b7\u5291", "year": 1081, "prof": "\u8b77\u7406\u5e2b", "subject": "\u57fa\u672c\u8b77\u7406\u5b78"} -{"answer": "B", "question": "70 \u6b72\u738b\u5148\u751f\u56e0\u547c\u5438\u5598\u7531\u5bb6\u4eba\u9001\u81f3\u6025\u8a3a\u5ba4\uff0c\u7576\u6642\u547c\u5438\u8cbb\u529b\u3001\u6709\u5598\u9cf4\u547c\u5438\u8072\u3001SaO2\uff1c92%\u3001BT\uff1a38.5\u00b0C\u3001SBP\uff1c90 mmHg\u3001GCS\uff1aE3V3M4\uff0c\u4f9d\u64da 2010 \u5e74\u5be6\u65bd\u4e4b\u81fa\u7063\u6025\u75c7\u6aa2\u50b7\u6025\u8feb\u5ea6\u5206\u7d1a\u91cf\u8868\uff08TTAS\uff09\uff0c\u6b64\u75c5\u4eba\u4e4b\u6aa2\u50b7\u5206\u985e\uff0c\u61c9\u5c6c\u4e0b\u5217\u4f55\u8005\uff1f \nA. \u4e00\u7d1a\uff08\u5fa9\u7526\u6025\u6551\uff09 \nB. \u4e8c\u7d1a\uff08\u5371\u6025\uff09 \nC. \u4e09\u7d1a\uff08\u7dca\u6025\uff09 \nD. \u56db\u7d1a\uff08\u6b21\u7dca\u6025\uff09", "year": 1042, "prof": "\u8b77\u7406\u5e2b", "subject": "\u5167\u5916\u79d1\u8b77\u7406\u5b78"} -{"answer": "D", "question": "\u925b\u4e2d\u6bd2\u6703\u5728\u9aa8\u9abc\u4e2d\u4f55\u8655\u5f62\u6210\u6297\u9178\u967d\u6027\u6838\u5167\u5305\u542b\u9ad4\uff1f\nA.\u9020\u9aa8\u7d30\u80de\nB.\u8840\u7ba1\u5167\u76ae\u7d30\u80de\nC.\u7e96\u7dad\u82bd\u7d30\u80de\nD.\u8755\u9aa8\u7d30\u80de", "year": 1091, "prof": "\u7378\u91ab\u5e2b", "subject": "\u7378\u91ab\u75c5\u7406\u5b78"} -{"answer": "D", "question": "\u6b63\u5e38\u52d5\u7269\u652f\u6c23\u7ba1\u80ba\u6ce1\u6c96\u6d17\u6db2\uff08Bronchoalveolar lavage\uff09\u4e2d\uff0c\u901a\u5e38\u4ee5\u4e0b\u5217\u4f55\u7a2e\u7d30\u80de\u70ba\u4e3b\uff1f\nA.\u4e0a\u76ae\u7d30\u80de\nB.\u55dc\u4e2d\u6027\u7403\nC.\u6dcb\u5df4\u7403\nD.\u5de8\u566c\u7d30\u80de", "year": 1091, "prof": "\u7378\u91ab\u5e2b", "subject": "\u7378\u91ab\u5be6\u9a57\u8a3a\u65b7\u5b78"} -{"answer": "D", "question": "\u95dc\u65bc\u52d5\u60c5\u7d20\uff08estrogens\uff09\u85e5\u7406\u4f5c\u7528\u7684\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f \nA.\u523a\u6fc0\u53ca\u7dad\u6301\u6210\u9577\u52d5\u7269\u751f\u6b96\u9053\u4e4b\u529f\u80fd \nB.\u9020\u6210\u5b50\u5bae\u9838\u7684\u64f4\u5f35 \nC.\u523a\u6fc0\u4e73\u817a\u4e4b\u751f\u9577 \nD.\u4e0d\u5177\u6709\u86cb\u767d\u8cea\u540c\u5316\u529f\u80fd", "year": 1071, "prof": "\u7378\u91ab\u5e2b", "subject": "\u7378\u91ab\u85e5\u7406\u5b78"} -{"answer": "A", "question": "\u5728\u9032\u884c\u725b\u96bb\u5e1d\u738b\u5207\u958b\u8853\uff08Cesarean section\uff09\u6642\uff0c\u9664\u4e86\u65bd\u6253\u5c40\u90e8\u6216\u5340\u57df\u9ebb\u9189\u5291\u4e4b\u5916\uff0c\u70ba\u4e86\u907f\u514d\u6bcd\u725b\u56e0\u624b\u8853\u75bc\u75db\u800c\u5012\u4e0b\uff0c\u9084\u53ef\u65bd\u6253\u4e0b\u5217\u4f55\u7a2e\u85e5\u7269\uff1f \nA.flunixin meglumine \nB.xylazine \nC.pentobarbital \nD.diazepam", "year": 1071, "prof": "\u7378\u91ab\u5e2b", "subject": "\u7378\u91ab\u666e\u901a\u75be\u75c5\u5b78"} -{"answer": "C", "question": "\u725b\u767c\u751f\u7b2c\u56db\u80c3\u98df\u6eef\u6642\uff0c\u6613\u767c\u751f\u4e0b\u5217\u4f55\u7a2e\u75c7\u72c0\uff1f\nA.\u4ee3\u8b1d\u6027\u9178\u4e2d\u6bd2\nB.\u547c\u5438\u6027\u9178\u4e2d\u6bd2\nC.\u4ee3\u8b1d\u6027\u9e7c\u4e2d\u6bd2\nD.\u547c\u5438\u6027\u9e7c\u4e2d\u6bd2", "year": 1082, "prof": "\u7378\u91ab\u5e2b", "subject": "\u7378\u91ab\u666e\u901a\u75be\u75c5\u5b78"} -{"answer": "A", "question": "\u725b\u96bb\u67d3\u8272\u9ad4\u7570\u5e38\u75be\u75c5\u4e2d\u7684\u67d3\u8272\u9ad4\u6613\u4f4d\uff08translocation\uff09\u6700\u5e38\u767c\u751f\u5728\u90a3\u5169\u5c0d\u67d3\u8272\u9ad4\uff1f\nA.1/29\nB.7/21\nC.1/4\nD.10/15", "year": 1082, "prof": "\u7378\u91ab\u5e2b", "subject": "\u7378\u91ab\u666e\u901a\u75be\u75c5\u5b78"} -{"answer": "C", "question": "\u8c93\u55dc\u4e2d\u6027\u7403\u5728\u5faa\u74b0\u6c60\u548c\u908a\u7de3\u6c60\u7684\u6bd4\u4f8b\u70ba\u4f55\uff1f \nA.1\uff1a1\nB.3\uff1a1\nC.1\uff1a3\nD.1\uff1a5", "year": 1122, "prof": "\u7378\u91ab\u5e2b", "subject": "\u7378\u91ab\u5be6\u9a57\u8a3a\u65b7\u5b78"} -{"answer": "A", "question": "\u6771\u65b9\u773c\u87f2\uff08Thelazia callipaeda\uff09\u5bc4\u751f\u5728\u72ac\u3001\u5154\u548c\u4eba\u7684\u7d50\u819c\u56ca\u5167\uff0c\u4e0b\u5217\u4f55\u8005\u662f\u52a9\u5176\u50b3\u64ad\u7684\u5a92\u4ecb\uff1f\nA.\u8805\u985e\nB.\u6591\u868a\nC.\u8001\u9f20\nD.\u58c1\u8768", "year": 1091, "prof": "\u7378\u91ab\u5e2b", "subject": "\u7378\u91ab\u516c\u5171\u885b\u751f\u5b78"} -{"answer": "A", "question": "\u8acb\u554f\u5728\u725b\u4e73\u7684\u52a0\u71b1\u6bba\u83cc\u6cd5\u4e2d\uff0c\u7528\u65bc\u9ad8\u6eab\u77ed\u6642\u9593\u6bba\u83cc\u6cd5\u7684\u6eab\u5ea6\u662f\u591a\u5c11\u2103\uff1f \nA.70 \nB.90 \nC.130 \nD.150", "year": 1042, "prof": "\u7378\u91ab\u5e2b", "subject": "\u7378\u91ab\u516c\u5171\u885b\u751f\u5b78"} -{"answer": "A", "question": "\u6709\u95dc\u8c6c\u75d8\u611f\u67d3\u8c6c\u96bb\u5f8c\u4e4b\u75c7\u72c0\u53ca\u75c5\u8b8a\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6b63\u78ba\uff1f \nA.\u4ee5\u591a\u767c\u6027\u76ae\u819a\u75c5\u8b8a\u5448\u73fe\nB.\u5e38\u96c6\u4e2d\u65bc\u81c9\u90e8\u76ae\u819a\nC.\u6703\u6709\u9ad8\u71d2\u4e0d\u9000\u4e4b\u75c7\u72c0\nD.\u53ef\u5728\u76ae\u819a\u75c5\u8b8a\u5340\u767c\u73fe\u55dc\u9e7c\u6027\u8cea\u5167\u5305\u6db5\u9ad4", "year": 1122, "prof": "\u7378\u91ab\u5e2b", "subject": "\u7378\u91ab\u50b3\u67d3\u75c5\u5b78"} -{"answer": "D", "question": "\u4e0b\u5217\u4f55\u8005\u4e0d\u662f\u672a\u4f86\u547c\u5438\u5668\u64cd\u4f5c\u4ecb\u9762\u6240\u5fc5\u9700\u7684\u57fa\u672c\u529f\u80fd\uff1f \nA.\u8f38\u5165\u63a7\u5236\u548c\u8b66\u793a\u8a0a\u865f\u53c3\u6578\uff08control and alarm parameters\uff09 \nB.\u5075\u6e2c\u547c\u5438\u5668\u72c0\u614b\uff08ventilator's status\uff09 \nC.\u5075\u6e2c\u75c5\u4eba\u548c\u547c\u5438\u5668\u4e92\u52d5\u7684\u72c0\u614b\uff08ventilator-patient interaction status\uff09 \nD.\u5075\u6e2c\u75c5\u4eba\u5410\u6c23\u672b\u4e8c\u6c27\u5316\u78b3\u6fc3\u5ea6\uff08end-tidal CO2 concentration\uff09", "year": 1062, "prof": "\u547c\u5438\u6cbb\u7642\u5e2b", "subject": "\u547c\u5438\u5668\u539f\u7406\u53ca\u61c9\u7528"} -{"answer": "C", "question": "\u80da\u80ce\u5fc3\u81df\u4e3b\u8981\u7531\u4e0b\u5217\u4f55\u8005\u767c\u80b2\u800c\u4f86\uff1f \nA.\u4e2d\u9593\u4e2d\u80da\u5c64\uff08intermediate mesoderm\uff09\nB.\u810a\u7d22\uff08notochord\uff09\nC.\u81df\u58c1\u4e2d\u80da\u5c64\uff08splanchnic mesoderm\uff09\nD.\u9ad4\u58c1\u4e2d\u80da\u5c64\uff08somatic mesoderm\uff09", "year": 1102, "prof": "\u547c\u5438\u6cbb\u7642\u5e2b", "subject": "\u5fc3\u80ba\u57fa\u790e\u91ab\u5b78"} -{"answer": "A", "question": "\u547c\u5438\u6cbb\u7642\u5e2b\u4ee5\u5176\u5c08\u696d\u64cd\u7e31\u75c5\u60a3\u540c\u610f\u6216\u62d2\u7d55\u6cbb\u7642\uff0c\u6b64\u4e92\u52d5\u6a21\u5f0f\u9055\u53cd\u4f55\u7a2e\u539f\u5247\uff1f\nA.\u5c0a\u91cd\u2f83\u4e3b\nB.\u2f8f\u5584\nC.\u4e0d\u50b7\u5bb3\nD.\u516c\u5e73\u6b63\u7fa9", "year": 1081, "prof": "\u547c\u5438\u6cbb\u7642\u5e2b", "subject": "\u57fa\u790e\u547c\u5438\u6cbb\u7642\u5b78"} -{"answer": "B", "question": "\u80ce\u5152\u5faa\u74b0\u7684\u81cd\u52d5\u8108\u5728\u6210\u9ad4\u9000\u5316\u6210\u4e0b\u5217\u4f55\u7a2e\u7d50\u69cb\uff1f \nA.\u809d\u5713\u97cc\u5e36\uff08round ligament\uff09\nB.\u5167\u5074\u81cd\u97cc\u5e36\uff08medial umbilical ligament\uff09\nC.\u975c\u8108\u97cc\u5e36\uff08ligamentum venosum\uff09\nD.\u52d5\u8108\u97cc\u5e36\uff08ligamentum arteriosum\uff09", "year": 1022, "prof": "\u547c\u5438\u6cbb\u7642\u5e2b", "subject": "\u5fc3\u80ba\u57fa\u790e\u91ab\u5b78"} -{"answer": "D", "question": "Aerosol delivery\u4f7f\u7528\u5728\u6a5f\u68b0\u901a\u6c23\u75c5\u4eba\u6642\uff0c\u5f71\u97ff\u85e5\u7269\u5728\u80ba\u90e8\u6c89\u7a4d\u7684\u56e0\u7d20\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f \nA.\u589e\u52a0\u5438\u6c23\u6642\u9593\uff0c\u6c89\u7a4d\u6108\u9ad8\nB.\u6e1b\u5c11\u547c\u5438\u6b21\u6578\uff0c\u6c89\u7a4d\u6108\u9ad8\nC.\u6c23\u9ad4\u7684\u6fd5\u5ea6\u6703\u5f71\u97ff\u6c89\u7a4d\nD.\u547c\u5438\u9053\u963b\u585e\u4e4b\u56b4\u91cd\u7a0b\u5ea6\u4e0d\u6703\u5f71\u97ff\u6c89\u7a4d", "year": 1011, "prof": "\u547c\u5438\u6cbb\u7642\u5e2b", "subject": "\u547c\u5438\u6cbb\u7642\u5100\u5668\u8a2d\u5099\u5b78"} -{"answer": "D", "question": "\u4e0b\u5217\u4f55\u8005\u88ab\u7528\u4f86\u9810\u9632 isoniazid \u6cbb\u7642\u80ba\u7d50\u6838\u6642\u6240\u5f15\u8d77\u7684\u5468\u908a\u795e\u7d93\u75c5\u8b8a\u7684\u526f\u4f5c\u7528\uff1f \nA.\u7dad\u751f\u7d20 A \nB.\u7dad\u751f\u7d20 B2 \nC.\u7dad\u751f\u7d20 C \nD.\u7dad\u751f\u7d20 B6", "year": 1041, "prof": "\u547c\u5438\u6cbb\u7642\u5e2b", "subject": "\u5fc3\u80ba\u57fa\u790e\u91ab\u5b78"} -{"answer": "C", "question": "\u5c0d\u96e3\u4ee5\u6cbb\u7642\uff08difficult-to-treat\uff09\u4e4b\u6c23\u5598\u75c5\u4eba\uff0c\u4e0b\u5217\u8655\u7f6e\u4f55\u8005\u932f\u8aa4\uff1f \nA.\u78ba\u5b9a\u8a3a\u65b7\u662f\u5426\u6b63\u78ba \nB.\u78ba\u5b9a\u75c5\u60a3\u5c0d\u91ab\u56d1\u4e4b\u9806\u5f9e\u6027 \nC.\u9023\u7e8c\u4f7f\u7528\u6700\u9ad8\u5291\u91cf\u5438\u5165\u578b\u985e\u56fa\u9187\u8d85\u904e\u516d\u500b\u6708 \nD.\u8655\u7406\u5171\u75c5\u75c7\uff08comorbidity\uff09", "year": 1032, "prof": "\u547c\u5438\u6cbb\u7642\u5e2b", "subject": "\u547c\u5438\u75be\u75c5\u5b78"} -{"answer": "D", "question": "80\u6b72\u7537\u6027\u66fe\u56e0\u591a\u6b21\u6162\u6027\u963b\u585e\u6027\u80ba\u75c5\u6025\u6027\u60e1\u5316\u4f4f\u9662\uff0c\u52d5\u8108\u8840\u6c23\u9ad4\u5206\u6790\u70bapH\uff1a7.28\uff0cPaCO2\uff1a65 mm Hg\uff0cPaO2\uff1a61 mm Hg\uff0cHCO3-\uff1a24.1 mEq/L\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f \nA.\u8840\u6c27\u542b\u91cf\u4e0d\u5b9c\u592a\u9ad8\uff0c\u4ee5\u907f\u514dHaldane effect\u9020\u6210\u8840\u6f3f\u5167CO2\u5206\u58d3\u4e0a\u5347\nB.\u53ef\u8003\u616e\u4f7f\u7528\u975e\u4fb5\u8972\u6027\u6b63\u58d3\u547c\u5438\u5668\nC.\u975e\u4fb5\u8972\u6027\u6b63\u58d3\u547c\u5438\u5668\u7684\u5438\u6c23\u58d3\u529b\u8abf\u6574\u70ba\u6f6e\u6c23\u5bb9\u7a4d\uff08tidal volume\uff094\uff5e6 mL/kg\nD.\u82e5\u4f7f\u7528\u975e\u4fb5\u8972\u6027\u6b63\u58d3\u547c\u5438\u56681\uff5e2\u5c0f\u6642\u5f8c\uff0c\u52d5\u8108\u8840\u6c23\u9ad4\u5206\u6790PaCO2\u70ba62 mm Hg\uff0c\u53ef\u4ee5\u5c07EPAP\u8abf\u9ad8\u4ee5\u6539\u5584", "year": 1092, "prof": "\u547c\u5438\u6cbb\u7642\u5e2b", "subject": "\u91cd\u75c7\u547c\u5438\u6cbb\u7642\u5b78"} -{"answer": "D", "question": "\u6025\u6027\u547c\u5438\u7a98\u8feb\u75c7\u5019\u7fa4\uff08acute respiratory distress syndrome\uff09\u7684\u521d\u671f\u5e38\u9808\u8207\u5fc3\u81df\u8870\u7aed\u5f15\u8d77\u4e4b\u80ba\u6c34\u816b\u505a\u9451\u5225\u8a3a\u65b7\uff0c\u4e0b\u5217\u4f55\u5fb5\u8c61\u6bd4\u8f03\u50cf\u5fc3\u81df\u8870\u7aed\u5f15\u8d77\u4e4b\u80ba\u6c34\u816b\uff1f \nA.\u80ba\u5fae\u8840\u7ba1\u6954\u58d3\uff08pulmonary capillary wedge pressure\uff09\u5c0f\u65bc18 mm Hg\nB.\u80ba\u6ce1\u6c96\u6d17\u6db2\u86cb\u767d\u8cea\u542b\u91cf\u9ad8\nC.\u80ba\u7d44\u7e54\u5207\u7247\u986f\u793a\u7b2c\u4e8c\u578b\u80ba\u7d30\u80de\uff08pneumocyte\uff09\u589e\u751f\nD.\u80ba\u808b\u819c\u7a4d\u6db2\u70ba\u6ef2\u51fa\u6027\uff08transudative pleural effusion\uff09", "year": 1002, "prof": "\u547c\u5438\u6cbb\u7642\u5e2b", "subject": "\u91cd\u75c7\u547c\u5438\u6cbb\u7642\u5b78"} -{"answer": "D", "question": "\u4e0b\u5217\u5c0d\u65bc\u958b\u7a97\u5f0f\uff08fenestrated\uff09\u6c23\u5207\u7ba1\u7684\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f \nA.\u958b\u7a97\u7684\u4f4d\u7f6e\u5728\u6c23\u56ca\u7684\u4e0a\u65b9\n \nB.\u82e5\u8981\u9023\u63a5\u6b63\u58d3\u547c\u5438\u5668\u5fc5\u9808\u7f6e\u5165\u7121\u958b\u7a97\u7684\u5167\u7ba1\nC.\u5176\u529f\u80fd\u4e4b\u4e00\u662f\u53ef\u4ee5\u5354\u52a9\u60a3\u8005\u767c\u8072\nD.\u53ef\u4ee5\u5e6b\u52a9\u6c23\u9053\u62bd\u5438\u66f4\u5b8c\u5168", "year": 1002, "prof": "\u547c\u5438\u6cbb\u7642\u5e2b", "subject": "\u547c\u5438\u6cbb\u7642\u5100\u5668\u8a2d\u5099\u5b78"} -{"answer": "D", "question": "\u4e0b\u5217\u4f55\u7a2e\u8a8d\u77e5\u529f\u80fd\u7570\u5e38\uff0c\u6700\u5e38\u767c\u751f\u65bc\u53f3\u9802\u8449\u53d7\u50b7\uff1f \nA. \u4e0d\u6d41\u66a2\u578b\u5931\u8a9e\u75c7 \nB. \u8996\u89ba\u5931\u8a8d\u75c7 \nC. \u7a7a\u9593\u5ffd\u7565\u75c7 \nD. \u7d14\u5931\u8b80\u75c7", "year": 1082, "prof": "\u81e8\u5e8a\u5fc3\u7406\u5e2b", "subject": "\u81e8\u5e8a\u5fc3\u7406\u5b78\u7279\u8ad6\uff08\u4e8c\uff09"} -{"answer": "D", "question": "\u6709\u95dc\u5fc3\u7406\u75be\u60a3\u5718\u9ad4\u6cbb\u7642\u76ee\u6a19\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f \nA. \u6025\u6027\u4f4f\u9662\u60a3\u8005\u7684\u5718\u9ad4\u6cbb\u7642\u76ee\u6a19\u548c\u6162\u6027\u4f4f\u9662\u60a3\u8005\u7684\u5718\u9ad4\u6cbb\u7642\u76ee\u6a19\u4e26\u4e0d\u76f8\u540c \nB. \u5718\u9ad4\u6cbb\u7642\u76ee\u6a19\u53ef\u653e\u5728\u964d\u4f4e\u4f4f\u9662\u7684\u7126\u616e \nC. \u6cbb\u7642\u5e2b\u8207\u6210\u54e1\u90fd\u8981\u6e05\u695a\u5718\u9ad4\u7684\u76ee\u6a19 \nD. \u6162\u6027\u60a3\u8005\u5718\u9ad4\u6cbb\u7642\u7684\u76ee\u6a19\u53ef\u653e\u5728\u75c7\u72c0\u7684\u7de9\u89e3", "year": 1032, "prof": "\u81e8\u5e8a\u5fc3\u7406\u5e2b", "subject": "\u81e8\u5e8a\u5fc3\u7406\u5b78\u7279\u8ad6\uff08\u4e8c\uff09"} -{"answer": "D", "question": "\u6709\u95dc\u5b78\u7fd2\u969c\u7919\u7684\u6558\u8ff0\uff0c\u4e0b\uf99c\u4f55\u8005\u6b63\u78ba\uff1f \nA. Learning disorder \u8207 learning disability \u6307\u7a31\uf967\u540c\u7684\u5b78\u7fd2\u554f\u984c \n \nB. DSM-IV-TR \u6307\u51fa\uff0c\u667a\u80fd\uf967\u8db3\u60a3\u8005\u4e2d\uf967\u53ef\u80fd\u5408\u4f75\u5b78\u7fd2\u969c\u7919 \nC. DSM-IV-TR \u6307\u51fa\uff0c\u6ce8\u610f\uf98a\u7f3a\u9677\u60a3\u8005\u4e2d\uf967\u53ef\u80fd\u5408\u4f75\u5b78\u7fd2\u969c\u7919 \nD. \u5b78\u7fd2\u969c\u7919\u5fc5\u9808\u900f\u904e\u6a19\u6e96\u5316\u7684\u5b78\u696d\u6210\u5c31\u6e2c\u9a57\uff08\u5982\u95b1\uf95a\u3001\uf969\u5b78\u7b49\uff09\u6aa2\u6e2c", "year": 1021, "prof": "\u81e8\u5e8a\u5fc3\u7406\u5e2b", "subject": "\u81e8\u5e8a\u5fc3\u7406\u5b78\u7279\u8ad6\uff08\u4e8c\uff09"} -{"answer": "D", "question": "\u559d\u9152\u5f8c\u601d\u8003\u6703\u8b8a\u6162\u4e4b\u751f\u7406\u6a5f\u5236\u70ba\u4e0b\u5217\u4f55\u8005\uff1f \nA. \u8840\u6e05\u7d20\uff08serotonin\uff09\u91cf\u589e\u591a \nB. \u8840\u6e05\u7d20\u91cf\u6e1b\u5c11 \nC. \u9ea9\u6c28\u9178\uff08glutamate\uff09\u63a5\u53d7\u5668\u53d7\u5230\u6291\u5236 \nD. \u9ea9\u6c28\u9178\u63a5\u53d7\u5668\u53d7\u5230\u6fc0\u767c", "year": 1042, "prof": "\u81e8\u5e8a\u5fc3\u7406\u5e2b", "subject": "\u81e8\u5e8a\u5fc3\u7406\u5b78\u7279\u8ad6\uff08\u4e00\uff09"} -{"answer": "B", "question": "\u4e0b\u5217\u4f55\u8005\u662f Rudd \u7b49\u4eba\uff082001\uff09\u7684\u81ea\u6bba\u4fe1\u5ff5\u7cfb\u7d71\uff08suicidal belief system\uff09\u4e2d\u4e4b\u6838\u5fc3\u4fe1\u5ff5\uff08core belief\uff09\uff1f \nA. \u5916\u5728\u4e16\u754c\u662f\u53ef\u6015\u7684\uff0c\u5c0d\u6211\u4e0d\u5229\u7684 \nB. \u6211\u662f\u4e0d\u503c\u5f97\u88ab\u611b\u7684 \nC. \u8981\u5f88\u80fd\u5e79\uff0c\u624d\u662f\u6709\u7528\u7684\u4eba \nD. \u8981\u6709\u4eba\u611b\u6211\uff0c\u6211\u624d\u6703\u5feb\u6a02", "year": 1042, "prof": "\u81e8\u5e8a\u5fc3\u7406\u5e2b", "subject": "\u81e8\u5e8a\u5fc3\u7406\u5b78\u7279\u8ad6\uff08\u4e00\uff09"} -{"answer": "A", "question": "\u4e0b\u5217\u4f55\u8005\u662f\u754f\u907f\u578b\uff08avoidant\uff09\u4eba\u683c\u969c\u7919\u75c7\u60a3\u8005\u7684\u7279\u5fb5\uff1f \nA. \u70ba\u4e86\u907f\u514d\u906d\u53d7\u4eba\u969b\u7684\u6279\u8a55\u6216\u62d2\u7d55\u800c\u6975\u7aef\u8ff4\u907f\u4eba\u969b\u95dc\u4fc2\u548c\u4e92\u52d5 \nB. \u56e0\u70ba\u5bb3\u6015\u88ab\u62cb\u68c4\u800c\u9700\u8981\u9078\u64c7\u4f9d\u9644\u65bc\u4e00\u6bb5\u7a69\u5b9a\u7684\u4eba\u969b\u95dc\u4fc2 \nC. \u5c0d\u65bc\u61f2\u7f70\u5177\u6709\u9ad8\u5fcd\u53d7\u529b\uff0c\u5c0d\u65bc\u6b0a\u5a01\u8005\u4e0d\u65b7\u5617\u8a66\u53cd\u6297 \nD. \u53cd\u8986\u7684\u81ea\u50b7\u884c\u70ba\uff0c\u6709\u6975\u5f37\u7684\u81ea\u6bba\u885d\u52d5\u8207\u98a8\u96aa", "year": 1042, "prof": "\u81e8\u5e8a\u5fc3\u7406\u5e2b", "subject": "\u81e8\u5e8a\u5fc3\u7406\u5b78\u7279\u8ad6\uff08\u4e00\uff09"} -{"answer": "A", "question": "\u5c0f\u7f8e\u5728\u96fb\u8996\u4e0a\u770b\u5230\u5169\u96bb\u888b\u9f20\u6253\u67b6\uff0c\u7238\u7238\uf96f\uff1a\u300c\u770b\uff0c\u6253\u62f3\u64ca\uff01\u300d\u5c0f\u7f8e\u7b2c\u4e00\u6b21\u807d\u5230\u300c\u6253\u62f3\u64ca\u300d\uff0c\u4f46\u5979\u5df2\u7d93\u77e5\u9053\u300c\u888b\u9f20\u300d\u7684\u610f\u601d\uff1b\u56e0\u6b64\u5047\u8a2d\u300c\u6253\u62f3\u64ca\u300d\u548c\u300c\u888b\u9f20\u300d\u4ee3\u8868\u4e0d\u540c\u7684\u610f\u601d\uff0c\u6700\u5f8c\u63a8\u8ad6\u51fa\u65b0\u8a5e\u662f\u5728\u547d\u540d\u52d5\u4f5c\u800c\u975e\u7269\u9ad4\u3002\u4e0b\u5217\u4f55\u8005\u6700\u9069\u5408\u8aaa\u660e\u5c0f\u7f8e\u5b78\u7fd2\u8a5e\u7fa9\u7684\u904e\u7a0b\uff1f \nA. \u5c0d\u6bd4\u539f\u5247\uff08principle of contrast\uff09 \nB. \u904e\u5ea6\u5ef6\u4f38\uff08over-extension\uff09 \nC. \u904e\u5ea6\u898f\u5247\u5316\uff08over-regularization\uff09 \nD. \u64f4\u5c55\uff08expansion\uff09", "year": 1041, "prof": "\u81e8\u5e8a\u5fc3\u7406\u5e2b", "subject": "\u81e8\u5e8a\u5fc3\u7406\u5b78\u57fa\u790e"} -{"answer": "A", "question": "\u5f9e\u53e4\u5178\u5236\u7d04\u5b78\u7fd2\uf9e4\uf941\u67b6\u69cb\uf92d\u770b\uff0c\u4e0b\uf99c\u4f55\u8005\u7b26\u5408\u5236\u7d04\u53cd\u61c9\uff08conditioned response\uff09\u7684\u6982\uf9a3\uff1f \nA. \u7d93\uf98c\u904e\u6230\u722d\u7684\u9000\u4f0d\u8ecd\u4eba\uff0c\u807d\ufa0a\u97ad\u70ae\u8072\u6703\u5fc3\u8df3\u52a0\u5feb\u8840\u58d3\u4e0a\u5347 \nB. \u6c89\u8ff7\u8ced\u535a\u7684\u4eba\u6bcf\u5929\u53bb\u8ced\u5834\u6253\u724c \nC. \u9ed1\u7329\u7329\u5b78\u6703\u5806\u7a4d\u7bb1\u5b50\uff0c\u4ee5\u53d6\u5f97\u639b\u5728\u5929\u82b1\u677f\u4e0a\u7684\u98df\u7269 \nD. \u95dc\u5728\uf944\u5b50\uf9e8\u9762\u7684\u8c93\u5b78\u6703\u6253\u958b\u9580\u9003\u8d70", "year": 1011, "prof": "\u81e8\u5e8a\u5fc3\u7406\u5e2b", "subject": "\u81e8\u5e8a\u5fc3\u7406\u5b78\u57fa\u790e"} -{"answer": "D", "question": "\u6cd5\u9662\u5728\u9032\u884c\u6848\u4ef6\u5ba3\u5224\u6642\uff0c\u5bb9\u6613\u53d7\u5230\u4e0b\u5217\u4f55\u7a2e\u5916\u5728\u56e0\u7d20\u7684\u5f71\u97ff\uff1f\nA. \u5927\u773e\u7684\u72af\u7f6a\u77e5\u8b58\uff08knowledge of crime\uff09\nB. \u5927\u773e\u7684\u72af\u7f6a\u614b\u5ea6\uff08attitude of crime\uff09\nC. \u570b\u5bb6\u516c\u5171\u653f\u7b56\uff08public policy\uff09\nD. \u5c0d\u793e\u6703\u7d93\u6fdf\uff08social economy\uff09\u7684\u5f71\u97ff", "year": 1102, "prof": "\u81e8\u5e8a\u5fc3\u7406\u5e2b", "subject": "\u81e8\u5e8a\u5fc3\u7406\u5b78\u7279\u8ad6\uff08\u4e00\uff09"} -{"answer": "A", "question": "\u6839\u64da Harvey \u7b49\u4eba\uff082004\uff09\u5c0d\u601d\u8003\u529f\u80fd\u5fc3\uf9e4\u75c5\uf9e4\u5b78\u5be6\u5fb5\u7814\u7a76\u7684\u6574\uf9e4\uff0c\u8a8d\u70ba\u4f55\u7a2e\u7126\u616e\u75be\u60a3\u8f03\u5c11\u88ab\u63a2\u7a76 recurrent thinking \u7684\u554f\u984c\uff1f \nA. \u7279\u5b9a\u754f\u61fc\u75c7\uff08Specific phobia\uff09 \nB. \u793e\u4ea4\u754f\u61fc\u75c7\uff08Social phobia\uff09 \nC. \u5f37\u8feb\u75be\u60a3\uff08OCD\uff09 \n \nD. \u5275\u50b7\u5f8c\u58d3\uf98a\u75be\u60a3\uff08PTSD\uff09", "year": 1022, "prof": "\u81e8\u5e8a\u5fc3\u7406\u5e2b", "subject": "\u81e8\u5e8a\u5fc3\u7406\u5b78\u7279\u8ad6\uff08\u4e00\uff09"} -{"answer": "D", "question": "\u8981\u78ba\u5b9a\u5b5f\u5fb7\u68ee\u541e\u56a5\u6cd5\uff08Mendelsohn maneuver\uff09\u8a13\u7df4\u7684\u6548\u679c\uff0c\u61c9\u6e2c\u91cf\u4e0b\u5217\u90a3\u500b\u6578\u503c\uff1f \nA. \u53e3\u8154\u901a\u904e\u6642\u9593\uff08oral transit time\uff09 \nB. \u54bd\u90e8\u5ef6\u9072\u6642\u9593\uff08pharyngeal delay time\uff09 \nC. \u547c\u5438\u9053\u95dc\u9589\u6642\u9577\uff08duration of airway closure\uff09 \nD. \u5589\u90e8\u4e0a\u62ac\u9ad8\u5ea6\uff08extent of laryngeal elevation\uff09", "year": 1082, "prof": "\u8a9e\u8a00\u6cbb\u7642\u5e2b", "subject": "\u55d3\u97f3\u8207\u541e\u56a5\u969c\u7919\u5b78"} -{"answer": "A", "question": "3 \u81f3 5 \u6b72\u5152\u7ae5\u80fd\u8003\uf97e\u6e9d\u901a\u5c0d\u8c61\u7684\u80cc\u666f\u77e5\uf9fc\uff0c\u5728\u4ea4\u8ac7\u904e\u7a0b\u4e2d\u8abf\u6574\u8a71\u8a9e\u8a0a\u606f\uff0c\u6216\u4f9d\u6e9d\u901a\u5c0d\u8c61\u7684\uf967\u540c\uff0c\u8abf\u6574\uf96f\u8a71\u7684\u65b9\u5f0f\uff0c\u9019\u6a23\u7684\u6e9d\u901a\u80fd\uf98a\u662f\uff1a \nA. \u8a9e\u7528\u524d\u8a2d\u80fd\uf98a\uff08presupposition ability\uff09 \n \nB. \u8a9e\u8a00\u5f8c\u8a2d\u80fd\uf98a\uff08metalinguistic ability\uff09 \nC. \u793e\u6703\u8a8d\u77e5\u80fd\uf98a\uff08socio-cognitive perspective ability\uff09 \n \nD. \u8868\u610f\u80fd\uf98a\uff08locutionary ability\uff09", "year": 1022, "prof": "\u8a9e\u8a00\u6cbb\u7642\u5e2b", "subject": "\u5152\u7ae5\u8a9e\u8a00\u969c\u7919\u5b78"} -{"answer": "C", "question": "\u8a55\u4f30\u904b\u52d5\u6027\u8a00\u8a9e\u969c\u7919\u5c0d\u6e9d\u901a\u6548\u80fd\u7684\u5f71\u97ff\uff0c\u53ef\u85c9\u7531\u6e05\u6670\ufa01\uff08intelligibility\uff09\u3001\u53ef\uf9e4\u89e3\ufa01\uff08comprehensibility\uff09\u53ca\u6548\uf961\uff08efficiency\uff09\uf92d\u5224\u65b7\u3002\u4e0b\uf99c\u6558\u8ff0\u4f55\u8005\u6700\u9069\u7576\uff1f \nA. \u4e8b\u5148\u77ad\u89e3\u8ac7\u8a71\u4e3b\u984c\u53ca\u5167\u5bb9\uff0c\u6709\u52a9\u65bc\u63d0\u6607\u6e05\u6670\ufa01 \nB. \u69cb\u97f3\u6b63\u78ba\u6027\u662f\u6c7a\u5b9a\u53ef\uf9e4\u89e3\ufa01\u512a\uf99d\u7684\u4e3b\u8981\u56e0\u7d20 \nC. \u60a3\u8005\u8a00\u8a9e\u6e05\u6670\ufa01\u4f73\uff0c\u4f46\u56e0\uf96f\u8a71\u901f\ufa01\u904e\u6162\uff0c\u9084\u662f\u6703\ufa09\u4f4e\u6548\uf961 \nD. \u4f7f\u7528\u6e9d\u901a\u624b\u52e2\u6216\uf9dd\u7528\u60c5\u5883\u7dda\uf96a\u5e6b\u52a9\u77ad\u89e3\uf96f\u8a71\u5167\u5bb9\uff0c\u53ef\u589e\u52a0\u6e05\u6670\ufa01", "year": 1021, "prof": "\u8a9e\u8a00\u6cbb\u7642\u5e2b", "subject": "\u795e\u7d93\u6027\u6e9d\u901a\u969c\u7919\u5b78"} -{"answer": "D", "question": "\u63a5\u53d7\u6a19\u6e96\u5589\u8072\u9580\u4e0a\u90e8\u5206\u5207\u9664\u8853\u7684\u60a3\u8005\uff0c\u6700\u9069\u5408\u6559\u5c0e\u5176\u4f7f\u7528\u4f55\u7a2e\u541e\u56a5\u624b\u6cd5\uff1f \nA. \u8d85\u4e0a\u8072\u9580\u541e\u56a5\u6cd5 \nB. \u4e0a\u8072\u9580\u541e\u56a5\u6cd5 \nC. \u50be\u5378\u541e\u56a5\u6cd5 \nD. \u7528\u529b\u541e\u56a5\u6cd5", "year": 1052, "prof": "\u8a9e\u8a00\u6cbb\u7642\u5e2b", "subject": "\u55d3\u97f3\u8207\u541e\u56a5\u969c\u7919\u5b78"} -{"answer": "D", "question": "\u6c23\u9ad4\u52d5\u529b\u5b78\u7684\u8a55\u4f30\u4e2d\uff0c\u6c23\u6d41\u901f\u7387\u7684\u6e2c\u91cf\u662f\u81e8\u5e8a\u4e0a\u5e38\u4f7f\u7528\u7684\u4e00\u500b\u53c3\u6578\u3002\u95dc\u65bc\u6c23\u6d41\u901f\u7387\u7684\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f \nA. \u6e2c\u91cf\u7684\u65b9\u5f0f\u662f\u4ee5\u8f15\u9b06\u7684\u8072\u97f3\u767c /pi pi pi pi \u2026\u2026\u2026./ \nB. \u5728\u6b63\u5e38\u7684\u72c0\u6cc1\u4e0b\uff0c\u5e73\u5747\u6c23\u6d41\u901f\u7387\u7d04\u5728 80-200 mL/sec \u4e4b\u9593 \nC. \u767c\u5589\u560e\u97f3\uff08glottal fry\uff09\u6642\u7684\u5e73\u5747\u6c23\u6d41\u901f\u7387\u8f03\u4f4e\uff0c\u7d04\u5728 10-15 mL/sec \u4e4b\u9593 \nD. \u5c0d\u65bc\u8072\u5e36\u9ebb\u75fa\u4e14\u8072\u5e36\u660e\u986f\u9589\u9396\u4e0d\u5168\u4e4b\u60a3\u8005\uff0c\u5e73\u5747\u6c23\u6d41\u901f\u7387\u53ef\u80fd\u9ad8\u9054 400-600 mL / sec", "year": 1052, "prof": "\u8a9e\u8a00\u6cbb\u7642\u5e2b", "subject": "\u55d3\u97f3\u8207\u541e\u56a5\u969c\u7919\u5b78"} -{"answer": "D", "question": "\u53e3\u5403\u4fee\u6b63\u6cbb\u7642\uff08stuttering modification therapy\uff09\u8207\u6d41\u66a2\u5851\u9020\u6cbb\u7642\uff08fluency shaping therapy\uff09\u5c0e\u5411\u7684\u6cbb\u7642\u65b9\u5f0f\uff0c\u5728\u81e8\u754c\u53e3\u5403\uff08borderline stuttering\uff09\u968e\u6bb5\u8655\u7f6e\u4e0a\u8f03\u70ba\u985e\u4f3c\u3002\u4e0b\u5217\u76f8\u4f3c\u9ede\u4f55\u8005\u6b63\u78ba\uff1f \nA. \u7686\u8457\u91cd\u65bc\u5152\u7ae5\u7684\u53e3\u5403\u884c\u70ba \nB. \u7686\u8457\u91cd\u65bc\u5c07\u5bb6\u9577\u7d0d\u5165\u6cbb\u7642\u8a08\u756b\u4e2d \nC. \u6cbb\u7642\u76ee\u6a19\u7686\u8a2d\u5b9a\u70ba\u63a7\u5236\u4e0b\u7684\u8aaa\u8a71\u6d41\u66a2\u5ea6 \nD. \u7686\u8457\u91cd\u65bc\u76f4\u63a5\u6cbb\u7642", "year": 1032, "prof": "\u8a9e\u8a00\u6cbb\u7642\u5e2b", "subject": "\u69cb\u97f3\u8207\u8a9e\u66a2\u969c\u7919\u5b78"} -{"answer": "A", "question": "\u4e0b\u5217\u4f55\u8005\u6700\u4e0d\u7b26\u5408\u5f62\u6210\u7b26\u865f\u8207\u53c3\u7167\u7269\u7684\u95dc\u4fc2\uff1f \nA. \u6709\u4e00\u5957\u975c\u614b\u7684\u898f\u5247 \n \nB. \u9700\u8981\u60c5\u5883\u8108\u7d61\u4e2d\u7684\u53c3\u7167\u7269 \nC. \u5305\u542b\u904e\u53bb\u7684\u7d93\u9a57 \n \nD. \u6709\u5171\u540c\u7684\u8981\u7d20", "year": 1072, "prof": "\u8a9e\u8a00\u6cbb\u7642\u5e2b", "subject": "\u5152\u7ae5\u8a9e\u8a00\u969c\u7919\u5b78"} -{"answer": "B", "question": "\u95dc\u65bc\u5589\u983b\u9583\u89c0\u6e2c\u5100\u7684\u5be6\u65bd\u7a0b\u5e8f\u53ca\u9069\u7528\u72c0\u6cc1\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6b63\u78ba\uff1f \nA. \u6aa2\u67e5\u6642\u8acb\u53d7\u6aa2\u8005\u91cd\u8907\u767c/pi/\u97f3\uff0c\u4ee5\u89c0\u5bdf\u8072\u5e36\u632f\u52d5\u7684\u578b\u614b \nB. \u900f\u904e\u5149\u6e90\u7684\u9583\u720d\uff0c\u53ef\u5448\u73fe\u8072\u5e36\u6162\u901f\u7684\u632f\u52d5\u578b\u614b\uff0c\u4f46\u82e5\u8072\u5e36\u632f\u52d5\u4e0d\u898f\u5247\uff0c\u5247\u7121\u6cd5\u5448\u73fe\u5b8c\u6574\u7684\u632f\u52d5\u9031\u671f \nC. \u5149\u6e90\u9583\u720d\u7684\u983b\u7387\u7537\u5973\u4e0d\u540c\uff0c\u7537\u6027\u70ba 100 Hz\uff0c\u5973\u6027\u70ba 220 Hz \nD. \u6709\u660e\u78ba\u7684\u64cd\u4f5c\u7a0b\u5e8f\u53ca\u5224\u8b80\u6a19\u6e96\uff0c\u662f\u76f8\u7576\u5ba2\u89c0\u7684\u6aa2\u67e5\u65b9\u5f0f", "year": 1072, "prof": "\u8a9e\u8a00\u6cbb\u7642\u5e2b", "subject": "\u55d3\u97f3\u8207\u541e\u56a5\u969c\u7919\u5b78"} -{"answer": "D", "question": "\u6b63\u5e38\u7684\u5927\u8166\u8a9e\u8a00\u8655\uf9e4\uf98c\u7a0b\u4e2d\uff0c\u4e0b\u908a\u7de3\u56de\uff08supramarginal gyrus\uff09\u4e3b\u8981\u662f\u5354\u52a9\u90a3\u4e00\u9805\u8a9e\u8a00\u8655\uf9e4\uf98c\u7a0b\uff1f \nA. \u97f3\u97fb\u8fa8\uf9fc \nB. \u8a9e\u8a5e\u8a18\u61b6 \nC. \u53e3\u8a9e\u8868\u9054 \nD. \u8a9e\uf906\u5206\u6790", "year": 1012, "prof": "\u8a9e\u8a00\u6cbb\u7642\u5e2b", "subject": "\u5152\u7ae5\u8a9e\u8a00\u969c\u7919\u5b78"} -{"answer": "A", "question": "\u6eab\ufa01\u89f8\u89ba\uf9ff\u6fc0\u7684\u505a\u6cd5\uff0c\u4e0b\uf99c\u4f55\u8005\u70ba\u6b63\u78ba\uff1f \nA. \u5782\u76f4\u6469\u64e6\u524d\uf99e\u9580\u5f13 \nB. \u6c34\u5e73\u6469\u64e6\u524d\uf99e\u9580\u5f13 \nC. \u5782\u76f4\u6469\u64e6\u5f8c\uf99e\u9580\u5f13 \nD. \u6c34\u5e73\u6469\u64e6\u5f8c\uf99e\u9580\u5f13", "year": 1012, "prof": "\u8a9e\u8a00\u6cbb\u7642\u5e2b", "subject": "\u55d3\u97f3\u8207\u541e\u56a5\u969c\u7919\u5b78"} -{"answer": "C", "question": "\u91dd\u5c0d\u5fc3\u7d5e\u75db\u75c5\u60a3\u63a5\u53d7\u6709\u6c27\u904b\u52d5\u8a13\u7df4\u5f8c\uff0c\u53ef\u5e36\u4f86\u751f\u7406\u4e0a\u9069\u61c9\u6027\u7684\u8b8a\u5316\uff0c\u4e0b\u5217\u8a13\u7df4\u6548\u679c\u4e4b\u6558\u8ff0\u4f55\u8005\u6b63\u78ba\uff1f\u2460\u63d0\u5347\u6700\u5927\u651d\u6c27\u91cf\u3000\u2461\u4e0b\u964d\u5fc3\u7d5e\u75db\u95be\u503c\u3000\u2462\u6b21\u5927\u904b\u52d5\u6642\u5fc3\u7387\u8840\u58d3\u4e58\u7a4d\u4e0a\u5347\u3000\u2463\u6b21\u5927\u904b\u52d5\u6642\u52d5\u975c\u8108\u6c27\u5dee\u503c\u4e0a\u5347 \nA.\u2460\u2462\u00a0\nB.\u2461\u2463\nC.\u2460\u2463\nD.\u2461\u2462", "year": 113, "prof": "\u7269\u7406\u6cbb\u7642\u5e2b", "subject": "\u5fc3\u80ba\u75be\u75c5\u8207\u5c0f\u5152\u75be\u75c5\u7269"} -{"answer": "B", "question": "\u6709\u95dc\u6309\u6469\u624b\u6cd5\u4e2d\u8f15\u64ab\u6cd5\uff08effleurage\uff09\u7684\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f \nA.\u9808\u671d\u975c\u8108\u8207\u6dcb\u5df4\u6d41\u52d5\u7684\u65b9\u5411\u65bd\u884c\nB.\u52d5\u4f5c\u958b\u59cb\u6642\u65bd\u52a0\u6700\u5927\u58d3\u529b\uff0c\u7136\u5f8c\u9010\u6f38\u6e1b\u8f15\u529b\u91cf\u65bd\u884c\nC.\u6bcf\u6b21\u7684\u8f15\u64ab\u5747\u9808\u5728\u4e00\u500b\u660e\u78ba\u7684\u505c\u9813\u9ede\u7d50\u675f\nD.\u662f\u5c0d\u523a\u6fc0\u5faa\u74b0\u7279\u5225\u6709\u6548\u7684\u4e00\u7a2e\u624b\u6cd5", "year": 1111, "prof": "\u7269\u7406\u6cbb\u7642\u5e2b", "subject": "\u7269\u7406\u6cbb\u7642\u6280\u8853\u5b78"} -{"answer": "C", "question": "\u6cbb\u7642\u80f8\u5ed3\u51fa\u53e3\u75c7\u5019\u7fa4\uff08thoracic outlet syndrome\uff09\uff0c\u61c9\u8a13\u7df4\u4e0b\u5217\u4f55\u8005\u7684\u808c\u529b\uff1f \nA.\u659c\u89d2\u808c\uff08scaleni\uff09 \nB.\u9396\u9aa8\u4e0b\u808c\uff08subclavius\uff09 \nC.\u4e0a\u659c\u65b9\u808c\uff08upper trapezius\uff09 \nD.\u80f8\u5c0f\u808c\uff08pectoralis minor\uff09", "year": 1012, "prof": "\u7269\u7406\u6cbb\u7642\u5e2b", "subject": "\u9aa8\u79d1\u75be\u75c5\u7269\u7406\u6cbb\u7642\u5b78"} -{"answer": "C", "question": "C5\u5b8c\u5168\u6027\u810a\u9ad3\u640d\u50b7\u60a3\u8005\uff0c\u5df2\u53ef\u5b8c\u5168\u812b\u96e2\u547c\u5438\u5668\u81ea\u884c\u547c\u5438\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f \nA.\u5750\u59ff\u4e0b\u53ef\u4ee5\u7528\u6c23\u5e36\uff08pneumobelt\uff09\u4f86\u5354\u52a9\u5438\u5410\u6c23\u6642\u6a6b\u8188\u7684\u79fb\u52d5 \nB.\u975e\u4fb5\u5165\u6027\u7684\u9593\u6b47\u6b63\u58d3\u547c\u5438\u5668\u53ef\u4ee5\u589e\u52a0\u80f8\u5ed3\u6d3b\u52d5\u5ea6 \nC.\u53ef\u5229\u7528\u5438\u5410\u6c23\u6a5f\uff08mechanical insufflation / exsufflation\uff09\u4f86\u8a13\u7df4\u6a6b\u8188\u808c\u529b \nD.\u53ef\u4ee5\u7528\u624b\u58d3\u5f0f\u65b9\u5f0f\u4f86\u5354\u52a9\u5176\u54b3\u55fd", "year": 1021, "prof": "\u7269\u7406\u6cbb\u7642\u5e2b", "subject": "\u5fc3\u80ba\u75be\u75c5\u8207\u5c0f\u5152\u75be\u75c5\u7269"} -{"answer": "D", "question": "\u4e0b\u5217\u4f55\u8005\u662f\u810a\u690e\u77ef\u6b63\u8853\uff08spinal manipulation\uff09\u7684\u7d55\u5c0d\u7981\u5fcc\u75c7\uff1f \nA.\u61f7\u5b55\u5a66\u5973 \nB.\u9aa8\u8cea\u758f\u9b06\u7684\u75c5\u4eba \nC.\u7d93\u5e38\u4f7f\u7528\u985e\u56fa\u9187\u7684\u75c5\u4eba \nD.\u6025\u6027\u810a\u690e\u95dc\u7bc0\u767c\u708e", "year": 1062, "prof": "\u7269\u7406\u6cbb\u7642\u5e2b", "subject": "\u7269\u7406\u6cbb\u7642\u6280\u8853\u5b78"} -{"answer": "D", "question": "\u57fa\u862d\uff0d\u5df4\u745e\u5fb7\u6c0f\u75c7\u5019\u7fa4\u75c5\u60a3\u904b\u52d5\u8a13\u7df4\u904e\u7a0b\u4e2d\uff0c\u4e0b\u5217\u4f55\u8005\u4e26\u975e\u986f\u793a\u75c5\u60a3\u6709\u904e\u5ea6\u8a13\u7df4\u7684\u50be\u5411\uff1f \nA.\u8840\u6db2\u4e2d\u808c\u80fa\u9178\u6fc0\u9176\uff08creatine kinase\uff09\u6578\u503c\u4e0a\u5347 \nB.\u80a2\u9ad4\u5c40\u90e8\u767c\u751f\u7570\u5e38\u9ebb\u523a\u611f \nC.\u75b2\u4e4f\u6301\u7e8c\u4e00\u5929\u4ee5\u4e0a \nD.\u51fa\u73fe\u5614\u5410\u53cd\u5c04", "year": 1072, "prof": "\u7269\u7406\u6cbb\u7642\u5e2b", "subject": "\u795e\u7d93\u75be\u75c5\u7269\u7406\u6cbb\u7642\u5b78"} -{"answer": "D", "question": "\u9ad5\u9aa8\uff08patella\uff09\u5728\u9aa8\u7684\u5206\u985e\u4e2d\u662f\u5c6c\u65bc\uff1a \nA.\u9577\u9aa8\uff08long bone\uff09 \nB.\u6241\u5e73\u9aa8\uff08flat bone\uff09 \nC.\u4e0d\u898f\u5247\u9aa8\uff08irregular bone\uff09 \nD.\u7a2e\u5b50\u9aa8\uff08sesamoid bone\uff09", "year": 1061, "prof": "\u7269\u7406\u6cbb\u7642\u5e2b", "subject": "\u7269\u7406\u6cbb\u7642\u57fa\u790e\u5b78"} -{"answer": "A", "question": "\u95dc\u65bc\u4eba\u9ad4\u76ae\u819a\u4e2d\u6eab\u5ea6\u611f\u53d7\u5668\uff08thermoreceptors\uff09\u7684\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f \nA.\u51b7\u63a5\u53d7\u5668\uff08cold receptors\uff09\u4f4d\u65bc\u8f03\u6df1\u7684\u771f\u76ae\u5c64\uff08dermis\uff09\uff1b\u6eab\u63a5\u53d7\u5668\uff08warm receptors\uff09\u4e3b\u8981\u5206\u5e03\u65bc\u8868\u76ae\u5c64\n\uff08epidermis\uff09\u4e0b\u65b9\nB.\u51b7\u63a5\u53d7\u5668\uff08cold receptors\uff09\u7684\u9069\u7576\u63a5\u53d7\u7bc4\u570d\u70ba10\uff5e40\u2103\uff1b\u6eab\u63a5\u53d7\u5668\uff08warm receptors\uff09\u7684\u9069\u7576\u63a5\u53d7\u7bc4\u570d\u70ba30\uff5e\n45\u2103\uff1b\u6975\u51b7\u8207\u6975\u71b1\u5247\u6709\u75db\u7684\u611f\u89ba\nC.\u51b7\u89ba\u7531C\u578b\u8207A\u03b4\u795e\u7d93\u7e96\u7dad\u50b3\u905e\uff1b\u6eab\u89ba\u5247\u7531C\u578b\u795e\u7d93\u7e96\u7dad\u50b3\u905e\nD.\u6eab\u5ea6\u611f\u53d7\u5668\uff08thermoreceptors\uff09\u6709\u5f88\u5927\u7684\u9069\u61c9\u6027\uff08adaptation\uff09\uff0c\u53ef\u5e6b\u52a9\u4eba\u80fd\u6f38\u6f38\u8b8a\u5f97\u9069\u61c9\u65b0\u7684\u6eab\u5ea6\u74b0\u5883", "year": 1102, "prof": "\u7269\u7406\u6cbb\u7642\u5e2b", "subject": "\u7269\u7406\u6cbb\u7642\u57fa\u790e\u5b78"} -{"answer": "A", "question": "\u4e0b\u5217\u95dc\u65bc\u5167\u5206\u6ccc\u5668\u5b98\u7d44\u7e54\u7d50\u69cb\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f \nA.\u8166\u4e0b\u817a\u524d\u8449\u9060\u90e8\uff08pars distalis of anterior lobe\uff09\u7684\u5167\u5206\u6ccc\u7d30\u80de\u6703\u805a\u96c6\u5f62\u6210\u5713\u7403\u72c0\u7d50\u69cb\nB.\u814e\u4e0a\u817a\u76ae\u8cea\u675f\u72c0\u5e36\u7d30\u80de\uff08zona fasciculata of adrenal cortex\uff09\u6703\u805a\u96c6\u5f62\u6210\u5713\u7403\u72c0\u7d50\u69cb\nC.\u814e\u4e0a\u817a\u7684\u7403\u72c0\u5e36\uff08zona glomerulosa of adrenal cortex\uff09\u662f\u5728\u814e\u4e0a\u817a\u76ae\u8cea\u7684\u6700\u5167\u5c64\u9760\u8fd1\u9ad3\u8cea\uff08medulla\uff09\u7684\u90e8\u5206\nD.\u5728\u814e\u4e0a\u817a\u9ad3\u8cea\uff08adrenal medulla\uff09\u4e2d\uff0c\u55dc\u927b\u7d30\u80de\uff08chromaffin cells\uff09\u7684\u6392\u5217\u662f\u5448\u675f\u72c0\u7d50\u69cb", "year": 1102, "prof": "\u7269\u7406\u6cbb\u7642\u5e2b", "subject": "\u7269\u7406\u6cbb\u7642\u57fa\u790e\u5b78"} -{"answer": "C", "question": "\u5728\u767c\u5c55\u5e02\u5834\u884c\u92b7\u6642\uff0c\u9700\u5148\u8a55\u4f30\u4e00\u4e9b\u5916\u5728\u8207\u5167\u5728\u7684\u72c0\u6cc1\uff0c\u4e0b\u5217\u90a3\u500b\u73fe\u6cc1\u662f\u5c6c\u65bc\u5167\u5728\u72c0\u6cc1\uff1f \nA.\u7af6\u722d\u5c0d\u624b\nB.\u9867\u5ba2\nC.\u6a5f\u69cb\u8ca1\u52d9\nD.\u74b0\u5883", "year": 1022, "prof": "\u7269\u7406\u6cbb\u7642\u5e2b", "subject": "\u7269\u7406\u6cbb\u7642\u5b78\u6982\u8ad6"} -{"answer": "A", "question": "192Ir\uff08\u534a\u5316\u671f74\u5929\uff09\u7684\u6bd4\u6d3b\u5ea6\u7d04\u70ba\u591a\u5c11Ci/g\uff1f \nA.9289\nB.8790 \nC.7780 \nD.457.9", "year": 1092, "prof": "\u91ab\u4e8b\u653e\u5c04\u5e2b", "subject": "\u91ab\u5b78\u7269\u7406\u5b78\u8207\u8f3b\u5c04\u5b89\u5168"} -{"answer": "C", "question": "\u6709\u95dc\u8f38\u8840\u53cd\u61c9\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f \nA.\u6700\u5e38\u898b\u70ba\u767c\u71b1\u6027\u975e\u6eb6\u8840\u6027\u53cd\u61c9\uff08febrile nonhemolytic reaction\uff09\nB.\u5148\u524d\u81f4\u654f\u7684\u53d7\u8840\u8005\uff08sensitized recipients\uff09\uff0c\u53ef\u80fd\u6703\u767c\u751f\u56b4\u91cd\u7684\u904e\u654f\u53cd\u61c9\nC.\u6025\u6027\u6eb6\u8840\u53cd\u61c9\u6700\u5e38\u662f\u7531\u9810\u5148\u5f62\u6210\u7684 IgG \u6297\u9ad4\u5f15\u767c\nD.\u6703\u5f15\u8d77\u6025\u6027\u80ba\u640d\u50b7\uff0c\u751a\u81f3\u81f4\u6b7b", "year": 113, "prof": "\u91ab\u4e8b\u653e\u5c04\u5e2b", "subject": "\u57fa\u790e\u91ab\u5b78"} -{"answer": "C", "question": "\u5728\u8d85\u5c0e\u9ad4 MR \u78c1\u9ad4\u4e2d\uff0c\u7531\u5b54\u5f91\u5916\u5f80\u5167\u7684\u7dda\u5708\u9806\u5e8f\u70ba\u4f55\uff1f\u2460\u4e3b\u78c1\u5834\u7dda\u5708 \u2461\u68af\u5ea6\u7dda\u5708 \u2462\u5c04\u983b\u7dda\u5708 \u2463\u5c4f\u853d\u7dda\u5708 \nA.\u2460\u2461\u2462\u2463 \nB.\u2461\u2463\u2460\u2462 \nC.\u2463\u2460\u2461\u2462 \nD.\u2462\u2463\u2460\u2461", "year": 1121, "prof": "\u91ab\u4e8b\u653e\u5c04\u5e2b", "subject": "\u653e\u5c04\u7dda\u5668\u6750\u5b78"} -{"answer": "B", "question": "IRMA\u6aa2\u67e5\uff0c\u7576\u6297\u539f\u7684\u6fc3\u5ea6\u9ad8\u65bc\u67d0\u7bc4\u570d\u6642\uff0c\u6e2c\u91cf\u5230\u7684\u653e\u5c04\u6027\u5f37\u5ea6\u6703\u4e0b\u964d\uff0c\u9019\u7a2e\u6548\u61c9\u7a31\u70ba\uff1a \nA.decreasing effect \nB.hook effect \nC.convergent effect \nD.artificial effect", "year": 1002, "prof": "\u91ab\u4e8b\u653e\u5c04\u5e2b", "subject": "\u6838\u5b50\u91ab\u5b78\u8a3a\u7642\u539f\u7406\u8207\u6280"} -{"answer": "B", "question": "\u4e00\u822c\u800c\u8a00\uff0c\u76f4\u7dda\u52a0\u901f\u5668\u6240\u9644\u52a0\u7684physical wedge\uff0c\u5176\u89d2\u5ea6\u6709\u4e0b\u5217\u90a3\u5e7e\u7a2e\uff1f \nA.10\u00b0\u300120\u00b0\u300130\u00b0\u300140\u00b0 \nB.15\u00b0\u300130\u00b0\u300145\u00b0\u300160\u00b0 \nC.20\u00b0\u300130\u00b0\u300140\u00b0\u300160\u00b0 \nD.15\u00b0\u300125\u00b0\u300135\u00b0\u300145\u00b0", "year": 1021, "prof": "\u91ab\u4e8b\u653e\u5c04\u5e2b", "subject": "\u653e\u5c04\u7dda\u6cbb\u7642\u539f\u7406\u8207\u6280\u8853"} -{"answer": "D", "question": "\u9060\u8ddd\u653e\u5c04\u7dda\u5b78\uff08teleradiology\uff09\u7684\u904b\u4f5c\u6a21\u578b\u4e2d\uff0c\u4e0b\u5217\u4f55\u8005\u9700\u8981teleradiology management center\u4f5c\u70ba\u4e2d\u4ecb\uff1f \nA.off-hour reading\nB.ASP\uff08application service provider\uff09model\nC.web-based teleradiology\nD.pure teleradiology", "year": 1112, "prof": "\u91ab\u4e8b\u653e\u5c04\u5e2b", "subject": "\u653e\u5c04\u7dda\u8a3a\u65b7\u539f\u7406\u8207\u6280\u8853"} -{"answer": "C", "question": "\u7576X\u5149\u7ba1\u96fb\u58d3\u8abf\u6574\u8d85\u904e\u98fd\u548c\u96fb\u58d3\uff08saturation voltage\uff09\u6642\uff0c\u7ba1\u96fb\u6d41\u4e26\u4e0d\u6703\u56e0\u7ba1\u96fb\u58d3\u4e0a\u5347\u2f7d\u7dda\u6027\u4e0a\u5347\uff0c\u5176\u539f\u56e0\u70ba\u4f55\uff1f\nA.\u7dda\u6027\u805a\u7126\u539f\u7406\uff08line-focus principle\uff09\nB.\u71b1\u96e2\u2f26\u767c\u5c04\uff08thermionic emission\uff09\nC.\u7a7a\u9593\u96fb\u8377\u6548\u61c9\uff08space charge effect\uff09\nD.\u2f9c\u8ddf\u6548\u61c9\uff08heel effect\uff09", "year": 1081, "prof": "\u91ab\u4e8b\u653e\u5c04\u5e2b", "subject": "\u653e\u5c04\u7dda\u5668\u6750\u5b78"} -{"answer": "C", "question": "\u5c0d\u65bc\u5c3e\u690e\u7684\u651d\u5f71\u6558\u8ff0\u4f55\u8005\u6700\u6b63\u78ba\uff1f \nA.\u75c5\u4eba\u5e73\u8eba\uff0cX\u5149\u5411\u982d15\u5ea6\u5c04\u5411\u6065\u9aa8\u806f\u5408\u4e0b5\u516c\u5206 \nB.\u75c5\u4eba\u4fef\u81e5\uff0cX\u5149\u5411\u982d15\u5ea6\u76f4\u5c04\u6065\u9aa8\u806f\u5408 \nC.\u75c5\u4eba\u5e73\u8eba\uff0cX\u5149\u5411\u5c3e10\u5ea6\u5c04\u5411\u6065\u9aa8\u806f\u5408\u4e0a5\u516c\u5206 \nD.\u75c5\u4eba\u5074\u81e5\uff0cX\u5149\u5411\u5c3e10\u5ea6\u76f4\u5c04\u6065\u9aa8\u806f\u5408", "year": 1072, "prof": "\u91ab\u4e8b\u653e\u5c04\u5e2b", "subject": "\u653e\u5c04\u7dda\u8a3a\u65b7\u539f\u7406\u8207\u6280\u8853"} -{"answer": "A", "question": "\u5361\u6ce2\u2ec4\u2f52\u2f81\u7624\uff08Kaposi sarcoma\uff09\u7684\u767c\u2f63\u8207\u4e0b\u5217\u4f55\u7a2e\u75c5\u6bd2\u6700\u6709\u95dc\uff1f\nA.HHV-8\uff08human herpes virus-8\uff09\nB.EBV\uff08Epstein-Barr virus\uff09\nC.HPV\uff08human papillomavirus\uff09\nD.HSV\uff08herpes simplex virus\uff09", "year": 1081, "prof": "\u91ab\u4e8b\u653e\u5c04\u5e2b", "subject": "\u57fa\u790e\u91ab\u5b78"} -{"answer": "B", "question": "\u8f03\u5e38\u767c\u751f\u5728\u8179\u90e8\u4e3b\u52d5\u8108\uff0c\u4e14\u8f03\u6613\u5f62\u6210\u542b\u8840\u6813\u4e4b\u68ad\u72c0\u52d5\u8108\u7624\u70ba\uff1a \nA.\u6885\u6bd2\u6027\u52d5\u8108\u7624 \nB.\u52d5\u8108\u7ca5\u72c0\u786c\u5316\u6027\u52d5\u8108\u7624 \nC.\u4e3b\u52d5\u8108\u525d\u96e2\uff08aortic dissection\uff09 \nD.\u6f3f\u679c\u578b\u52d5\u8108\u7624\uff08berry aneurysm\uff09", "year": 1012, "prof": "\u91ab\u4e8b\u653e\u5c04\u5e2b", "subject": "\u57fa\u790e\u91ab\u5b78"} -{"answer": "D", "question": "\u4e0b\u5217\u4f55\u7a2e\u75be\u75c5\u7684\u9aa8\u9ad3\u4e2d\u4e4bmegakaryocyte\u901a\u5e38\u6703\u6e1b\u5c11\uff1f \nA.Disseminated intravascular coagulation\uff08DIC\uff09\nB.Thrombotic thrombocytopenic purpura\uff08TTP\uff09\nC.Immune thrombocytopenic purpura\uff08ITP\uff09\nD.Aplastic anemia", "year": 1091, "prof": "\u91ab\u4e8b\u6aa2\u9a57\u5e2b", "subject": "\u81e8\u5e8a\u8840\u6db2\u5b78\u8207\u8840\u5eab\u5b78"} -{"answer": "C", "question": "\u6703\u9670\u90e8\u7684\u5c16\u572d\u6fd5\u75a3\uff08condyloma acuminatum\uff09\uff0c\u8207\u4e0b\u5217\u4f55\u8005\u6700\u6709\u95dc\uff1f \nA.\u6dcb\u75c5\uff08gonorrhea\uff09\nB.\u4eba\u985e\u75b1\u75b9\u75c5\u6bd2\uff08human herpes virus\uff09\nC.\u4eba\u985e\u4e73\u7a81\u7624\u75c5\u6bd2\uff08human papillomavirus\uff09\nD.\u675c\u514b\u96f7\u55dc\u8840\u687f\u83cc\uff08Haemophilus ducreyi\uff09", "year": 1092, "prof": "\u91ab\u4e8b\u6aa2\u9a57\u5e2b", "subject": "\u81e8\u5e8a\u751f\u7406\u5b78\u8207\u75c5\u7406\u5b78"} -{"answer": "D", "question": "\u75f0\u6db2\u5448\u7070\u8272\u6216\u7565\u5e36\u68d5\u8272\uff0c\u6700\u6709\u53ef\u80fd\u7684\u539f\u56e0\u70ba\u4f55\uff1f \nA.\u7d30\u83cc\u611f\u67d3 \nB.\u9ef4\u83cc\u611f\u67d3 \nC.\u80ba\u7d50\u6838 \nD.\u62bd\u7159", "year": 1032, "prof": "\u91ab\u4e8b\u6aa2\u9a57\u5e2b", "subject": "\u91ab\u5b78\u5206\u5b50\u6aa2\u9a57\u5b78\u8207\u81e8\u5e8a"} -{"answer": "D", "question": "\u4e0b\u5217\u4f55\u7a2e\u57fa\u56e0\u7f3a\u9677\u901a\u5e38\u4e0d\u6703\u5f15\u8d77severe combined immunodeficiency\uff08SCID\uff09\uff1f \nA.ADA\uff08adenosine deaminase\uff09 \nB.RAG1/2\uff08recombinase activating gene\uff09 \nC.Cytokine receptor common gamma chain \nD.G-6PD\uff08glucose-6 phosphate dehydrogenase\uff09", "year": 1072, "prof": "\u91ab\u4e8b\u6aa2\u9a57\u5e2b", "subject": "\u81e8\u5e8a\u8840\u6e05\u514d\u75ab\u5b78\u8207\u81e8\u5e8a"} -{"answer": "D", "question": "\u95dc\u65bc\u687f\u83cc\u6027\u8840\u7ba1\u7624\uff08bacillary angiomatosis\uff09\u7684\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u6b63\u78ba\uff1f \nA.\u662f\u7531\u97d3\u745f\u52d2\u5df4\u901a\u6c0f\u83cc\uff08Bartonella henselae\uff09\u5f15\u8d77\u7684\u60e1\u6027\u8840\u7ba1\u816b\u7624\nB.\u4e3b\u8981\u767c\u751f\u5728\u5065\u5eb7\u6210\u4eba\u88ab\u8c93\u6293\u5230\u5f8c\u5f15\u8d77\u7684\u6162\u6027\u611f\u67d3\u5f8c\u6240\u81f4\nC.\u75c5\u8b8a\u7684\u539f\u56e0\u662f\u88ab\u6d3b\u5316\u7684\uff34\u6dcb\u5df4\u7d30\u80de\u7522\u751f\u5e72\u64fe\u7d20-\u03b3\uff08interferon-\u03b3\uff09\uff0c\u85c9\u7531\u6d3b\u5316\u5de8\u566c\u7d30\u80de\uff08macrophage\uff09\u523a\u6fc0\u8840\n\u7ba1\u5167\u76ae\u7d30\u80de\u589e\u751f\nD.\u7528\u6297\u751f\u7d20\u6cbb\u7642\u53ef\u6cbb\u7652", "year": 1112, "prof": "\u91ab\u4e8b\u6aa2\u9a57\u5e2b", "subject": "\u81e8\u5e8a\u751f\u7406\u5b78\u8207\u75c5\u7406\u5b78"} -{"answer": "A", "question": "\u95dc\u65bc\u5fae\u6d41\u9ad4\u6676\u7247\uff08Microfluidic chip\uff09\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6b63\u78ba\uff1f \nA.\u53ef\u5c07PCR\u53cd\u61c9\u7684\u6642\u9593\u7531\u6578\u5c0f\u6642\u7e2e\u77ed\u81f3\u6578\u5341\u5206\u9418 \nB.\u53ef\u898b\u5149\u9175\u7d20\u5448\u8272\u6cd5\u662f\u76ee\u524d\u6240\u7528\u4e3b\u8981\u7684\u5075\u6e2c\u65b9\u6cd5 \nC.\u6d41\u9ad4\u7684\u63a7\u5236\u4e00\u5b9a\u9700\u85c9\u7531\u555f\u52d5\u6a5f\uff08Actuator\uff09\u4f86\u8abf\u63a7 \nD.\u4e7e\u8755\u523b\uff08Dry etching\uff09\u662f\u4ee5\u5316\u5b78\u8755\u523b\u5291\uff08Chemical etchant\uff09\u8655\u7406\uff0c\u53ef\u5f97\u8f03\u65b9\u6b63\u7684\u69cb\u5f62\u7ba1\u9053", "year": 1071, "prof": "\u91ab\u4e8b\u6aa2\u9a57\u5e2b", "subject": "\u91ab\u5b78\u5206\u5b50\u6aa2\u9a57\u5b78\u8207\u81e8\u5e8a"} -{"answer": "C", "question": "\u4e00\u822c\u800c\u8a00\uff0c\u4e0b\u5217\u4f55\u7a2e\u6aa2\u9ad4\u8f03\u9069\u5408\u64cd\u4f5c\u53ad\u6c27\u83cc\u57f9\u990a\uff1f \nA.\u75f0\u6db2\nB.\u4e2d\u6bb5\u5c3f\nC.\u80f8\u808b\u819c\u6db2\nD.\u9670\u9053\u5206\u6ccc\u7269", "year": 113, "prof": "\u91ab\u4e8b\u6aa2\u9a57\u5e2b", "subject": "\u5fae\u751f\u7269\u5b78\u8207\u81e8\u5e8a\u5fae\u751f\u7269"} -{"answer": "A", "question": "\u95dc\u65bczanamivir\u6291\u5236\u6d41\u611f\u75c5\u6bd2\u4e4b\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f \nA.\u7121\u6cd5\u6291\u5236B\u578b\u6d41\u611f\u75c5\u6bd2 \nB.\u70baneuraminidase\u4e4b\u6291\u5236\u5291 \nC.\u53ef\u6709\u6548\u6291\u5236\u65b0\u578bH1N1\u6d41\u611f\u75c5\u6bd2\u3014A\uff08H1N1\uff09pdm09\u3015 \nD.\u901a\u5e38\u5728\u767c\u751f\u6d41\u611f\u75c7\u72c048\u5c0f\u6642\u5167\u7d66\u4e88\u6b64\u985e\u85e5\u7269\u624d\u53ef\u6709\u6548\u6cbb\u7642", "year": 1072, "prof": "\u91ab\u4e8b\u6aa2\u9a57\u5e2b", "subject": "\u81e8\u5e8a\u8840\u6e05\u514d\u75ab\u5b78\u8207\u81e8\u5e8a"} -{"answer": "A", "question": "\u4e0b\uf99c\u4f55\u8005\uf967\u662f\u9020\u6210\uf953\u819c\u8154\u7a4d\u6c34\u7684\u539f\u56e0\uff1f \nA. \u5fae\u8840\u7ba1\u901a\u900f\u6027\u6e1b\u5c11 \n \nB. \u5fae\u8840\u7ba1\u6db2\u9ad4\u975c\u6c34\u58d3\uf98a\u589e\u52a0 \nC. \u5fae\u8840\u7ba1\u81a0\u9ad4\u6ef2\u900f\u58d3\u6e1b\u5c11 \nD. \uf9f5\u5df4\u7ba1\u518d\u5438\u6536\u6e1b\u5c11", "year": 1001, "prof": "\u91ab\u4e8b\u6aa2\u9a57\u5e2b", "subject": "\u81e8\u5e8a\u93e1\u6aa2\u5b78"} -{"answer": "C", "question": "\u8840\u6f3f\u4ea4\u63db\u8853\uff0c\u5b8c\u6210\u4e00\u500b\u8840\u6db2\u9ad4\u7a4d\u4e4b\u7f6e\u63db\u5f8c\uff0c\u539f\u8840\u6db2\u4e2d\u4e4b\u6210\u5206\u9810\u4f30\u5269\u9918\u591a\u5c11%\uff1f \nA.70 \nB.50 \nC.30 \nD.10", "year": 1031, "prof": "\u91ab\u4e8b\u6aa2\u9a57\u5e2b", "subject": "\u81e8\u5e8a\u8840\u6db2\u5b78\u8207\u8840\u5eab\u5b78"} -{"answer": "D", "question": "\u6b63\u5e38\u541e\u56a5\u904e\u7a0b\u4e2d\uff0c\u6709\u95dc\u54bd\u90e8\u968e\u6bb5\uff08pharyngeal stage\uff09\u4e4b\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u6b63\u78ba\uff1f \nA.\u8072\u5e36\uff08vocal cords\uff09\u6253\u958b\uff0c\u8b93\u98df\u7269\u9806\u5229\u901a\u904e\nB.\u6b63\u5e38\u50b3\u9001\u6642\u9593\u70ba5\u79d2\nC.\u5589\u90e8\u4e0b\u964d\uff0c\u6703\u53ad\u4e0a\u5347\nD.\u547c\u5438\u6703\u77ed\u66ab\u505c\u6b62", "year": 1112, "prof": "\u8077\u80fd\u6cbb\u7642\u5e2b", "subject": "\u751f\u7406\u969c\u7919\u8077\u80fd\u6cbb\u7642\u5b78"} -{"answer": "A", "question": "\u6709\u95dc\u300c\u5fa9\u5065\u7684\u529f\u80fd\u8207\u74b0\u5883\u7684\u5b89\u5168\u6027\u8a55\u91cf\u300d\uff08Safety Assessment of Function and the Environment for Rehabilitation\uff09\u7684\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u6b63\u78ba\uff1f \nA.\u5305\u542b\u500b\u6848\u662f\u5426\u4f7f\u7528\u8a18\u61b6\u7684\u8f14\u5177\uff0c\u5982\u9b27\u9418 \nB.\u4e0d\u5305\u542b\u500b\u6848\u4f7f\u7528\u5927\u773e\u4ea4\u901a\u904b\u8f38\u5de5\u5177\u7684\u72c0\u6cc1 \nC.\u5305\u542b\u500b\u6848\u95dc\u7bc0\u6d3b\u52d5\u5ea6 \nD.\u4e0d\u5305\u542b\u4f11\u9592\u6d3b\u52d5\u53c3\u8207", "year": 1021, "prof": "\u8077\u80fd\u6cbb\u7642\u5e2b", "subject": "\u8077\u80fd\u6cbb\u7642\u6280\u8853\u5b78"} -{"answer": "B", "question": "\u4e0b\u5217\u4f55\u9805\u56e0\u7d20\u5c07\u5f71\u97ff\u7368\u7acb\u65bc\u793e\u5340\u74b0\u5883\u4e2d\u4f7f\u7528\u8f2a\u6905\u7684\u80fd\u529b\uff1f\u2460\u53ef\u57f7\u884c\u9032\u51fa\u9580\u64cd\u4f5c \u2461\u5f9e\u4ea4\u901a\u5de5\u5177\u4e2d\u88dd\u8f09\u53ca\u5378\u9664\u8f2a\u6905 \u2462\u6709\u80fd\u529b\u65bc1\uff1a20\u4e4b\u659c\u5761\u9032\u884c\u4e0a\u4e0b\u5761\u64cd\u4f5c \u2463\u4e0d\u540c\u5e73\u9762\u4e4b\u8f2a\u6905\u8f49\u4f4d \u2464\u638c\u63e1\u4fdd\u990a\u8207\u7dad\u4fee\u8f2a\u6905\u4e4b\u8cc7\u8a0a \nA.\u2460\u2461\u2462\u2463\nB.\u2460\u2461\u2463\u2464\nC.\u50c5\u2460\u2461\u2463\nD.\u2462\u2464", "year": 1092, "prof": "\u8077\u80fd\u6cbb\u7642\u5e2b", "subject": "\u8077\u80fd\u6cbb\u7642\u6280\u8853\u5b78"} -{"answer": "B", "question": "\u5c0f\u7f8e\u70ba\u7cbe\u795e\u5206\u88c2\u75c7\u60a3\u8005\uff0c\u8b1b\u8a71\u6642\u5e38\u51fa\u73fe\u820c\u982d\u8f15\u5ea6\u4e0d\u81ea\u4e3b\u7684\u5410\u51fa\uff0c\u6216\u5634\u5df4\u5e38\u505a\u5480\u56bc\u72c0\uff0c\u6b64\u70ba\u4f55\u7a2e\u73fe\u8c61\uff1f \nA.\u6025\u6027\u808c\u5f35\u529b\u7570\u5e38\uff08acute dystonia\uff09 \nB.\u9072\u767c\u6027\u4e0d\u81ea\u4e3b\u904b\u52d5\uff08tardive dyskinesia\uff09 \nC.\u975c\u5750\u4e0d\u80fd\uff08akathisia\uff09 \nD.\u5e15\u91d1\u68ee\u6c0f\u986b\u6296\uff08Parkinsonian tremor\uff09", "year": 1012, "prof": "\u8077\u80fd\u6cbb\u7642\u5e2b", "subject": "\u5fc3\u7406\u969c\u7919\u8077\u80fd\u6cbb\u7642\u5b78"} -{"answer": "C", "question": "\u65b9\u6848\u7d50\u69cb\uff08program structure\uff09\u662f\u65b9\u6848\u8a55\u4f30\u9805\u76ee\u4e4b\u4e00\uff0c\u4e0b\u5217\u4f55\u8005\u4e0d\u5c6c\u65bc\u65b9\u6848\u7d50\u69cb\u4e4b\u5167\u5bb9\uff1f \nA.\u8a2d\u5099\u5668\u6750\nB.\u5834\u5730\u8207\u4eba\u529b\u8cc7\u6e90\nC.\u4ecb\u5165\u7684\u6d3b\u52d5\u5167\u5bb9\u8a2d\u8a08\nD.\u9810\u7b97\u8207\u7d93\u8cbb", "year": 1122, "prof": "\u8077\u80fd\u6cbb\u7642\u5e2b", "subject": "\u8077\u80fd\u6cbb\u7642\u5b78\u6982\u8ad6"} -{"answer": "B", "question": "\u9935\u5976\u6642\uff0c\u63d0\u4f9b\u81c9\u9830\u652f\u6301\uff08cheek support\uff09\u7684\u76ee\u7684\u6709\u90a3\u4e9b\uff1f\u2460\u589e\u52a0\u5438\u542e\u6b63\u58d3 \u2461\u589e\u52a0\u5438\u542e\u8ca0\u58d3 \u2462\u4fc3\u9032\u5634\u5507\u548c\u5976\u5634\u7684\u5bc6\u5408 \u2463\u63d0\u4f9b\u58d3\u89ba\u4ee5\u6e1b\u654f\u611f \nA.\u2460\u2462\nB.\u2461\u2462\nC.\u2460\u2463\nD.\u2461\u2463", "year": 1112, "prof": "\u8077\u80fd\u6cbb\u7642\u5e2b", "subject": "\u5c0f\u5152\u8077\u80fd\u6cbb\u7642\u5b78"} -{"answer": "C", "question": "\u6709\u95dc\u5c07\u793e\u5340\u95dc\u61f7\u64da\u9ede\u7684\u9577\u8f29\u5b78\u6703\u901a\u8a0a\u8edf\u9ad4\u7684\u61c9\u7528\u4f5c\u70ba\u4e00\u500b\u65b9\u6848\u7684\u65b9\u91dd\uff0c\u4ee5SMART\u5206\u6790\u6642\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f\nA.S\uff0d\u4e0d\u5920\u660e\u78ba\uff0c\u6c92\u6709\u8aaa\u660e\u662f\u90a3\u4e00\u7a2e\u901a\u8a0a\u8edf\u9ad4\uff1f\u624b\u6a5f\u6216\u662f\u96fb\u8166\uff1f\nB.M\uff0d\u4e0d\u80fd\u6e2c\u91cf\uff0c\u4e0d\u77e5\u5982\u4f55\u754c\u5b9a\u5b78\u6703\u61c9\u7528\u662f\u5426\u9054\u6a19\uff1f\nC.T\uff0d\u6709\u660e\u78ba\u6307\u51fa\u662f\u793e\u5340\u95dc\u61f7\u64da\u9ede\u7684\u9577\u8f29\uff0c\u662f\u672c\u65b9\u6848\u7684\u5c0d\u8c61\nD.R\uff0d\u662f\u793e\u5340\u9577\u8f29\u751f\u6d3b\u4e2d\u6709\u9700\u8981\u7684\u4e8b\u9805", "year": 1091, "prof": "\u8077\u80fd\u6cbb\u7642\u5e2b", "subject": "\u8077\u80fd\u6cbb\u7642\u6280\u8853\u5b78"} -{"answer": "A", "question": "\u4e0b\u5217\u6709\u95dc\u611f\u89ba\u5340\u8fa8\uff08sensory discrimination\uff09\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f \nA.\u6307\u500b\u9ad4\u89e3\u91cb\u53ca\u8fa8\u5225\u611f\u89ba\u8a0a\u606f\u5728\u6642\u9593\u8207\u7a7a\u9593\u4e4b\u6027\u8cea\u7684\u80fd\u529b \nB.\u9ad4\u611f\u89ba\u5340\u8fa8\uff08somatosensory discrimination\uff09\u6307\u524d\u5ead\u89ba\u5340\u8fa8\u548c\u672c\u9ad4\u89ba\u5340\u8fa8 \nC.\u500b\u9ad4\u8eab\u9ad4\u57fa\u6a21\u4e4b\u767c\u5c55\u4e3b\u8981\u4ef0\u8cf4\u65bc\u524d\u5ead\u89ba\u5340\u8fa8\u548c\u89f8\u89ba\u5340\u8fa8 \nD.\u524d\u5ead\u89ba\u5340\u8fa8\u8b93\u500b\u9ad4\u4e86\u89e3\u52d5\u4f5c\u6642\u80a2\u9ad4\u65bd\u529b\u4e4b\u5927\u5c0f\u53ca\u65b9\u5411", "year": 1051, "prof": "\u8077\u80fd\u6cbb\u7642\u5e2b", "subject": "\u5c0f\u5152\u8077\u80fd\u6cbb\u7642\u5b78"} -{"answer": "C", "question": "\u8077\u80fd\u6cbb\u7642\u5e2b\u53ef\u4ee5\u2f64\u8a31\u591a\u2f45\u5f0f\u5354\u52a9\u5152\u7ae5\u5b78\u7fd2\u66f8\u5beb\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA.\u53ef\u4f7f\u2f64\u5782\u76f4\u7684\u5e73\u2faf\u66f8\u5beb\u4ee5\u4fc3\u9032\u63e1\u7b46\u59ff\u52e2\nB.\u6163\u2f64\u53f3\u2f3f\u8005\uff0c\u5c07\u7d19\u7684\u4e0a\u2f45\u5411\u5de6\u659c\u653e25\uff5e30\u5ea6\nC.\u2f54\u5e73\u684c\u2faf\u7684\u2fbc\u5ea6\u4f4e\u65bc\u2f3f\u8098\u5c48\u66f290\u5ea6\u4e4b\u4f4d\u7f6e2\u540b\nD.\u5229\u2f64\u6709\u683c\u7dda\u7684\u7d19\u5f35\u53ef\u589e\u9032\u5152\u7ae5\u66f8\u5beb\u7684\u53ef\u8fa8\u8b58\u5ea6\uff08legibility\uff09", "year": 1081, "prof": "\u8077\u80fd\u6cbb\u7642\u5e2b", "subject": "\u5c0f\u5152\u8077\u80fd\u6cbb\u7642\u5b78"} -{"answer": "B", "question": "\u6709\u95dc\u6708\u7d93\u5468\u671f\u8b8a\u5316\u8207\u6fc0\u7d20\u95dc\u806f\u6027\u7684\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f \nA.\u9ec3\u9ad4\u523a\u6fc0\u7d20\uff08LH\uff09\u5728\u6392\u5375\u524d\u7684\u5927\u91cf\u5206\u6ccc\uff0c\u662f\u9020\u6210\u6392\u5375\u7684\u4e3b\u8981\u539f\u56e0 \nB.\u52d5\u60c5\u7d20\uff08estrogen\uff09\u53ea\u6703\u5728\u6ffe\u6ce1\u671f\u5206\u6ccc \nC.\u6ffe\u6ce1\u58c1\u4e4b\u9846\u7c92\u7d30\u80de\uff08granulosa cell\uff09\u5206\u6ccc\u7684\u52d5\u60c5\u7d20\u8207\u5375\u7684\u767c\u80b2\u6210\u719f\u6709\u95dc \nD.\u9ec3\u9ad4\u7d20\uff08progesterone\uff09\u53ea\u6703\u5728\u9ec3\u9ad4\u671f\u5206\u6ccc", "year": 1032, "prof": "\u8077\u80fd\u6cbb\u7642\u5e2b", "subject": "\u89e3\u5256\u5b78\u8207\u751f\u7406\u5b78"} -{"answer": "C", "question": "\u53ef\u4ee5\u540c\u6642\u5728\u7d30\u80de\u819c\u4e0a\u63d0\u4f9b\u89aa\u6c34\uff08hydrophilic\uff09\u53ca\u89aa\u8102\uff08hydrophobic\uff09\u7279\u6027\u7684\u7269\u8cea\u70ba\u4f55\uff1f\u2460phosphatidylethanolamine \u2461sphingomyelin \u2462cerebroside \u2463ganglioside \u2464cholesteryl ester \nA.\u50c5\u2460\u2462\u2463 \nB.\u50c5\u2461\u2464 \nC.\u50c5\u2460\u2461\u2462\u2463 \nD.\u2460\u2461\u2462\u2463\u2464", "year": 1062, "prof": "\u7259\u91ab\u5e2b", "subject": "\u7259\u91ab\u5b78(\u4e00)"} -{"answer": "D", "question": "\u4e0b\u5217\u4f55\u8005\u4e0d\u662f\u982d\u9838\u90e8\u653e\u5c04\u7dda\u6cbb\u7642\u9020\u6210\u4e4b\u526f\u4f5c\u7528\uff1f \nA.\u9ecf\u819c\u708e\uff08mucositis\uff09 \nB.\u7259\u95dc\u7dca\u9589\uff08trismus\uff09 \nC.\u653e\u5c04\u7dda\u6027\u9aa8\u58de\u6b7b\uff08osteoradionecrosis\uff09 \nD.\u904e\u5ea6\u6d41\u6d8e\uff08excessive salivation\uff09", "year": 1041, "prof": "\u7259\u91ab\u5e2b", "subject": "\u7259\u91ab\u5b78(\u4e8c)"} -{"answer": "C", "question": "\u4e0b\u5217\u9020\u6210\u6025\u6027\u7570\u5e38\u54ac\u5408\uff08acute malocclusion\uff09\u7684\u6558\u8ff0\u4f55\u8005\u6b63\u78ba\uff1f\u2460\u4e0a\u5916\u7ffc\u808c\uff08superior lateral pterygoidmuscle\uff09\u808c\u8089\u75d9\u6523\uff08muscle spasm\uff09\uff0c\u9020\u6210\u540c\u5074\u5f8c\u7259\u7121\u63a5\u89f8 \u2461\u5167\u7ffc\u808c\uff08medial pterygoid muscle\uff09\u808c\u8089\u75d9\u6523\uff08muscle spasm\uff09\uff0c\u9020\u6210\u540c\u5074\u5f8c\u7259\u7121\u63a5\u89f8 \u2462\u9873\u984e\u95dc\u7bc0\u95dc\u7bc0\u8154\u6ce8\u5c04\u73bb\u5c3f\u9178\uff0c\u9020\u6210\u540c\u5074\u5f8c\u7259\u7121\u63a5\u89f8 \u2463\u95dc\u7bc0\u76e4\u5f8c\u708e\uff08retrodiscitis\uff09\uff0c\u9020\u6210\u540c\u5074\u5f8c\u7259\u7121\u63a5\u89f8 \nA.\u50c5\u2460\u2462\nB.\u2461\u2463\nC.\u2462\u2463\nD.\u2460\u2461\u2462", "year": 1121, "prof": "\u7259\u91ab\u5e2b", "subject": "\u7259\u91ab\u5b78(\u4e94)"} -{"answer": "C", "question": "\u4e0b\u5217\u4f55\u7a2e\u72c0\u6cc1\u5728\u77ef\u6b63\u5b8c\u6210\u5f8c\u4e00\u5b9a\u9700\u8981\u4f7f\u7528\u6c38\u4e45\u56fa\u5b9a\u6027\u7684\u7dad\u6301\u5668\uff1f \nA.\u7259\u9f52\u56b4\u91cd\u65cb\u8f49\u7684\u6210\u4eba\u75c5\u60a3\nB.\u5b89\u683c\u6c0f\u4e8c\u7d1a\u54ac\u5408\u4e0d\u6b63\u4e14\u62d4\u7259\u6cbb\u7642\u7684\u75c5\u60a3\nC.\u5177\u6709\u5ee3\u6cdb\u6027\u9f52\u9593\u5206\u958b\uff08generalized spacing\uff09\u7684\u75c5\u60a3\nD.\u6cbb\u7642\u4e2d\u9700\u7259\u5f13\u64f4\u5f35\uff08expansion\uff09\u7684\u75c5\u60a3", "year": 1002, "prof": "\u7259\u91ab\u5e2b", "subject": "\u7259\u91ab\u5b78(\u516d)"} -{"answer": "D", "question": "\u4e0b\u5217\u90a3\u7a2e\u89e3\u5256\u7d50\u69cb\u5728\u81e8\u5e8a\u8f03\u4e0d\u5bb9\u6613\u89f8\u6478\u5230\uff1f \nA.\u4e0b\u984e\u679d\u524d\u7de3\u5916\u659c\u7dda\uff08external oblique line\uff09 \nB.\u524d\u5ead\u7a79\u7abf\uff08fornix vestibuli\uff09 \nC.\u9826\u808c\uff08mentalis muscle\uff09 \nD.\u4e0b\u984e\u5b54\uff08mandibular foramen\uff09", "year": 1041, "prof": "\u7259\u91ab\u5e2b", "subject": "\u7259\u91ab\u5b78(\u4e00)"} -{"answer": "C", "question": "\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f \nA.dextran\u5177\u6709\u03b1\uff081\u21924\uff09\u9375\u53ca\u03b1\uff081\u21926\uff09\u9375 \nB.glycogen\u5177\u6709\u03b1\uff081\u21924\uff09\u9375\u53ca\u03b1\uff081\u21926\uff09\u9375 \nC.amylose\u5177\u6709\u03b1\uff081\u21924\uff09\u9375\u53ca\u03b1\uff081\u21926\uff09\u9375 \nD.amylopectin\u5177\u6709\u03b1\uff081\u21924\uff09\u9375\u53ca\u03b1\uff081\u21926\uff09\u9375", "year": 1012, "prof": "\u7259\u91ab\u5e2b", "subject": "\u7259\u91ab\u5b78(\u4e00)"} -{"answer": "C", "question": "\u7576\u75c5\u4eba\u9032\u884c\u963b\u751f\u9f52\u624b\u8853\u524d\uff0c\u6709\u4e0b\u5217\u4f55\u7a2e\u60c5\u6cc1\u6642\uff0c\u6700\u9700\u7d66\u8207\u9810\u9632\u6027\u6297\u751f\u7d20\uff1f \nA.\u63a5\u53d7\u904e\u51a0\u72c0\u52d5\u8108\u652f\u67b6\u690d\u5165 \nB.\u63a5\u53d7\u904e\u51a0\u72c0\u52d5\u8108\u7e5e\u9053\u624b\u8853 \nC.\u66fe\u7d93\u60a3\u6709\u611f\u67d3\u6027\u5fc3\u5167\u819c\u708e\uff0c\u73fe\u5df2\u75ca\u7652 \nD.\u88dd\u7f6e\u5fc3\u81df\u7bc0\u5f8b\u5668", "year": 1112, "prof": "\u7259\u91ab\u5e2b", "subject": "\u7259\u91ab\u5b78(\u4e8c)"} -{"answer": "D", "question": "\u4f9d\u64daSocransky\u7b49\u5b78\u8005\u91dd\u5c0d\u7259\u9f66\u4e0b\u7259\u83cc\u6591\u5fae\u751f\u7269\u7d44\u5408\u7269\uff08microbial complexes\uff09\u7684\u7814\u7a76\uff0c\u4e0b\u5217\u90a3\u7a2e\u7d30\u83cc\u5c6c\u65bcorange complex species\uff1f \nA.V. parvula \nB.E. corrodens \nC.S. sanguis \nD.F. nucleatum", "year": 1031, "prof": "\u7259\u91ab\u5e2b", "subject": "\u7259\u91ab\u5b78(\u4e09)"} -{"answer": "D", "question": "\u771f\u6838\u7d30\u80de\u5229\u7528\u4e0b\u5217\u90a3\u4e00\u7a2e\u6838\u7cd6\u6838\u9178\u805a\u5408\u9176\uff08RNA polymerase\uff09\u5408\u6210\u6240\u6709\u7684\u50b3\u905e\u6838\u7cd6\u6838\u9178\uff08tRNA\uff09\u5206\u5b50\uff1f \nA.\u591a\u817a\u82f7\u9178\u805a\u5408\u9176\uff08poly(A) polymerase\uff09\nB.\u7b2c\u4e00\u578b\u6838\u7cd6\u6838\u9178\u805a\u5408\u9176\uff08RNA polymerase I\uff09\nC.\u7b2c\u4e8c\u578b\u6838\u7cd6\u6838\u9178\u805a\u5408\u9176\uff08RNA polymerase II\uff09\nD.\u7b2c\u4e09\u578b\u6838\u7cd6\u6838\u9178\u805a\u5408\u9176\uff08RNA polymerase III\uff09", "year": 1101, "prof": "\u7259\u91ab\u5e2b", "subject": "\u7259\u91ab\u5b78(\u4e00)"} -{"answer": "A", "question": "\u95dc\u65bc\u6297\u751f\u7d20\u624b\u8853\u9810\u9632\u7642\u6cd5\u539f\u5247\u7684\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f \nA.\u61c9\u4f7f\u7528\u5ee3\u6548\u6297\u751f\u7d20\uff0c\u4ee5\u6c42\u6709\u6548\u6291\u5236\u7f55\u898b\u7684\u624b\u8853\u50b7\u53e3\u4e4b\u75c5\u539f\u83cc\nB.\u82e5\u6240\u6709\u689d\u4ef6\u7686\u5747\u7b49\u6642\uff0c\u61c9\u9078\u64c7\u4f7f\u7528\u50f9\u683c\u6700\u4f4e\u7684\u85e5\u7269\nC.\u7642\u7a0b\u5118\u53ef\u80fd\u7e2e\u77ed\uff0c\u6700\u7406\u60f3\u7684\u60c5\u6cc1\u662f\u50c5\u4f7f\u7528\u4e00\u6b21\u5291\u91cf\nD.\u65b0\u578b\u7684\u5ee3\u6548\u6297\u751f\u7d20\u5fc5\u9808\u4e88\u4ee5\u4fdd\u7559\uff0c\u4ee5\u63d0\u4f9b\u6297\u85e5\u6027\u83cc\u7a2e\u611f\u67d3\u7684\u6cbb\u7642", "year": 1102, "prof": "\u7259\u91ab\u5e2b", "subject": "\u7259\u91ab\u5b78(\u4e8c)"} -{"answer": "B", "question": "\u6709\u95dc\u4f4e\u5f35\u6027\u529f\u80fd\u4e0d\u826f\u5206\u5a29\u7684\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u6b63\u78ba\uff1f \nA.\u5b50\u5bae\u6536\u7e2e\u77ed\u4e14\u5f37\u5ea6\u5dee\uff0c\u4f46\u6301\u7e8c\u6642\u9593\u9577 \nB.\u901a\u5e38\u767c\u751f\u65bc\u5206\u5a29\u6d3b\u52d5\u671f\uff0c\u5b50\u5bae\u808c\u8089\u904e\u5ea6\u4f38\u5c55\uff0c\u4f7f\u6536\u7e2e\u529b\u8b8a\u5dee \nC.\u901a\u5e38\u56e0\u5b50\u5bae\u808c\u8089\u904e\u5ea6\u4f38\u5c55\uff0c\u800c\u51fa\u73fe\u80ce\u5152\u52d5\u8108\u8840\u6c27\u904e\u5c11\u7684\u60c5\u5f62 \nD.\u5b50\u5bae\u767c\u751f\u4f4e\u5f35\u6027\u529f\u80fd\u4e0d\u826f\u6642\uff0c\u56e0\u6536\u7e2e\u5f37\uff0c\u9020\u6210\u7522\u5a66\u75b2\u5026\u4e0d\u9069", "year": 1052, "prof": "\u52a9\u7522\u5e2b", "subject": "\u52a9\u7522\u5b78\uff08\u4e8c\uff09"} -{"answer": "C", "question": "\u4e00\u500b\u542b\u6709\u6e90\u81ea\u65bc\u4e09\u500b\u4e0d\u540c\u80da\u5c64\uff08germ layer\uff09\u7d44\u7e54\u7684\u816b\u7624\u7a31\u70ba\uff1a \nA.\u591a\u5f62\u6027\u817a\u7624\uff08pleomorphic adenoma\uff09 \nB.\u6df7\u5408\u7624\uff08mixed tumor\uff09 \nC.\u7578\u80ce\u7624\uff08teratoma\uff09 \nD.\u7cbe\u7d30\u80de\u7624\uff08seminoma\uff09", "year": 1042, "prof": "\u52a9\u7522\u5e2b", "subject": "\u57fa\u790e\u91ab\u5b78"} -{"answer": "D", "question": "\u82b1\u67f3\u6027\u6dcb\u5df4\u8089\u82bd\u816b\uff08lymphogranuloma venerum\uff09\u662f\u4e00\u7a2e\u5e38\u898b\u7684\u6027\u75c5\uff0c\u4fd7\u7a31\u82b1\u67f3\u75c5\uff0c\u5176\u75c5\u539f\u83cc\u662f\uff1a \nA.EB \u75c5\u6bd2 \nB.\u55ae\u7d14\u75b1\u75b9\u75c5\u6bd2 \nC.\u5c0f\u87ba\u65cb\u83cc\uff08Spirillum minor\uff09 \nD.\u7802\u773c\u62ab\u8863\u83cc\uff08Chlamydia trachomatis\uff09L \u8840\u6e05\u578b", "year": 1021, "prof": "\u52a9\u7522\u5e2b", "subject": "\u57fa\u790e\u91ab\u5b78"} -{"answer": "C", "question": "\u5b30\u5152\u6dfb\u52a0\u526f\u98df\u54c1\u7684\u539f\u5247\u70ba\u4f55\uff1f\u2460\u7531\u5c11\u91cf\u958b\u59cb\uff0c\u6162\u6162\u52a0\u5230\u9069\u91cf \u2461\u61c9\u540c\u6642\u6dfb\u52a0\u591a\u7a2e\u65b0\u7684\u98df\u7269\u4ee5\u5747\u8861\u71df\u990a \u2462\u767c\u73fe\u98df\u7269\u5f15\u8d77\u7684\u904e\u654f\u53cd\u61c9\u6642\uff0c\u61c9\u7acb\u5373\u505c\u98df \u2463\u51fa\u751f\u5f8c 3 \u500b\u6708\u53ef\u4ee5\u958b\u59cb\u6dfb\u52a0 \u2464\u9700\u89c0\u5bdf\u5b30\u5e7c\u5152\u5927\u4fbf\u60c5\u5f62 \u2465\u53ef\u7acb\u523b\u65b7\u5976 \nA.\u2460\u2461\u2462\nB.\u2463\u2464\u2465\nC.\u2460\u2462\u2464\nD.\u2461\u2463\u2465", "year": 1122, "prof": "\u52a9\u7522\u5e2b", "subject": "\u5404\u79d1\u8b77\u7406\u5b78"} -{"answer": "D", "question": "\u4e0b\u5217\u4f55\u8005\u4e0d\u662f\u5f15\u7522\u7684\u9069\u61c9\u75c7\uff1f \nA.\u5b50\u5bae\u5167\u80ce\u5152\u6b7b\u4ea1\nB.\u598a\u5a20\u7cd6\u5c3f\u75c5\nC.\u7834\u6c34\u5df2\u8d85\u904e24\u5c0f\u6642\nD.\u80ce\u982d\u9aa8\u76c6\u4e0d\u5c0d\u7a31", "year": 1092, "prof": "\u52a9\u7522\u5e2b", "subject": "\u52a9\u7522\u5b78\uff08\u4e8c\uff09"} -{"answer": "A", "question": "\u5433\u5973\u58eb\u8868\u793a\uff0c\u751f\u7522\u5f8c\u7b2c\u4e09\u5929\u665a\u4e0a\u7761\u89ba\u6642\u6d41\u5f88\u591a\u6c57\uff0c\u591a\u5230\u8863\u670d\u90fd\u6fd5\u4e86\uff0c\u4e0b\u5217\u5224\u65b7\u4f55\u8005\u6700\u6b63\u78ba\uff1f \nA.\u662f\u6b63\u5e38\u73fe\u8c61\uff0c\u70ba\u4e00\u7a2e\u5229\u5c3f\u4f5c\u7528 \nB.\u662f\u6b63\u5e38\u73fe\u8c61\uff0c\u56e0\u70ba\u5927\u91cf\u8840\u6db2\u6d41\u5411\u7d44\u7e54\u9593\u9699 \nC.\u662f\u7570\u5e38\u73fe\u8c61\uff0c\u8868\u793a\u814e\u81df\u518d\u5438\u6536\u529f\u80fd\u6709\u554f\u984c \nD.\u662f\u7570\u5e38\u73fe\u8c61\uff0c\u8868\u793a\u9ad4\u6db2\u96fb\u89e3\u8cea\u4e0d\u5e73\u8861", "year": 1042, "prof": "\u52a9\u7522\u5e2b", "subject": "\u52a9\u7522\u5b78\uff08\u4e00\uff09"} -{"answer": "D", "question": "\u6709\u95dc\u63a5\u53d7\u50b3\u7d71\u55ae\u80fa\u6c27\u5316\u9176\u6291\u5236\u5291\uff08monoamine oxidase inhibitor\uff0cMAOI\uff09\u6cbb\u7642\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f\nA.\u5373\u4f7f\u4f75\u7528\u542b\u6709\u4e7e\u916a\u80fa\uff08tyramine\uff09\u7684\u98df\u7269\uff0c\u81e8\u5e8a\u4e0a\u4e5f\u5f88\u5c11\u6703\u5f15\u767c\u9ad8\u8840\u58d3\u5371\u6a5f\nB.\u6bd4\u8d77\u4e09\u74b0\u6297\u9b31\u5291\uff0c\u50b3\u7d71 MAOI \u6703\u7522\u751f\u8f03\u591a\u93ae\u975c\u8207\u6297\u81bd\u9e7c\u4f5c\u7528\nC.\u9577\u671f\u4f7f\u7528 MAOI\uff0c\u4e5f\u4e0d\u6613\u7522\u751f\u9ad4\u91cd\u589e\u52a0\u3001\u6027\u529f\u80fd\u969c\u7919\u7b49\u526f\u4f5c\u7528\nD.\u75c5\u4eba\u5b9c\u907f\u514d\u98df\u7528\u4e73\u916a\u3001\u5564\u9152", "year": 1082, "prof": "\u52a9\u7522\u5e2b", "subject": "\u5404\u79d1\u8b77\u7406\u5b78"} -{"answer": "D", "question": "\u7522\u5f8c\u51fa\u8840\u8d85\u904e\u591a\u5c11c.c.\u6642\uff0c\u53ef\u80fd\u6703\u767c\u751f\u4f4e\u8840\u5bb9\u7a4d\u4f11\u514b\uff08Hypovolemic shock\uff09\uff1f \nA.500 c.c. \nB.750 c.c. \nC.1,000 c.c. \nD.1,500 c.c.", "year": 1072, "prof": "\u52a9\u7522\u5e2b", "subject": "\u52a9\u7522\u5b78\uff08\u4e8c\uff09"} -{"answer": "D", "question": "\u6709\u95dc\u534a\u4e73\u7cd6\u8840\u75c7\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6b63\u78ba\uff1f \nA.\u6703\u56b4\u91cd\u5f71\u97ff\u8166\u8207\u9ad4\u683c\u767c\u80b2\uff0c\u75c7\u72c0\u5728\u51fa\u751f\u4e8c\u5230\u4e09\u500b\u6708\u5f8c\u6162\u6162\u51fa\u73fe\uff0c\u5982\u4e0d\u53ca\u6642\u767c\u73fe\u52a0\u4ee5\u6cbb\u7642\uff0c\u5247\u6703\n\u9020\u6210\u5446\u5c0f\u75c7 \nB.\u5982\u4e0d\u53ca\u6642\u8a3a\u65b7\u3001\u6cbb\u7642\u4e26\u98f2\u98df\u63a7\u5236\uff0c\u5c07\u9020\u6210\u5b30\u5152\u7684\u667a\u80fd\u4e0d\u8db3\u3001\u9aa8\u9abc\u7578\u578b\u3001\u75d9\u6523\u53ca\u773c\u7403\u6c34\u6676\u9ad4\u812b\u4f4d \nC.\u7121\u6cd5\u6709\u6548\u5229\u7528\u98df\u7269\u4e2d\u86cb\u767d\u8cea\uff0c\u901a\u5e38\u6703\u5c0e\u81f4\u56b4\u91cd\u667a\u80fd\u4e0d\u8db3\u6216\u6b7b\u4ea1\u3002\u82e5\u80fd\u65e9\u671f\u767c\u73fe\uff0c\u65bc\u51fa\u751f\u4e09\u500b\u6708\n\u5167\u7d66\u4e88\u7279\u6b8a\u98f2\u98df\u6216\u7dad\u751f\u7d20\uff0c\u5247\u5927\u90e8\u5206\u5b30\u5152\u53ef\u6709\u6b63\u5e38\u7684\u667a\u80fd\u767c\u5c55 \nD.\u5b30\u5152\u9935\u5976\u5f8c\u5e38\u767c\u751f\u5614\u5410\u3001\u660f\u7761\u7684\u73fe\u8c61\uff0c\u540c\u6642\u9020\u6210\u773c\u775b\u3001\u809d\u81df\u53ca\u8166\u90e8\u640d\u5bb3", "year": 1001, "prof": "\u52a9\u7522\u5e2b", "subject": "\u52a9\u7522\u5b78\uff08\u4e8c\uff09"} -{"answer": "D", "question": "\u5c45\u5bb6\u8b77\u7406\u5e2b\u8a62\u554f\u4e0b\u80a2\u7671\u7613\u7684\u500b\u6848\u51fa\u9662\u5f8c\u7531\u8ab0\u7167\u9867\uff0c\u500b\u6848\u8aaa\u300c\u4e0d\u53ef\u80fd\u662f\u59bb\u5b50\uff0c\u5979\u751a\u9ebc\u90fd\u8aaa\u300e\u597d\u8a71\u4e0d\u8aaa\u7b2c\u4e8c\u904d\u300f\uff0c\u5be6\u5728\u7121\u6cd5\u6e9d\u901a\u300d\u3002\u8acb\u554f\u500b\u6848\u548c\u59bb\u5b50\u7684\u6e9d\u901a\u4e0d\u826f\u578b\u614b\uff0c\u4e0b\u5217\u4f55\u8005\u6b63\u78ba\uff1f \nA.\u8cac\u5099\u5c0d\u65b9\nB.\u4ee5\u504f\u6982\u5168\nC.\u66ff\u5c0d\u65b9\u4e0d\u5b9a\u7fa9\nD.\u4e0d\u9858\u6f84\u6e05\u554f\u984c", "year": 1102, "prof": "\u52a9\u7522\u5e2b", "subject": "\u5404\u79d1\u8b77\u7406\u5b78"} -{"answer": "A", "question": "\u4e00\u4f4d\u60a3\u6709\u9ad8\u8840\u58d3\u7684\u75c5\u4eba\uff0c\u5176\u8840\u58d3\u5df2\u7528\u85e5\u7269\u63a7\u5236\uff0c\u56e0\u4e0b\u80a2\u9aa8\u6298\u63a5\u53d7\u975e\u6025\u8a3a\u9aa8\u79d1\u624b\u8853\uff0c\u800c\u7d66\u4e88 Epidural anesthesia\uff0c\u6309\u7f8e\u570b\u9ebb\u9189\u5c08\u79d1\u91ab\u5e2b\u5b78\u6703\uff08ASA\uff09\u7684\u8eab\u9ad4\uf9fa\u6cc1\u5206\uf9d0\u662f\uff1a \nA. ASA Class P2 \nB. ASA Class P3 \nC. ASA Class P4 \nD. ASA Class P5", "year": 1002, "prof": "\u91ab\u5e2b", "subject": "\u91ab\u5b78(\u516d)"} -{"answer": "D", "question": "\u4e00\u540d26\u6b72\u7537\u6027\uff0c\u5df2\u7d93\u9577\u9054\u4e00\u0815\u4ee5\u4e0a\u8b8a\u5f97\u793e\u4ea4\u9000\u7e2e\uff0c\u8db3\u4e0d\u51fa\u6236\u3002\u8fd1\u516d\u500b\u6708\u4ee5\u4f86\u5e38\u0843\u6709\u4eba\u8ddf\u8e64\u4ed6\uff0c\u8981\u9677\u5bb3\u4ed6\uff0c\u6709\u6642\u81ea\u8a00\u81ea\u8a9e\u597d\u50cf\u5728\u548c\u5225\u4eba\u5c0d\u8a71\uff0c\u82e5\u8a72\u75c5\u4eba\u78ba\u8a3a\u70ba\u601d\u89ba\u5931\u8abf\u75c7\uff08schizophrenia\uff09\uff0c\u4e0b\u083b\u6558\u8ff0\u4f55\u8005\u6700\u6b63\u78ba\uff1f \nA.\u5fc3\u0a3a\u6cbb\u090b\u7684\u7b2c\u4e00\u9078\u64c7\u662f\ufa1d\ufa19\u5206\u6790 \nB.\u85e5\u7269\u6cbb\u090b\u7b2c\u4e00\u9078\u64c7\u662f\u591a\u5df4\u80fa\u518d\u56de\u6536\u6291\u5236\u5291\uff08dopamine reuptake inhibitors\uff09 \nC.\u5408\u4f75\u5c3c\u53e4\u4e01\uff08nicotine\uff09\u6feb\u7528\u6642\uff0c\u75c5\u4eba\u8840\u4e2d\u7684\u6297\u7cbe\u795e\u75c5\u85e5\u85e5\u7269\u6fc3\u5ea6\u6703\u589e\u52a0 \nD.\u795e\u7d93\u79d1\u5b78\u6587\u737b\u5831\u544a\uff0c\u601d\u89ba\u5931\u8abf\u75c7\uff08schizophrenia\uff09\u60a3\u8005\u8166\u90e8\u6703\u6709\u795e\u7d93\u5143\u6a39\u7a81\u6216\u8ef8\u7a81\u6e1b\u5c11\u7684\u60c5\u5f62", "year": 1052, "prof": "\u91ab\u5e2b", "subject": "\u91ab\u5b78(\u56db)"} -{"answer": "C", "question": "\u75c5\u4eba\u767c\u751f\u7f3a\u6c27\uf9fa\u614b\uff0c\uf9b5\u5982\u547c\u5438\u8870\u7aed\u6216\u4f11\u514b\u6642\uff0c\u6703\u6539\u8b8a\u8461\u8404\ufa03\u7684\u4ee3\u8b1d\uff0c\u6b64\u6642\u75c5\u4eba\u62bd\u8840\u6aa2\u67e5\u4e2d\uff0c\u4e0b\uf99c\u4f55\u8005\u6fc3\ufa01\u6703\u4e0a\u5347\uff1f \nA. Acetyl-CoA \nB. Ethanol \nC. Lactate \nD. Acetaldehyde", "year": 1002, "prof": "\u91ab\u5e2b", "subject": "\u91ab\u5b78(\u4e8c)"} -{"answer": "C", "question": "\u95dc\u65bc\u57fa\u5e95\u7d30\u80de\u764c\u7684\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f \nA.\u6700\u5e38\u898b\u7684\u76ae\u819a\u764c \nB.\u5177\u6709\u5c40\u90e8\u4fb5\u72af\u6027 \nC.\u5bb9\u6613\u8f49\u79fb \nD.\u8207\u65e5\u5149\u66dd\u66ec\u6709\u95dc", "year": 1062, "prof": "\u91ab\u5e2b", "subject": "\u91ab\u5b78(\u56db)"} -{"answer": "A", "question": "\u67d0 case-control study \u7814\u7a76\u67d0\u57fa\u56e0\u578b\u8207\u4e73\u764c\u7684\u95dc\u4fc2\uff0c\u5c07\u57fa\u56e0\u578b\u5206\u70ba GG+GT \u8207 TT \uf978\uf9d0\uff0c\u8a08\u7b97\u5f97\u77e5 GG+GT\u7d44\u6bd4 TT \u7d44\u7684\u52dd\u7b97\u6bd4\uff08Odds Ratio\uff09\u70ba 2.4\uff0c95%\u4fe1\u8cf4\u5340\u9593\uff0895% Confidence Interval\uff09\u70ba\uff081.4, 4.3\uff09\u3002\u4e0b\uf99c\u4f55\u8005\u6b63\u78ba\uff1f \nA. \u5177 GG+GT \u57fa\u56e0\u578b\u8f03 TT \u578b\uf9e0\u767c\u751f\u4e73\u764c\uff0c\u6709\u7d71\u8a08\u4e0a\u986f\u8457\u610f\u7fa9 \nB. \u5177 GG+GT \u57fa\u56e0\u578b\u8f03 TT \u578b\uf967\uf9e0\u767c\u751f\u4e73\u764c\uff0c\u6709\u7d71\u8a08\u4e0a\u986f\u8457\u610f\u7fa9 \nC. \u5177 GG+GT \u57fa\u56e0\u578b\u8f03 TT \u578b\uf9e0\u767c\u751f\u4e73\u764c\uff0c\u6c92\u6709\u7d71\u8a08\u4e0a\u986f\u8457\u610f\u7fa9 \nD. \u5177 GG+GT \u57fa\u56e0\u578b\u8f03 TT \u578b\uf967\uf9e0\u767c\u751f\u4e73\u764c\uff0c\u6c92\u6709\u7d71\u8a08\u4e0a\u986f\u8457\u610f\u7fa9", "year": 1012, "prof": "\u91ab\u5e2b", "subject": "\u91ab\u5b78(\u4e00)"} -{"answer": "D", "question": "puromycin \u662f\u4e00\u7a2e\u6297\u751f\u7d20\uff08antibiotics\uff09\uff0c\u53ef\u4ee5\u6291\u5236\u7d30\u83cc\u4e4b\u86cb\u767d\u8cea\u5408\u6210\uff0c\u662f\u7531\u65bc\u5b83\u53ef\u4ee5\uff1a \nA. \u6291\u5236\u7d30\u83cc\u4e4b\u6838\ufa03\u9ad4\u7d50\u5408\u65bc mRNA \u4e0a \nB. \u4f54\u64da mRNA \u4e4b\u8d77\u59cb\u5bc6\u78bc\u4f4d\u7f6e \nC. \u4fc3\u9032\u6838\ufa03\u9ad4\u4e4b\u5206\u89e3 \n \nD. \u7d50\u5408\u5728\u6838\ufa03\u9ad4\u4e4b A site\uff0c\u7834\u58de\u80dc\u80bd\u9375\u4e4b\u751f\u5408\u6210", "year": 1012, "prof": "\u91ab\u5e2b", "subject": "\u91ab\u5b78(\u4e8c)"} -{"answer": "A", "question": "\u4e00\u4f4d62\u6b72\u75c5\u4eba\uff0c\u904e\u53bb\u6709\u5fc3\u81df\u75c5\u53f2\uff0c\u6b63\u5728\u63a5\u53d7\u6cbb\u7642\uff0c\u6700\u8fd1\u56e0\u51fa\u8840\u50be\u5411\u63a5\u53d7\u6aa2\u67e5\uff0c\u5468\u908a\u8840\u4e2d\u8840\u7d05\u7d20\u3001\u767d\u8840\u7403\u53ca\u8840\u5c0f\u677f\u6578\u6b63\u5e38\uff0cprothrombin time\uff08PT\uff09INR 3.5\uff0cactivated partial thromboplastin time 26\u201d\uff08\u6b63\u5e38\u5c0d\u716727\u201d\uff09\u3002\u4e0b\u5217\u4f55\u8005\u662f\u5f15\u8d77\u9019\u4f4d\u75c5\u4eba\u5bb9\u6613\u51fa\u8840\u7684\u6700\u53ef\u80fd\u539f\u56e0\uff1f \nA.coumadin treatment \nB.heparin treatment \nC.liver disease \nD.von Willebrand disease", "year": 1062, "prof": "\u91ab\u5e2b", "subject": "\u91ab\u5b78(\u4e09)"} -{"answer": "C", "question": "\u7576\u75c5\u539f\u83cc\u5165\u4fb5\u8178\u9053\u6642\uff0c\u8178\u9053\u4e0a\u76ae\u7d30\u80de\u6700\u4e0d\u53ef\u80fd\u5229\u7528\u4e0b\u5217\u4f55\u7a2e\u5206\u5b50\u4f86\u5e6b\u52a9\u6e05\u9664\u75c5\u539f\u83cc\uff1f \nA.TLRs \nB.NOD1 \u53ca NOD2 \nC.PGE2 \nD.MIC-A \u53ca MIC-B", "year": 113, "prof": "\u91ab\u5e2b", "subject": "\u91ab\u5b78(\u4e8c)"} -{"answer": "B", "question": "\u4e0b\uf99c\u90a3\u4e00\u9805\u70ba\u8a08\u7b97\u7d14\u6c34\u6e05\u9664\uf961\uff08free-water clearance, CH2O\uff09\u7684\u516c\u5f0f\uff08V = urine flow rate; Cosm = osmolar clearance\uff09\uff1f \nA. CH2O = V + Cosm \nB. CH2O = V\uff0dCosm \nC. CH2O = V\uff0eCosm \nD. CH2O = V / Cosm", "year": 1001, "prof": "\u91ab\u5e2b", "subject": "\u91ab\u5b78(\u4e8c)"} -{"answer": "A", "question": "\u6709\u95dc basal ganglia \uf96b\u8207\u9aa8\u9abc\u808c\u904b\u52d5\u4e4b\u8abf\u7bc0\uff0c\u8207\u5927\u8166\u76ae\u8cea\uff08cerebral cortex\uff09\u53ca\u8996\u4e18\uff08thalamus\uff09\u9593\u4e4b\u795e\u7d93\u8a0a\u606f\u50b3\u905e\u4e3b\u8981\uf937\u5f91\u70ba\u4f55\uff1f \nA. cerebral cortex\u2192striatum\u2192globus pallidus\u2192thalamus\u2192cerebral cortex \nB. cerebral cortex\u2192globus pallidus\u2192striatum\u2192thalamus\u2192cerebral cortex \nC. cerebral cortex\u2192thalamus\u2192striatum\u2192globus pallidus\u2192cerebral cortex \nD. cerebral cortex\u2192striatum\u2192thalamus\u2192globus pallidus\u2192cerebral cortex", "year": 1021, "prof": "\u91ab\u5e2b", "subject": "\u91ab\u5b78(\u4e8c)"} -{"answer": "C", "question": "\u4f9d\u7167\u300a\u91dd\u7078\u79d1\u5b78\u300b\u6240\u8ff0\uff0c\u8af8\u7d93\u4e4b\u4ea4\u6703\u7a74\u5171\u6709\u591a\u5c11\u500b\uff1f\nA. 55\nB. 88\nC. 101\nD. 202", "year": 1102, "prof": "\u4e2d\u91ab\u5e2b", "subject": "\u4e2d\u91ab\u81e8\u5e8a\u91ab\u5b78\uff08\u56db\uff09"} -{"answer": "D", "question": "\u539a\u6734\u7528\u65bc\u4e2d\u7126\u865b\u5bd2\u8139\u6eff\u7684\u6cbb\u7642\uff0c\u6700\u9069\u5b9c\u8207\u90a3\u4e9b\u85e5\u5408\u7528\uff1f\nA. \u84bc\u672e\u3001\u9673\u76ae\nB. \u5927\u9ec3\u3001\u67b3\u5be6\nC. \u9ec3\u82a9\u3001\u767d\u828d\nD. \u4eba\u53c3\u3001\u751f\u8591", "year": 1112, "prof": "\u4e2d\u91ab\u5e2b", "subject": "\u4e2d\u91ab\u57fa\u790e\u91ab\u5b78\uff08\u4e8c\uff09"} -{"answer": "C", "question": "\u6709\u95dc\u53d7\u50b7\u810a\u690e\u7684\u7a69\u5b9a\u5ea6\u6709\u8cf4\u5f8c\u5074\u97cc\u5e36\u8907\u5408\u7d50\u69cb\uff08posterior ligamentous complex\uff09\u7684\u5b8c\u6574\u6027\uff0c\u4e0b\u5217\u4f55\u8005\u4e0d\u5c6c\u65bc\u5f8c\u5074\u97cc\u5e36\u8907\u5408\u7d50\u69cb\uff1f \nA.\u68d8\u4e0a\u97cc\u5e36\uff08supraspinous ligament\uff09\nB.\u68d8\u9593\u97cc\u5e36\uff08interspinous ligament\uff09\nC.\u5f8c\u7e31\u97cc\u5e36\uff08posterior longitudinal ligament\uff09\nD.\u9ec3\u97cc\u5e36\uff08ligamentum flavum\uff09", "year": 113, "prof": "\u4e2d\u91ab\u5e2b", "subject": "\u4e2d\u91ab\u81e8\u5e8a\u91ab\u5b78\uff08\u4e09\uff09"} -{"answer": "D", "question": "\u6709\u95dc\u7078\u6cd5\u9069\u61c9\u75c7\u4e2d\uff0c\u4e0b\u5217\u6558\u8ff0\u6709\u5e7e\u9805\u6b63\u78ba\uff1f\u2460\u865b\u7646 \u2461\u907a\u7cbe \u2462\u75f0\u98f2 \u2463\u51b7\u54ee \u2464\u4e45\u75e2 \u2465\u591a\u5c3f \u2466\u75fa\u75db \u2467\u80c3\u75db \nA. 5 \nB. 6 \nC. 7 \nD. 8", "year": 1041, "prof": "\u4e2d\u91ab\u5e2b", "subject": "\u4e2d\u91ab\u81e8\u5e8a\u91ab\u5b78\uff08\u56db\uff09"} -{"answer": "B", "question": "\u300a\u651d\u751f\u773e\u5999\u65b9\u300b\u5b9a\u5598\u6e6f\u4e4b\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u6700\u4e0d\u9069\u5b9c\uff1f\nA. \u4e3b\u6cbb\u98a8\u5bd2\u5916\u675f\uff0c\u75f0\u71b1\u5167\u860a\nB. \u4ee5\u9ebb\u9ec3\u3001\u767d\u679c\u70ba\u4e3b\u85e5\uff08\u541b\u85e5\uff09\nC. \u767d\u679c\u53ef\u9632\u9ebb\u9ec3\u8f9b\u6563\u592a\u904e\u800c\u8017\u50b7\u80ba\uff0c\u4e26\u4ee5\u5176\u6536\u589e\u5f37\u5176\u5e73\u5598\u4e4b\u4f5c\u7528\nD. \u4ee5\u6851\u8449\u3001\u9ec3\u82a9\u4e4b\u82e6\u5bd2\uff0c\u6e05\u7009\u80ba\u71b1\uff0c\u6b62\u54b3\u5e73\u5598", "year": 1112, "prof": "\u4e2d\u91ab\u5e2b", "subject": "\u4e2d\u91ab\u57fa\u790e\u91ab\u5b78\uff08\u4e8c\uff09"} -{"answer": "A", "question": "\u4e0b\u5217\u4f55\u8005\u662f\u6fd5\u6eab\u75c5\u75c5\u7a0b\u4e2d\u300c\u6fd5\u963b\u6c23\u5206\u300d\u6700\u53ef\u80fd\u7684\u820c\u8c61\uff1f \nA. \u82d4\u9ec3\u539a\u800c\u81a9 \n \nB. \u82d4\u767d\u539a\u800c\u9ecf\u81a9 \nC. \u82d4\u767d\u539a\u800c\u4e7e\u71e5 \n \nD. \u767d\u82d4\u6ed1\u81a9\u539a\u5982\u7a4d\u7c89\uff0c\u800c\u820c\u8cea\u7d2b\u7d73", "year": 1082, "prof": "\u4e2d\u91ab\u5e2b", "subject": "\u4e2d\u91ab\u81e8\u5e8a\u91ab\u5b78\uff08\u4e00\uff09"} -{"answer": "D", "question": "\u6709\u95dc\u5c3a\u795e\u7d93\u58d3\u8feb\u75c7\uff08ulnar nerve compression\uff09\u4e4b\u6558\u8ff0\uff0c\u4e0b\uf99c\u4f55\u8005\u932f\u8aa4\uff1f \nA. \u901a\u5e38\u4f34\u96a8\u5c0f\u6307\u8207\u7121\u540d\u6307\u7684\u9ebb\u75fa\uf9ff\u75db \nB. \u56b4\u91cd\u8005\u6703\u4f34\u6709\u5c0f\u9b5a\u969b\u808c\u8089\u840e\u7e2e\uff08hypothenar atrophy\uff09 \nC. \uf9f6\u5e8a\u4e0a\u8f03\u6b63\u4e2d\u795e\u7d93\u58d3\u8feb\u75c7\u5c11\ufa0a \nD. \u6700\u5e38\u7522\u751f\u58d3\u8feb\u7684\u4f4d\u7f6e\u5728\u624b\u8155\u5c3a\u5074\u4e4b\u795e\u7d93\u901a\u904e\u8655", "year": 1002, "prof": "\u4e2d\u91ab\u5e2b", "subject": "\u4e2d\u91ab\u81e8\u5e8a\u91ab\u5b78\uff08\u4e09\uff09"} -{"answer": "B", "question": "36\u6b72\u7537\u6027\u60a3\u8005\uff0c\u4e3b\u8a34\u982d\u75db20\u5929\uff0c\u8868\u73fe\u70ba\u982d\u5169\u5074\u81f3\u8033\u5f8c\u5287\u75db\uff0c\u4f75\u6709\u53e3\u6e34\u3001\u53e3\u82e6\u3001\u4fbf\u79d8\u3001\u5614\u5410\u7b49\u75c7\u72c0\uff0c\u671b\u8a3a\u51fa\u73fe\u820c\u8cea\u7d05\uff0c\u82d4\u9ec3\uff0c\u8108\u8c61\u70ba\u5f26\u6578\u3002\u4f9d\u64da\u75c5\u4eba\u7684\u81e8\u5e8a\u75c7\u72c0\u8207\u9ad4\u5fb5\uff0c\u4e0b\u5217\u8a3a\u65b7\u4f55\u8005\u6700\u9069\u5b9c\uff1f\nA. \u5916\u611f\u98a8\u71b1\nB. \u809d\u81bd\u71b1\u8b49\nC. \u809d\u6c23\u9b31\u7d50\nD. \u5916\u611f\u5bd2\u90aa\u517c\u593e\u80c3\u71b1", "year": 1092, "prof": "\u4e2d\u91ab\u5e2b", "subject": "\u4e2d\u91ab\u81e8\u5e8a\u91ab\u5b78\uff08\u4e00\uff09"} -{"answer": "A", "question": "21\u6b72\u7537\u5927\u5b78\u751f\u6628\u5929\u8d77\u51fa\u73fe\u53f3\u4e0b\u8179\u75db\u53ca\u7e5e\u81cd\u75db\uff0c\u4ee5\u624b\u6309\u4e4b\u53f3\u4e0b\u8179\u5247\u75db\u52a0\u5287\uff0c\u6709\u53cd\u8df3\u75db\uff0c\u61f7\u7591\u662f\u6025\u6027\u95cc\u5c3e\u708e\uff0c\u82e5\u4f7f\u7528\u91dd\u7078\u6cbb\u7642\uff0c\u6240\u9078\u7528\u4e3b\u8981\u4e4b\u7a74\u4f4d\u4e0d\u5305\u62ec\u4e0b\u5217\u4f55\u8005\uff1f\nA. \u5929\u67f1\nB. \u95cc\u5c3e\nC. \u66f2\u6c60\nD. \u5929\u6a1e", "year": 1092, "prof": "\u4e2d\u91ab\u5e2b", "subject": "\u4e2d\u91ab\u81e8\u5e8a\u91ab\u5b78\uff08\u56db\uff09"} -{"answer": "A", "question": "\u6cbb\u7642\u6eab\u75c5\u6d25\u6c23\u5927\u865b\uff0c\u5316\u6e90\u6b32\u7aed\u7684\u65b9\u5291\uff0c\u4e0b\u5217\u4f55\u8005\u6700\u9069\u5b9c\uff1f \nA. \u53c3\u9644\u9f8d\u7261\u6e6f \nB. \u751f\u8108\u6563 \nC. \u767d\u864e\u52a0\u4eba\u53c3\u6e6f \nD. \u9023\u6885\u6e6f", "year": 1052, "prof": "\u4e2d\u91ab\u5e2b", "subject": "\u4e2d\u91ab\u81e8\u5e8a\u91ab\u5b78\uff08\u4e00\uff09"} -{"answer": "C", "question": "\u67d0\u75c5\u60a3\u8868\u793a\u81ea\u5df1\u70ba\u5f8c\u5929\u4e4b\u807d\u640d\uff0c\u4e0b\u5217\u4f55\u8005\u539f\u56e0\u6700\u4e0d\u53ef\u80fd\uff1f\nA. \u9ebb\u75b9\nB. \u5de8\u7d30\u80de\u75c5\u6bd2\nC. \u9873\u9aa8\u9aa8\u6298\nD. \u816e\u817a\u708e", "year": 1092, "prof": "\u807d\uf98a\u5e2b", "subject": "\u807d\u8a9e\u6e9d\u901a\u969c\u7919\u5b78"} -{"answer": "A", "question": "\u4e0b\u5217\u6709\u95dc\u5916\u5074\u4e0a\u6a44\u6b16\u6838\uff08lateral superior olive, LSO\uff09\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f \nA. LSO \u5c0d\u540c\u5074\uff08ipsilateral\uff09\u523a\u6fc0\u901a\u5e38\u5448\u6291\u5236\u53cd\u61c9\uff08inhibitory\uff09 \nB. LSO \u5c0d\u540c\u5074\uff08ipsilateral\uff09\u523a\u6fc0\u901a\u5e38\u5448\u523a\u6fc0\u53cd\u61c9\uff08excitatory\uff09 \nC. LSO \u5c0d\u5c0d\u5074\uff08contralateral\uff09\u523a\u6fc0\u901a\u5e38\u5448\u523a\u6fc0\u53cd\u61c9\uff08excitatory\uff09 \nD. LSO \u53ea\u63a5\u53d7\u96d9\u8033\uff08binaural\uff09\u523a\u6fc0\u4e0d\u63a5\u53d7\u55ae\u8033\uff08monaural\uff09\u523a\u6fc0", "year": 1082, "prof": "\u807d\uf98a\u5e2b", "subject": "\u57fa\u790e\u807d\u529b\u79d1\u5b78"} -{"answer": "B", "question": "\u807d\u89ba\u969c\u7919\u5b78\u751f\u500b\u5225\u5316\u6559\u80b2\u8a08\u756b\uff08IEP\uff09\u7684\u64ec\u5b9a\u8207\u57f7\u884c\uff0c\u4e0d\u5305\u62ec\u4e0b\u5217\u4f55\u8005\uff1f\nA. \u512a\u52a3\u52e2\u80fd\u529b\nB. \u5b78\u671f\u76ee\u6a19\u548c\u5b78\u5e74\u76ee\u6a19\nC. \u5404\u79d1\u6210\u7e3e\u6392\u540d\nD. \u7279\u6b8a\u9700\u6c42", "year": 1102, "prof": "\u807d\uf98a\u5e2b", "subject": "\u807d\u89ba\u8207\u5e73\u8861\u7cfb\u7d71\u4e4b\u5275\u5065"} -{"answer": "D", "question": "\u907f\u514d\u52a9\u807d\u5668\u904e\u5ea6\u64f4\u97f3\u800c\u5c0e\u81f4\u9032\u4e00\u6b65\u807d\u529b\u640d\u5931\uff0c\u9078\u914d\u6642\u61c9\u8a72\u57f7\u884c\u4e0b\u5217\u4f55\u9805\u6aa2\u67e5\uff1f \nA. \u5be6\u8033\u585e\u5165\u589e\u76ca\uff08real ear insertion gain\uff09 \n \nB. \u5be6\u8033\u4f69\u6234\u53cd\u61c9\uff08real ear aided response\uff09 \nC. \u529f\u80fd\u6027\u589e\u76ca\u6e2c\u8a66\uff08functional gain test\uff09 \n \nD. \u5be6\u8033\u8655\u65b9\u516c\u5f0f\u7684 OSPL90 \u8f38\u51fa\u97f3\u91cf\u6e2c\u8a66", "year": 1032, "prof": "\u807d\uf98a\u5e2b", "subject": "\u807d\u89ba\u8f14\u5177\u539f\u7406\u8207\u5be6\u52d9\u5b78"} -{"answer": "A", "question": "Distortion product OAE\uff08DPOAE\uff09\u8a0a\u865f\u81f3\u5c11\u8981\u5927\u65bc\u80cc\u666f\u566a\u97f3\u591a\u5c11\u5206\u8c9d\u4ee5\u4e0a\uff0c\u624d\u53ef\u4ee5\u8a8d\u5b9a\u662f\u6b63\u5e38 DPOAE\uff1f \nA. 6 \u5206\u8c9d \nB. 10 \u5206\u8c9d \nC. 15 \u5206\u8c9d \nD. 20 \u5206\u8c9d", "year": 1022, "prof": "\u807d\uf98a\u5e2b", "subject": "\u96fb\u751f\u7406\u807d\u529b\u5b78"} -{"answer": "B", "question": "\u6885\u5c3c\u723e\u6c0f\u75c7\uff08Meniere\u2019s disease\uff09\u65bc\u81e8\u5e8a\u4e0a\u6709\u90a3\u4e9b\u7279\u5fb5\uff0c\u4e0b\u5217\u4f55\u8005\u6700\u6b63\u78ba\uff1f\u2460\u807d\u640d \u2461\u7729\u6688\u767c\u4f5c \u2462\u8033\u9cf4 \u2463\u8033\u8139\u611f \nA. \u50c5\u2461\u2462\u2463 \nB. \u50c5\u2460\u2461 \nC. \u50c5\u2460\u2461\u2462 \nD. \u2460\u2461\u2462\u2463", "year": 1032, "prof": "\u807d\uf98a\u5e2b", "subject": "\u807d\u8a9e\u6e9d\u901a\u969c\u7919\u5b78"} -{"answer": "A", "question": "\u95dc\u65bc\u74e6\u767b\u67cf\u683c\u6c0f\u75c7\uff08Waardenburg syndrome\uff09\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6700\u4e0d\u9069\u5207\uff1f\nA. \u5e38\u4f34\u96a8\u8679\u819c\u7570\u8272\u75c7\nB. \u807d\u640d\u7a0b\u5ea6\u5f9e\u8f15\u5ea6\u5230\u91cd\u5ea6\u90fd\u6709\u53ef\u80fd\nC. \u5e38\u5408\u4f75\u5fc3\u81df\u65b9\u9762\u75be\u75c5\nD. \u5e38\u6709\u5169\u773c\u5167\u7725\u904e\u5bec", "year": 1122, "prof": "\u807d\uf98a\u5e2b", "subject": "\u807d\u8a9e\u6e9d\u901a\u969c\u7919\u5b78"} -{"answer": "D", "question": "\u807d\u89ba\u969c\u7919\u8005\u7684\u6e9d\u901a\u529f\u80fd\u7d20\u70ba\u6559\u80b2\u91cd\u9ede\uff0c\u76ee\u524d\u4e16\u754c\u5404\u570b\u555f\u8070\u6559\u80b2\u754c\u4e3b\u8981\u6e9d\u901a\u6a21\u5f0f\u70ba\u4e0b\u5217\u4f55\u8005\uff1f \nA. \u53e3\u8a9e\u6cd5\uff08oral approach\uff09 \nB. \u7d9c\u5408\u6e9d\u901a\u6cd5\uff08total communication approach\uff09 \nC. \u96d9\u8a9e\u6e9d\u901a\u6cd5\uff08bilingualism\uff09 \nD. \u624b\u8a9e\u6cd5\uff08manual approach\uff09", "year": 1032, "prof": "\u807d\uf98a\u5e2b", "subject": "\u807d\u8a9e\u6e9d\u901a\u969c\u7919\u5b78"} -{"answer": "A", "question": "\u4e0b\uf99c\u9078\u9805\u4e2d\uff0c\u90a3\u4e00\u500b\u662f\u8a9e\u8a00\u793e\u6703\u5b78\u6d3e\u8a8d\u70ba\u4e4b\u5152\u7ae5\u7fd2\u5f97\u8a9e\u8a00\u7684\u6700\u5927\u52d5\uf98a\uff1f \nA. \u4f7f\u7528 \nB. \u8a8d\u77e5 \nC. \u751f\uf9e4\u7d50\u69cb \nD. \uf9ff\u6fc0\u53cd\u61c9", "year": 1021, "prof": "\u807d\uf98a\u5e2b", "subject": "\u807d\u8a9e\u6e9d\u901a\u969c\u7919\u5b78"} -{"answer": "B", "question": "\u4e0b\u5217\u95dc\u65bc\u9589\u585e\u6548\u61c9\uff08occlusion effect\uff09\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u9589\u585e\u6548\u61c9\u5728\u4f4e\u983b\u7387\u6642\u8f03\u5927\nB. \u53ea\u6709\u5728\u5916\u8033\u9053\u9aa8\u8cea\u90e8\uff08bony portion\uff09\u7684\u90e8\u5206\u88ab\u9589\u585e\u4e4b\u5f8c\uff0c\u624d\u6703\u7522\u751f\u9589\u585e\u6548\u61c9\nC. \u96d9\u8033\u50b3\u5c0e\u578b\u807d\u89ba\u969c\u7919\u7684\u500b\u6848\uff0c\u4e0d\u6703\u51fa\u73fe\u9589\u585e\u6548\u61c9\u7684\u73fe\u8c61\nD. \u81e8\u5e8a\u4e0a\u7684\u97f3\u53c9\u6e2c\u9a57 Bing test\uff0c\u5c31\u662f\u5229\u7528\u9589\u585e\u6548\u61c9\u7684\u539f\u7406\u505a\u5224\u65b7", "year": 1122, "prof": "\u807d\uf98a\u5e2b", "subject": "\u57fa\u790e\u807d\u529b\u79d1\u5b78"} -{"answer": "C", "question": "\u5728\u88fd\u4f5c\u53ef\u64a4\u6027\u4e0a\u984e\u64f4\u5f35\u77ef\u6b63\u88dd\u7f6e\u6642\uff0c\u6a39\u8102\u5e8a\u5916\u5f62\u7dda\u5728\u81fc\u9f52\u90e8\u4f4d\uff0c\u8981\u8986\u84cb\u591a\u5c11\u7259\u51a0\u9ad8\u5ea6\uff1f\nA. 1/5\nB. 1/4\nC. 1/3\nD. 1/2", "year": 1122, "prof": "\u7259\u9ad4\u6280\u8853\u5e2b", "subject": "\u7259\u9ad4\u6280\u8853\u5b78\uff08\u56db\uff09"} -{"answer": "C", "question": "\u6709\u95dc\u74f7\u4ee5\u70d8\u70e4\uff08\u71d2\u6210\uff09\u6eab\u5ea6\u4f86\u5206\u985e\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f \nA. \u7fa9\u9f52\u7528\u7684\u9676\u9f52\u662f\u4f4e\u6eab\u70d8\u70e4\u74f7 \nB. \u4f7f\u7528\u92c1\u5316\u74f7\u4f5c\u70ba\u74f7\u5957\u51a0\u7684\u51a0\u5fc3\u6750\u6599\u662f\u4e2d\u6eab\u70d8\u70e4\u74f7 \nC. \u4f7f\u7528\u6700\u591a\u7684\u91d1\u5c6c\u71d2\u7d50\u7528\u74f7\u70ba\u4f4e\u6eab\u70d8\u70e4\u74f7 \nD. \u4f4e\u6eab\u70d8\u70e4\u74f7\u7684\u71b1\u81a8\u8139\u7387\u6700\u597d\u8207\u71d2\u7d50\u7528\u5408\u91d1\u76f8\u8fd1", "year": 1072, "prof": "\u7259\u9ad4\u6280\u8853\u5e2b", "subject": "\u7259\u9ad4\u6280\u8853\u5b78\uff08\u4e8c\uff09"} -{"answer": "B", "question": "\u6709\u95dc\u7259\u51a0\u88dc\u7db4\u7269\u8207\u7259\u5468\u7d44\u7e54\u95dc\u4fc2\u7684\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f \nA. \u7259\u51a0\u88dc\u7db4\u7269\u7684\u908a\u7de3\u53ef\u8a2d\u5b9a\u5728\u7834\u58de\u4e0a\u76ae\u9644\u9023\uff08epithelial attachment\uff09\u7684\u4f4d\u7f6e \nB. \u7259\u51a0\u88dc\u7db4\u7269\u7684\u8868\u9762\u61c9\u7cbe\u7d30\u7814\u78e8 \nC. \u7259\u51a0\u88dc\u7db4\u7269\u7684\u8c50\u9686\u904e\u5927\uff0c\u7259\u9f66\u908a\u7de3\u5bb9\u6613\u6709\u98df\u7269\u505c\u6eef \nD. \u7259\u51a0\u88dc\u7db4\u7269\u7684\u8c50\u9686\u4e0d\u8db3\uff0c\u7259\u9f66\u6703\u904e\u5ea6\u523a\u6fc0", "year": 1042, "prof": "\u7259\u9ad4\u6280\u8853\u5e2b", "subject": "\u7259\u9ad4\u6280\u8853\u5b78\uff08\u4e8c\uff09"} -{"answer": "C", "question": "\u9444\u9020\u5b8c\u6210\u7684\u7fa9\u9f52\u9808\u7d93\u904e\u9069\u7576\u7684\u8abf\u6574\u624d\u53ef\u4ea4\u4ed8\u91ab\u5e2b\u9032\u884c\u8a66\u6234\uff0c\u4ee5\u4e0b\u7684\u8abf\u6574\u904e\u7a0b\u4f55\u8005\u932f\u8aa4\uff1f \nA. \u7576\u7fa9\u9f52\u8868\u9762\u6709\u660e\u986f\u9444\u9020\u5b54\u7a74\u6216\u660e\u986f\u7684\u9444\u808c\u76ba\u88c2\uff0c\u61c9\u5f9e\u881f\u578b\u958b\u59cb\u91cd\u65b0\u88fd\u4f5c \nB. \u7fa9\u9f52\u5167\u90e8\u56e0\u5305\u57cb\u7522\u751f\u7684\u5c0f\u6c23\u6ce1\uff0c\u53ef\u4ee5\u7528\u78e8\u91dd\u614e\u91cd\u7684\u9664\u53bb \nC. \u7259\u9f66\u4e0b\u65b9\u7684\u7fa9\u9f52\u908a\u7de3\u90e8\u4e0d\u8db3\u7684\u60c5\u6cc1\uff0c\u56e0\u5728\u53e3\u5167\u7121\u6cd5\u76f4\u63a5\u76ee\u8996\u6545\u53ef\u4ee5\u7528\u92b2\u63a5\u4fee\u88dc \nD. \u7fa9\u9f52\u5167\u51a0\u9762\u7684\u4fee\u98fe\u53ef\u7528 50\u03bcm \u7684\u6c27\u5316\u92c1\u5674\u7802\u8655\u7406", "year": 1042, "prof": "\u7259\u9ad4\u6280\u8853\u5e2b", "subject": "\u7259\u9ad4\u6280\u8853\u5b78\uff08\u4e8c\uff09"} -{"answer": "B", "question": "\u4f7f\u7528\u706b\u7130\u5439\u7ba1\uf92d\u52a0\u71b1\u7194\u89e3\uf90a\u5c6c\u6642\uff0c\u63a5\u89f8\uf90a\u5c6c\u7684\u706b\u7130\u90e8\u5206\u61c9\u8a72\u662f\uff1a \nA. \u6700\u5916\u9762\u4e00\u5c64\uff1a\u6c27\u5316\u5e36 \nB. \u5f9e\u5916\u9762\u7b97\uf92d\u7b2c\u4e8c\u5c64\uff1a\u9084\u539f\u5e36 \nC. \u5f9e\u5916\u9762\u7b97\uf92d\u7b2c\u4e09\u5c64\uff1a\u71c3\u71d2\u5e36 \nD. \u6700\u9760\u8fd1\u5439\u7ba1\uff08\u6700\u5167\u5c64\uff09\uff1a\u672a\u71c3\u71d2\u5e36", "year": 1022, "prof": "\u7259\u9ad4\u6280\u8853\u5e2b", "subject": "\u7259\u9ad4\u6280\u8853\u5b78\uff08\u4e8c\uff09"} -{"answer": "A", "question": "\u95dc\u65bc\uf9f7\u5373\u6027\u7fa9\u9f52\uff08immediate denture\uff09\u7684\u6558\u8ff0\uff0c\u4e0b\uf99c\u4f55\u8005\u6700\u6b63\u78ba\uff1f \nA. \u50b3\u7d71\uf9f7\u5373\u6027\u7fa9\u9f52\u53ef\u7dad\u6301\u54ac\u5408\u5782\u76f4\u9ad8\ufa01 \nB. \u50b3\u7d71\uf9f7\u5373\u6027\u7fa9\u9f52\u53ef\u7531\u73fe\u5b58\u7fa9\u9f52\u52a0\u5de5\u88fd\u4f5c \nC. \u66ab\u6642\u6027\uf9f7\u5373\u6027\u7fa9\u9f52\u9069\u5408\u65bc\u53ea\u6709\u524d\u7259\u5b58\u5728\u7684\u60a3\u8005 D. \u66ab\u6642\u6027\uf9f7\u5373\u6027\u7fa9\u9f52\u6703\u58d3\u8feb\u62d4\u7259\u50b7\u53e3", "year": 1022, "prof": "\u7259\u9ad4\u6280\u8853\u5e2b", "subject": "\u7259\u9ad4\u6280\u8853\u5b78\uff08\u4e09\uff09"} -{"answer": "C", "question": "\u4e0b\u5217\u95dc\u65bc\u6d3b\u52d5\u5c40\u90e8\u7fa9\u9f52\u91d1\u5c6c\u652f\u67b6\uff08framework\uff09 \u88fd\u4f5c\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f \nA. \u91d1\u5c6c\u652f\u67b6\u4e4b\u7d42\u63a5\u7dda\uff08finishing line\uff09\u53ef\u9632\u6b62\u6a39\u8102\u7684\u525d\u96e2\u65b7\u88c2\uff0c\u4f46\u61c9\u529b\u4e5f\u5bb9\u6613\u96c6\u4e2d\uff0c\u6545\u5167\u5916\u7d42\u63a5\u7dda\u8981\n\u8a2d\u8a08\u6210\u4e92\u76f8\u96e2\u958b \nB. \u70ba\u9632\u7fa9\u9f52\u57fa\u5e95\u7684\u6a39\u8102\u5f9e\u91d1\u5c6c\u525d\u96e2\u4ee5\u53ca\u8272\u7d20\u6c89\u7a4d\uff0c\u7d42\u63a5\u7dda\u90e8\u4f4d\u53ca\u7db2\u72c0\u7d50\u69cb\uff08mesh construction\uff09\u5e38\u9032\n\u884c\u5674\u7802\uff0c\u6216\u662f\u91d1\u5c6c\u5e95\u5291\u7684\u5857\u5e03 \nC. \u5c07\u9444\u9053\u8a2d\u5b9a\u65bc\u8010\u706b\u6a21\u578b\u5f8c\u65b9\u7684\u9444\u9053\u5782\u76f4\u63a5\u6cd5\uff0c\u9069\u5408\u61c9\u7528\u65bc\u4e0b\u984e\u91d1\u5c6c\u652f\u67b6\u7684\u88fd\u4f5c \nD. \u91d1\u5c6c\u652f\u67b6\u9444\u9020\u5f8c\uff0c\u61c9\u907f\u514d\u65bc\u9ad8\u6eab\u72c0\u614b\u4e0b\u65bc\u6c34\u4e2d\u6025\u51b7\uff0c\u4ee5\u9632\u9444\u9020\u9ad4\u9f9c\u88c2\u8b8a\u5f62", "year": 1032, "prof": "\u7259\u9ad4\u6280\u8853\u5e2b", "subject": "\u7259\u9ad4\u6280\u8853\u5b78\uff08\u4e09\uff09"} -{"answer": "C", "question": "\u7259\u9ad4\u6280\u8853\u6240\u5ba4\u5167\u5de5\u4f5c\u5834\u6240\uff0c\u4f9d\u64da\uf92f\u5de5\u5b89\u5168\u885b\u751f\u8a2d\u65bd\u898f\u5247\u61c9\u8a2d\u7f6e\u8db3\u5920\uf92f\u5de5\u4f7f\u7528\u4e4b\u901a\u9053\uff0c\u4e0b\uf99c\u4f55\u8005\u932f\u8aa4\uff1f \nA. \u61c9\u6709\u9069\u61c9\u5176\u7528\u9014\u4e4b\u5bec\ufa01\uff0c\u5176\u4e3b\u8981\u4eba\ufa08\u9053\uf967\u5f97\u5c0f\u65bc\u4e00\u516c\u5c3a \nB. \u5404\u6a5f\u68b0\u9593\u6216\u5176\u4ed6\u8a2d\u5099\u9593\u901a\u9053\uf967\u5f97\u5c0f\u65bc\u516b\u5341\u516c\u5206 \nC. \u81ea\uf937\u9762\u8d77\u7b97\u4e00\u516c\u5c3a\u9ad8\ufa01\u4e4b\u7bc4\u570d\u5167\uff0c\uf967\u5f97\u6709\u969c\u7919\u7269\u3002\u4f46\u56e0\u5de5\u4f5c\u4e4b\u5fc5\u8981\uff0c\u7d93\u63a1\u9632\u8b77\u63aa\u65bd\u8005\uff0c\uf967\u5728\u6b64\u9650 \nD. \u4e3b\u8981\u4eba\ufa08\u9053\u53ca\u6709\u95dc\u5b89\u5168\u9580\u3001\u5b89\u5168\u68af\u61c9\u6709\u660e\u986f\u6a19\u793a", "year": 1022, "prof": "\u7259\u9ad4\u6280\u8853\u5e2b", "subject": "\u7259\u9ad4\u6280\u8853\u5b78\uff08\u56db\uff09"} -{"answer": "A", "question": "\u4e0b\u984e\u5728\u7b2c\u4e00\u5927\u81fc\u9f52\u840c\u767c\u524d\u62d4\u9664\u7b2c\u4e8c\u4e73\u81fc\u9f52\u6642\uff0c\u6700\u53ef\u80fd\u9020\u6210\u55ae\u5074\u9f52\u5217\u591a\u5c11\u7a7a\u9593\u7684\u55aa\u5931\uff1f \nA. 0\uff5e1 mm \nB. 2\uff5e5 mm \nC. 8\uff5e10 mm \nD. \u4e0d\u6703\u6709\u7a7a\u9593\u55aa\u5931", "year": 1082, "prof": "\u7259\u9ad4\u6280\u8853\u5e2b", "subject": "\u7259\u9ad4\u6280\u8853\u5b78\uff08\u56db\uff09"} -{"answer": "A", "question": "\u70ba\u7522\u751f\u6c27\u5316\u92ef\uff0d\u52a0\u5f37\u77fd\u9178\u92f0\u74f7\uff08zirconia-reinforced lithium silicate ceramics\uff09\u6700\u7d42\u7d50\u6676\u5316\u7684\u96d9\u76f8\u5fae\u7d30\u7d50\u69cb\uff0c\u4e0b\u5217\u4f55\u8005\u662f\u6700\u9069\u7576\u7684\u8655\u7406\u6eab\u5ea6\u8207\u6642\u9593\uff1f\nA. \u7d04 840\u00b0C \u8655\u7406 8 \u5206\u9418\nB. \u7d04 920\u00b0C \u8655\u7406 16 \u5206\u9418\nC. \u7d04 1165\u00b0C \u8655\u7406 2 \u5c0f\u6642\nD. \u7d04 1350\u00b0C \u5230 1450\u00b0C \u4e4b\u9593\uff0c\u8655\u7406 4 \u5c0f\u6642", "year": 1092, "prof": "\u7259\u9ad4\u6280\u8853\u5e2b", "subject": "\u7259\u9ad4\u6280\u8853\u5b78\uff08\u4e8c\uff09"} -{"answer": "A", "question": "\u5728\u4e00\u500b\u5de2\u5f0f\u75c5\u4f8b\u5c0d\u7167\u7814\u7a76\uff08nested case-control study\uff09\u4e2d\uff0c\u4ee5\u4e0b\u90a3\u500b\u9673\u8ff0\u662f\u6b63\u78ba\u7684\uff1f\nA. \u5c0d\u7167\u7d44\u662f\u5f9e\u8207\u75c5\u4f8b\u76f8\u540c\u4f86\u6e90\u7684\u4eba\u7fa4\u4e2d\u9078\u6a23\nB. \u6703\u4f9d\u64da\u66b4\u9732\u72c0\u614b\u4f86\u9078\u64c7\u75c5\u4f8b\u7d44\nC. \u6b64\u7814\u7a76\u8a2d\u8a08\u80fd\u5920\u76f4\u63a5\u4f30\u8a08\u75be\u75c5\u767c\u751f\u7387\nD. \u5728\u9019\u7a2e\u8a2d\u8a08\u4e2d\uff0c\u5fc5\u9808\u9032\u884c\u75c5\u4f8b\u548c\u5c0d\u7167\u7684\u914d\u5c0d", "year": 1122, "prof": "\u516c\u5171\u885b\u751f\u5e2b", "subject": "\u6d41\u884c\u75c5\u5b78"} -{"answer": "A", "question": "\u81e8\u5e8a\u8a66\u9a57\u7684\u7814\u7a76\u65b9\u6cd5\u6bd4\u8f03\u4e0d\u9069\u7528\u65bc\u4e0b\u5217\u4f55\u7a2e\u7814\u7a76\uff1f\nA. \u91dd\u7078\u5c0d\u4e2d\u98a8\u5fa9\u5065\u6cbb\u7642\u7684\u6548\u679c\nB. \u7dad\u751f\u7d20 C \u4e4b\u670d\u7528\u5c0d\u611f\u5192\u7684\u9810\u9632\u6548\u679c\nC. \u807d\u53e4\u5178\u97f3\u6a02\u6cbb\u7642\u5c0d\u6539\u5584\u7126\u616e\u7684\u6548\u679c\nD. \u6c99\u5875\u66b4\u7684\u66b4\u9732\u5c0d\u6c23\u5598\u75c5\u4eba\u767c\u75c5\u7684\u5f71\u97ff", "year": 1112, "prof": "\u516c\u5171\u885b\u751f\u5e2b", "subject": "\u6d41\u884c\u75c5\u5b78"} -{"answer": "C", "question": "\u5728\u57f7\u884c\u5b58\u6d3b\u5206\u6790\u6642\u9700\u8981\u5b9a\u7fa9\u6bcf\u7b46\u500b\u6848\u7684\u8cc7\u6599\u4e4b\u8ffd\u8e64\u7d50\u679c\u662f\u5c6c\u65bc\u4e8b\u4ef6\uff08event\uff09\u8cc7\u6599\uff0c\u9084\u662f\u8a2d\u9650\uff08censor\uff09\u8cc7\u6599\uff0c\u67d0\u4e00\u7d50\u8178\u76f4\u8178\u764c\u7684\u6a19\u9776\u85e5\u54c1\u6cbb\u7642\u7814\u7a76\uff0c\u75c5\u4eba\u5728\u8a66\u9a57\u7d50\u675f\u5f8c\u6240\u767b\u9304\u7684\u8ffd\u8e64\u7d50\u679c\u5206\u5225\u662f\uff1aA=\u5b58\u6d3b\uff0cB=\u6b7b\u65bc\u80ba\u764c\uff0cC=\u6b7b\u65bc\u7d50\u8178\u76f4\u8178\u764c\uff0cD=\u6b7b\u65bc\u80ba\u764c\u53ca\u7d50\u8178\u76f4\u8178\u764c\u4ee5\u5916\u7684\u5176\u4ed6\u764c\u75c7\uff0cE=\u6b7b\u65bc\u975e\u764c\u75c7\u7684\u5176\u4ed6\u539f\u56e0\uff0c\u56e0\u6b64\u5728\u8a08\u7b97\u5404\u7a2e\u6b7b\u4ea1\u7387\u6642\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u8a08\u7b97\u764c\u75c7\u5b58\u6d3b\u7387\u6642\uff0cBCD \u8a2d\u5b9a\u6210\u4e8b\u4ef6\u8cc7\u6599\uff0cAE \u8a2d\u5b9a\u6210\u8a2d\u9650\u8cc7\u6599\nB. \u8a08\u7b97\u7d50\u8178\u76f4\u8178\u764c\u5b58\u6d3b\u7387\u6642\uff0cC \u8a2d\u5b9a\u6210\u4e8b\u4ef6\u8cc7\u6599\uff0cABDE \u8a2d\u5b9a\u6210\u8a2d\u9650\u8cc7\u6599\nC. \u8a08\u7b97\u7e3d\u5b58\u6d3b\u7387\u6642\uff0cBCDE \u8a2d\u5b9a\u6210\u4e8b\u4ef6\u8cc7\u6599\uff0cA \u8a2d\u5b9a\u6210\u8a2d\u9650\u8cc7\u6599\nD. \u8a08\u7b97\u80ba\u764c\u5b58\u6d3b\u7387\u6642\uff0cBC \u8a2d\u5b9a\u6210\u4e8b\u4ef6\u8cc7\u6599\uff0cADE \u8a2d\u5b9a\u6210\u8a2d\u9650\u8cc7\u6599", "year": 1112, "prof": "\u516c\u5171\u885b\u751f\u5e2b", "subject": "\u751f\u7269\u7d71\u8a08\u5b78"} -{"answer": "D", "question": "\u95dc\u65bc\u81fa\u7063\u5730\u5340\u98f2\u7528\u6c34\u7837\u66b4\u9732\u4ee5\u53ca\u5176\u5065\u5eb7\u6548\u61c9\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u6c34\u9ad4\u4e2d\u542b\u904e\u91cf\u7837\u6fc3\u5ea6\u4e4b\u554f\u984c\uff0c\u4e0d\u50c5\u767c\u751f\u65bc\u81fa\u7063\uff0c\u65bc\u4e16\u754c\u5176\u4ed6\u5730\u5340\uff0c\u4f8b\u5982\u6b50\u76df\u3001\u5916\u8499\u53e4\u3001\u4e2d\u570b\u3001\n\u5370\u5ea6\u3001\u5b5f\u52a0\u62c9\u3001\u7f8e\u570b\u7b49\uff0c\u4e5f\u66fe\u6709\u985e\u4f3c\u4e4b\u5831\u5c0e\nB. \u7837\u66b4\u9732\u8207\u7f3a\u8840\u6027\u5fc3\u81df\u75c5\u3001\u7cd6\u5c3f\u75c5\u4ee5\u53ca\u9ad8\u8840\u58d3\u6709\u95dc\nC. \u66fe\u7d93\u65bc\u81fa\u7063\u897f\u5357\u6cbf\u5cb8\u5730\u5340\u767c\u751f\u4e4b\u70cf\u8173\u75c5\u4e8b\u4ef6\uff0c\u5176\u5c45\u6c11\u4e3b\u8981\u662f\u9577\u671f\u98f2\u7528\u6dfa\u6c34\u4e95\uff08\u6df1\u5ea6 4\uff5e12 \u7c73\uff09\n\u6240\u9020\u6210\uff0c\u53cd\u4e4b\u98f2\u7528\u6df1\u6c34\u4e95\uff08\u6df1\u5ea6 120\uff5e180 \u7c73\uff09\u4e4b\u5c45\u6c11\uff0c\u5176\u4e0d\u826f\u5065\u5eb7\u6548\u61c9\u4e4b\u98a8\u96aa\u5247\u8f03\u4f4e\nD. \u7837\u66b4\u9732\u9664\u4e86\u8207\u76ae\u819a\u764c\u6709\u6b63\u5411\u76f8\u95dc\u4e4b\u5916\uff0c\u81fa\u7063\u5730\u5340\u4e4b\u7814\u7a76\u4e5f\u767c\u73fe\u7837\u66b4\u9732\u4e5f\u8207\u8180\u80f1\u764c\u3001\u814e\u81df\u764c\u3001\u80ba", "year": 1112, "prof": "\u516c\u5171\u885b\u751f\u5e2b", "subject": "\u74b0\u5883\u8207\u8077\u696d\u885b\u751f"} -{"answer": "B", "question": "\u5728\u63a2\u8a0e\u75be\u75c5\u56e0\u679c\u95dc\u4fc2\u6642\u5e38\u6703\u53d7\u5230\u5e72\u64fe\u56e0\u5b50\u7684\u5f71\u97ff\uff0c\u4ee5\u4e0b\u6558\u8ff0\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u5e72\u64fe\u56e0\u5b50\u4e0d\u80fd\u70ba\u66dd\u9732\u56e0\u5b50\u8207\u75be\u75c5\u4e4b\u9593\u7684\u4e2d\u4ecb\u56e0\u5b50\nB. \u5e72\u64fe\u56e0\u5b50\u5728\u4e0d\u540c\u66dd\u9732\u56e0\u5b50\u5206\u7d44\u4e2d\u7684\u5206\u5e03\u6bd4\u4f8b\u76f8\u540c\nC. \u63a7\u5236\u5e72\u64fe\u56e0\u5b50\u5e72\u64fe\u7684\u65b9\u6cd5\u70ba\u5206\u5c64\u5206\u6790\nD. \u5728\u63a7\u5236\u5e72\u64fe\u56e0\u5b50\u5f8c\uff0c\u66dd\u9732\u56e0\u5b50\u8207\u75be\u75c5\u4e4b\u9593\u5c31\u4e0d\u6703\u6709\u76f8\u95dc", "year": 1122, "prof": "\u516c\u5171\u885b\u751f\u5e2b", "subject": "\u6d41\u884c\u75c5\u5b78"} -{"answer": "A", "question": "Nutbeams \u63d0\u51fa\u5065\u5eb7\u8b58\u80fd\u53ef\u4ee5\u5206\u70ba\u4e09\u5927\u985e\uff0c\u5305\u542b\uff1a\u529f\u80fd\u6027\u8b58\u80fd\uff08functional literacy\uff09\u3001\u4e92\u52d5\u6027\u8b58\u80fd\uff08interactive literacy\uff09\u3001\u6279\u5224\u6027\u8b58\u80fd\uff08critical literacy\uff09\u7b49\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u9019\u4e09\u985e\u8b58\u80fd\u9700\u4e0d\u540c\u7a0b\u5ea6\u7684\u8a8d\u77e5\u80fd\u529b\uff0c\u4ee5\u6279\u5224\u6027\u5065\u5eb7\u8b58\u80fd\u9700\u8981\u6700\u9ad8\u7a0b\u5ea6\u7684\u8a8d\u77e5\u80fd\u529b\nB. \u807d\u3001\u8aaa\u3001\u8b80\u3001\u5beb\u7684\u80fd\u529b\u5c6c\u65bc\u4e92\u52d5\u6027\u8b58\u80fd\nC. \u80fd\u900f\u904e\u6709\u6548\u6e9d\u901a\u4ee5\u62d2\u7d55\u5371\u5bb3\u5065\u5eb7\u4e4b\u8a98\u60d1\uff0c\u5c6c\u65bc\u6279\u5224\u6027\u8b58\u80fd\nD. \u80fd\u660e\u8fa8\u4f3c\u662f\u800c\u975e\u7684\u8a0a\u606f\u6216\u8ff7\u601d\uff08myth\uff09\uff0c\u5c6c\u65bc\u529f\u80fd\u6027\u8b58\u80fd", "year": 1112, "prof": "\u516c\u5171\u885b\u751f\u5e2b", "subject": "\u5065\u5eb7\u793e\u6703\u884c\u70ba\u5b78"} -{"answer": "D", "question": "\u67d0\u4eba\u56e0\u4e0d\u78ba\u5b9a COVID-19 \u75ab\u82d7\u662f\u5426\u53ef\u6709\u6548\u9810\u9632\u5176\u67d3\u75ab\uff0c\u6545\u81f3\u4eca\u4ecd\u672a\u5b8c\u6210\u75ab\u82d7\u65bd\u6253\uff0c\u6b64\u6558\u8ff0\u5c6c\u65bc\u5065\u5eb7\u4fe1\u5ff5\u6a21\u5f0f\uff08Health Belief Model\uff09\u4e2d\u4e4b\u4f55\u7a2e\u6982\u5ff5\uff1f\nA. \u81ea\u89ba\u56b4\u91cd\u6027\uff08perceived severity\uff09\nB. \u81ea\u89ba\u7f79\u60a3\u6027\uff08perceived susceptibility\uff09\nC. \u81ea\u89ba\u5229\u76ca\uff08perceived benefits\uff09\nD. \u81ea\u89ba\u969c\u7919\uff08perceived barriers\uff09", "year": 1112, "prof": "\u516c\u5171\u885b\u751f\u5e2b", "subject": "\u5065\u5eb7\u793e\u6703\u884c\u70ba\u5b78"} -{"answer": "B", "question": "\u4e0b\u5217\u90a3\u4e00\u500b\u9078\u9805\u7684\u6558\u8ff0\u5167\u5bb9\u53cd\u6620\u4e86\u91ab\u7642\u670d\u52d9\u9ad4\u7cfb\u7684\u300c\u5b8f\u89c0\u6548\u7387\u300d\uff1f\nA. \u91ab\u7642\u54c1\u8cea\u7684\u63d0\u5347\nB. \u91ab\u7642\u53ef\u8fd1\u6027\u66f4\u516c\u5e73\nC. \u91ab\u7642\u670d\u52d9\u7684\u904b\u4f5c\u6548\u7387\u63d0\u9ad8\nD. \u7e3d\u9ad4\u91ab\u7642\u8cbb\u7528\u7684\u63a7\u5236", "year": 1122, "prof": "\u516c\u5171\u885b\u751f\u5e2b", "subject": "\u885b\u751f\u884c\u653f\u8207\u7ba1\u7406"} -{"answer": "B", "question": "\u96a8\u8457\u4eba\u53e3\u9ad8\u9f61\u5316\uff0c\u8a31\u591a\u7e23\u5e02\u653f\u5e9c\u53ca\u6c11\u9593\u6a5f\u69cb\u7d1b\u7d1b\u63a8\u51fa\u9280\u9aee\u5c31\u696d\u5e73\u53f0\u5a92\u5408\u670d\u52d9\u6216\u662f\u9ad8\u9f61\u5c31\u696d\u670d\u52d9\uff0c\u9019\u6a23\u7684\u8da8\u52e2\u7b26\u5408\u885b\u751f\u798f\u5229\u90e8\u63a8\u52d5\u9ad8\u9f61\u53cb\u5584\u57ce\u5e02\u7684\u90a3\u500b\u9762\u5411\uff1f\nA. \u5b89\u5c45\nB. \u89aa\u8001\nC. \u656c\u8001\nD. \u4e0d\u8001", "year": 1122, "prof": "\u516c\u5171\u885b\u751f\u5e2b", "subject": "\u5065\u5eb7\u793e\u6703\u884c\u70ba\u5b78"} -{"answer": "B", "question": "\u5728\u63a2\u8a0e\u5a92\u9ad4\u5c0d\u6c11\u773e\u4e4b\u5f71\u97ff\u6642\uff0c\u6709\u4e9b\u5e38\u7528\u4e4b\u50b3\u64ad\u7406\u8ad6\u8207\u6982\u5ff5\uff0c\u5176\u4e2d\u300c\u4eba\u5011\u53d7\u5927\u773e\u5a92\u9ad4\u5f71\u97ff\u800c\u5f62\u5851\u5176\u5c0d\u771f\u5be6\u4e16\u754c\u4e4b\u8a8d\u77e5\u300d\u5c6c\u65bc\u4e0b\u5217\u4f55\u8005\uff1f\nA. \u77e5\u6e9d\uff08the knowledge gap\uff09\nB. \u6db5\u5316\uff08cultivation\uff09\nC. \u8b70\u984c\u8a2d\u5b9a\uff08agenda setting\uff09\nD. \u98a8\u96aa\u6e9d\u901a\uff08risk communication\uff09", "year": 1112, "prof": "\u516c\u5171\u885b\u751f\u5e2b", "subject": "\u5065\u5eb7\u793e\u6703\u884c\u70ba\u5b78"} -{"answer": "D", "question": "\u6709\u95dc\u8996\u7db2\u819c\u6bcd\u7d30\u80de\u7624\uff08retinoblastoma\uff09\u4e4b\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u96d6\u6703\u5c0e\u81f4\u60a3\u7ae5\u8996\u529b\u53d7\u640d\u751a\u81f3\u5931\u660e\uff0c\u5e78\u800c\u7121\u751f\u547d\u5a01\u8105\u4e4b\u98a8\u96aa\nB. \u7c21\u55ae\u7be9\u6aa2\u65b9\u6cd5\u70ba\u89c0\u5bdf\u5152\u7ae5\u77b3\u5b54\u6709\u7121\u6b63\u5e38\u7d05\u53cd\u5c04\nC. \u591a\u6578\u597d\u767c\u65bc\u516d\u6b72\u4ee5\u4e0a\u4e4b\u5b78\u9f61\u5152\u7ae5\nD. \u6b64\u75be\u75c5\u7684\u7279\u8272\u70ba\u5927\u591a\u6578\u96d9\u5074\u767c\u75c5\u3001\u5076\u723e\u53ef\u89c0\u5bdf\u5230\u773c\u7403\u7d05\u816b\u75bc\u75db\uff0c\u65e9\u671f\u767c\u73fe\u6cbb\u7642\u975e\u5e38\u91cd\u8981", "year": 1112, "prof": "\u9a57\u5149\u5e2b", "subject": "\u4f4e\u8996\u529b\u5b78"} -{"answer": "A", "question": "\u60a3\u8005\u60f3\u8981\u914d\u786c\u5f0f\u900f\u6c23\u96b1\u5f62\u773c\u93e1\u3002\u4ed6\u4ee5\u524d\u7684\u91ab\u751f\u5728 1 \u5e74\u524d\u7d66\u4ed6\u914d\u8edf\u5f0f\u93e1\u7247\uff0c\u7531\u65bc\u93e1\u7247\u8868\u9762\u6c89\u7a4d\u7269\u548c\u6307\u7532\u6613\u6495\u88c2\u93e1\u7247\uff0c\u4ed6\u7d93\u6b77\u4e86\u8996\u529b\u6a21\u7cca\u548c\u983b\u7e41\u66f4\u63db\u93e1\u7247\u3002OD K 44.00D@180/44.25D@090 RX -3.25DS/-1.25DC\u00d7180OS K 43.50D@180/44.00D@090 RX -3.00DS/-1.25DC\u00d7180\u8a72\u60a3\u8005\u4e0b\u500b\u93e1\u7247\u61c9\u914d\u6234\u4ec0\u9ebc\u6750\u8cea\u8f03\u9069\u5408\uff1f\nA. \u8d85\u539a\u53c8\u4f4e DK \u786c\u5f0f\u7403\u9762\u900f\u6c23\u93e1\u7247\nB. \u5e74\u62cb\u6c34\u81a0\nC. \u96d9\u6563\u786c\u5f0f\u900f\u6c23\u93e1\u7247\nD. \u8584\u53c8\u9ad8 DK \u786c\u5f0f\u7403\u9762\u900f\u6c23\u93e1\u7247", "year": 1122, "prof": "\u9a57\u5149\u5e2b", "subject": "\u96b1\u5f62\u773c\u93e1\u5b78\u8207\u914d\u93e1\u5b78"} -{"answer": "C", "question": "\u5728\u6e2c\u91cf-9.00DS/-3.00DC\u00d7135 \u7684\u89d2\u5ea6\u8ef8\u6642\uff0c\u4ea4\u53c9\u5713\u67f1\u7ffb\u8f49\u93e1\u7684\u4f4d\u7f6e\u5176\u8ca0\u5713\u67f1\u93e1\u8ef8\u5728 90 \u5ea6\u6642\uff0c\u88ab\u6aa2\u8005\u8a8d\u70ba\u770b\u5f97\u8f03\u6e05\u695a\uff0c\u7576\u6bcf\u6b21\u89d2\u5ea6\u8abf\u6574\u4ee5 5 \u5ea6\u89d2\u70ba\u6e96\u6642\uff0c\u5247\u5176\u89d2\u5ea6\u8ef8\u61c9\u8abf\u81f3\u591a\u5c11\u5ea6\uff1f\nA. 090\nB. 130\nC. 135\nD. 140", "year": 1102, "prof": "\u9a57\u5149\u5e2b", "subject": "\u8996\u5149\u5b78"} -{"answer": "C", "question": "\u4e00\u900f\u93e1\u7b2c\u4e00\u7126\u8ddd\u9577\u70ba+25 \u516c\u5206\uff0c\u900f\u904e\u5149\u5b78\u4e2d\u5fc3\u4e0a\u65b9 4 \u516c\u5206\u8655\u89c0\u770b\u7269\u9ad4\u6642\uff0c\u6703\u7522\u751f\u591a\u5c11\u7a1c\u93e1\u6548\u61c9\uff1f\nA. 1.6\u0394 \u57fa\u5e95\u671d\u4e0b\nB. 1.6\u0394 \u57fa\u5e95\u671d\u4e0a\nC. 16\u0394 \u57fa\u5e95\u671d\u4e0b\nD. 16\u0394 \u57fa\u5e95\u671d\u4e0a", "year": 1122, "prof": "\u9a57\u5149\u5e2b", "subject": "\u8996\u89ba\u5149\u5b78"} -{"answer": "D", "question": "\u9a57\u5149\u4eba\u54e1\u57f7\u696d\u6642\u672a\u52a0\u5165\u6240\u5728\u5730\u516c\u6703\u8005\uff0c\u7531\u4e0b\u5217\u4f55\u8005\u8655\u7f70\uff1f \nA. \u7e23\u5e02\u653f\u5e9c \nB. \u516c\u6703 \nC. \u5de5\u6703 \nD. \u5730\u65b9\u6cd5\u9662", "year": 1082, "prof": "\u9a57\u5149\u5e2b", "subject": "\u773c\u7403\u89e3\u5256\u751f\u7406\u5b78\u8207\u502b\u7406"} -{"answer": "D", "question": "6 \u6709\u95dc\u9ad8\u5ea6\u8fd1\u8996\u7684\u4f75\u767c\u75c7\u6558\u8ff0\u4e2d\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f \nA. \u9ad8\u5ea6\u8fd1\u8996\u53ef\u80fd\u9020\u6210\u8996\u7db2\u819c\u5206\u5c64\uff08retinoschisis\uff09 \nB. \u9ad8\u5ea6\u8fd1\u8996\u75c5\u4eba\u5468\u908a\u8996\u7db2\u819c\u767c\u751f\u88c2\u5b54\u6a5f\u7387\u6703\u589e\u52a0\uff0c\u53ef\u80fd\u56e0\u6b64\u5c0e\u81f4\u8996\u7db2\u819c\u525d\u96e2 \nC. \u9ad8\u5ea6\u8fd1\u8996\u75c5\u60a3\u767c\u751f\u8108\u7d61\u819c\u65b0\u751f\u8840\u7ba1\u6a5f\u7387\u589e\u52a0\uff0c\u6703\u9020\u6210\u8996\u529b\u4e0b\u964d \nD. \u8108\u7d61\u819c\u65b0\u751f\u8840\u7ba1\u76ee\u524d\u6c92\u6709\u6cbb\u7642\u65b9\u6cd5", "year": 1082, "prof": "\u9a57\u5149\u5e2b", "subject": "\u4f4e\u8996\u529b\u5b78"} -{"answer": "D", "question": "\u95dc\u65bc\u524d\u623f\u89d2\u7684\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f\nA. Schwalbe \u6c0f\u7dda\uff08Schwalbe line\uff09\u4f4d\u65bc\u89d2\u819c\u5167\u76ae\u7d30\u80de\u8207\u5c0f\u6a11\u7db2\u7684\u4ea4\u754c\u8655\nB. \u978f\u819c\u68d8\uff08scleral spur\uff09\u4f4d\u65bc\u776b\u72c0\u9ad4\u8207\u5c0f\u6a11\u7db2\u7684\u4ea4\u754c\u8655\nC. \u9760\u8fd1\u978f\u819c\u68d8\u5074\u7684\u5c0f\u6a11\u7db2\u5176\u8272\u7d20\u6c89\u7a4d\uff08pigmentation\uff09\uff0c\u901a\u5e38\u6bd4\u9760\u8fd1 Schwalbe \u6c0f\u7dda\u5074\u7684\u8272\u7d20\u6c89\u7a4d\u591a\uff0c\u56e0\u6b64\u53ef\n\u7528\u4f86\u4f5c\u70ba\u89c0\u5bdf\u623f\u89d2\u7d50\u69cb\u7684\u53c3\u8003\u9ede\uff08landmark\uff09\nD. \u623f\u6c34\u7684\u8461\u8404\u819c\u978f\u819c\u6d41\u51fa\u901a\u9053\uff08uveoscleral outflow\uff09\u4f4d\u65bc\u978f\u819c\u68d8\u8207 Schwalbe \u6c0f\u7dda\u4e4b\u9593", "year": 1122, "prof": "\u9a57\u5149\u5e2b", "subject": "\u773c\u7403\u89e3\u5256\u751f\u7406\u5b78\u8207\u502b\u7406"} -{"answer": "C", "question": "\u6709\u95dc\u7729\u5149\uff08glare\uff09\u7684\u8655\u7f6e\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f \nA. \u6700\u7406\u60f3\u7684\u8655\u7406\u65b9\u5f0f\u70ba\u79fb\u9664\u7729\u5149\u4f86\u6e90 \nB. \u70ba\u964d\u4f4e\u7729\u5149\u53ef\u4f7f\u7528\u6ffe\u93e1 \nC. \u8abf\u6574\u74b0\u5883\u7684\u5149\u6e90\u89d2\u5ea6\u901a\u5e38\u7121\u6548 \nD. \u63db\u8f03\u4f4e\u4eae\u5ea6\u7684\u71c8\u6ce1\u70ba\u6539\u5584\u7729\u5149\u65b9\u5f0f\u4e4b\u4e00", "year": 1082, "prof": "\u9a57\u5149\u5e2b", "subject": "\u4f4e\u8996\u529b\u5b78"} -{"answer": "C", "question": "\u93e1\u6846\u88fd\u4f5c\u904e\u7a0b\u4e2d\u8981\u6ce8\u610f\u60a3\u8005\u914d\u6234\u773c\u93e1\u6642\uff0c\u901a\u5e38\u6703\u4f7f\u60a3\u8005\u773c\u775b\u7522\u751f\u7a1c\u93e1\u6548\u61c9\u73fe\u8c61\uff0c\u56e0\u6b64\u93e1\u6846\u88fd\u4f5c\u904e\u7a0b\u5149\u5b78\u93e1\u7247\u5728\u88dd\u914d\u93e1\u6846\u4e0a\u6703\u7522\u751f\u6c34\u5e73\u6216\u5782\u76f4\u7a1c\u93e1\u7684\u73fe\u8c61\uff0c\u9019\u6a23\u5782\u76f4\u7a1c\u93e1\u4e9b\u8a31\u7684\u8aa4\u5dee\u503c\u5728\u60a3\u8005\u773c\u775b\u5167\u662f\u4e0d\u4e00\u5b9a\u53ef\u88ab\u63a5\u53d7\uff1b\u82e5\u5782\u76f4\u7a1c\u93e1\u8aa4\u5dee\u503c\u904e\u5927\uff0c\u8d85\u51fa\u4e0b\u5217\u4f55\u7a2e\u7bc4\u570d\u7684\u6a19\u6e96\u662f\u4e0d\u53ef\u4ee5\u88ab\u63a5\u53d7\u7684\uff1f\nA. \u4e3b\u8981\u53c3\u8003\u9ede\u4f4d\u7f6e\u7684\u5782\u76f4\u8ddd\u96e2\u5c0f\u65bc 1.0 mm \u6216\u5782\u76f4\u7a1c\u93e1\u8d85\u904e 0.33\u0394\nB. \u4e3b\u8981\u53c3\u8003\u9ede\u4f4d\u7f6e\u7684\u5782\u76f4\u8ddd\u96e2\u5c0f\u65bc 1.0 mm \u4e14\u5782\u76f4\u7a1c\u93e1\u8d85\u904e 0.67\u0394\nC. \u4e3b\u8981\u53c3\u8003\u9ede\u4f4d\u7f6e\u7684\u5782\u76f4\u8ddd\u96e2\u5927\u65bc 1.0 mm \u4e14\u5782\u76f4\u7a1c\u93e1\u8d85\u904e 0.33\u0394\nD. \u4e3b\u8981\u53c3\u8003\u9ede\u4f4d\u7f6e\u7684\u5782\u76f4\u8ddd\u96e2\u5927\u65bc 1.0 mm \u6216\u5782\u76f4\u7a1c\u93e1\u8d85\u904e 0.67\u0394", "year": 1102, "prof": "\u9a57\u5149\u5e2b", "subject": "\u96b1\u5f62\u773c\u93e1\u5b78\u8207\u914d\u93e1\u5b78"} -{"answer": "D", "question": "\u773c\u775b\u7684\u8abf\u7bc0\u529f\u80fd\u9700\u8981\u9760\u6c34\u6676\u9ad4\u8207\u776b\u72c0\u808c\u5171\u540c\u5b8c\u6210\uff0c\u6709\u95dc\u770b\u8fd1\u7269\u6642\u4e4b\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u776b\u72c0\u808c\u653e\u9b06\uff0c\u61f8\u97cc\u5e36\u4fdd\u6301\u7dca\u5f35\uff0c\u6c34\u6676\u9ad4\u8b8a\u8584\nB. \u776b\u72c0\u808c\u653e\u9b06\uff0c\u61f8\u97cc\u5e36\u4fdd\u6301\u9b06\u5f1b\uff0c\u6c34\u6676\u9ad4\u8b8a\u539a\nC. \u776b\u72c0\u808c\u6536\u7e2e\uff0c\u61f8\u97cc\u5e36\u4fdd\u6301\u7dca\u5f35\uff0c\u6c34\u6676\u9ad4\u8b8a\u8584\nD. \u776b\u72c0\u808c\u6536\u7e2e\uff0c\u61f8\u97cc\u5e36\u4fdd\u6301\u9b06\u5f1b\uff0c\u6c34\u6676\u9ad4\u8b8a\u539a", "year": 1112, "prof": "\u9a57\u5149\u5e2b", "subject": "\u8996\u89ba\u5149\u5b78"} +{"year": "103_1", "subject": "解剖學與生理學", "prof": "職能治療師", "question": "下列何者開口於鼻咽？ \nA.耳咽管 \nB.咽門 \nC.外鼻孔 \nD.鼻淚管", "answer": "A", "prof_en": "Occupational Therapist", "subject_en": "Anatomy and Physiology"} +{"year": "111_2", "subject": "解剖學與生理學", "prof": "職能治療師", "question": "下列何種反射中樞不位於下視丘（hypothalamus）？ \nA.口渴中樞\nB.體溫調節中樞\nC.呼吸中樞\nD.進食中樞", "answer": "C", "prof_en": "Occupational Therapist", "subject_en": "Anatomy and Physiology"} +{"year": "103_1", "subject": "職能治療技術學", "prof": "職能治療師", "question": "擴大及輔助溝通器（augmentative and alternative communications devices）最適合下列何種患者使用？ \nA.構音困難（dysarthria） \nB.亂語症（paraphasia） \nC.緘默症（mutism） \nD.沃尼凱氏失語症（Wernicke's aphasia）", "answer": "A", "prof_en": "Occupational Therapist", "subject_en": "Occupational Therapy Techniques"} +{"year": "112_2", "subject": "小兒職能治療學", "prof": "職能治療師", "question": "小信是位早產兒，目前受孕後年齡（postmenstrual age, PMA）為35週，以奶瓶餵奶時常會有嗆到或發紺的情形，下列餵奶姿勢何者可能最適合他？ \nA.嬰兒呈半坐姿，且被仰姿橫抱餵奶\nB.嬰兒呈半坐姿，且被側臥餵奶\nC.嬰兒呈半坐姿，且與餵奶者面對面餵奶\nD.嬰兒呈平躺姿勢，且被仰姿橫抱餵奶", "answer": "B", "prof_en": "Occupational Therapist", "subject_en": "Pediatric Occupational Therapy"} +{"year": "112_2", "subject": "職能治療學概論", "prof": "職能治療師", "question": "下列何者不屬於職能治療行銷（marketing）或推廣工作之內容？ \nA.向保險給付單位說明職能治療的專業價值\nB.向各專科醫師說明職能治療所扮演的角色功能\nC.病患的需求評估\nD.實際提供病患服務", "answer": "D", "prof_en": "Occupational Therapist", "subject_en": "Introduction to Occupational Therapy"} +{"year": "104_1", "subject": "職能治療技術學", "prof": "職能治療師", "question": "下列關於交替運動不能（dysdiadochokinesia）測試方式，���列何者正確？ \nA.finger-to-nose test \nB.finger-to-finger test \nC.觀察病人伸手取物 \nD.雙側交替作手掌旋前旋後，抓握以及伸肘屈肘的動作", "answer": "D", "prof_en": "Occupational Therapist", "subject_en": "Occupational Therapy Techniques"} +{"year": "109_2", "subject": "職能治療學概論", "prof": "職能治療師", "question": "下列何者是第二次世界大戰後，對職能治療發展具有重大影響的運動？ \nA.復健運動（rehabilitation movement）\nB.手工藝運動（arts and crafts movement）\nC.安居運動（settlement-house movement）\nD.心理衛生運動（mental hygiene movement）", "answer": "A", "prof_en": "Occupational Therapist", "subject_en": "Introduction to Occupational Therapy"} +{"year": "102_1", "subject": "職能治療技術學", "prof": "職能治療師", "question": "下列何者不是個別治療的原因？ \nA.個案容易分心 \nB.較符經濟效益 \nC.易保護個案隱私 \nD.個案容易受傷", "answer": "B", "prof_en": "Occupational Therapist", "subject_en": "Occupational Therapy Techniques"} +{"year": "106_2", "subject": "生理障礙職能治療學", "prof": "職能治療師", "question": "協調性不佳（incoordination）的小腦損傷個案，如欲增進其日常生活活動表現之品質，下列敘述何者正確？ \nA.建議個案多使用長柄或彎曲把手之器具 \nB.使用砂包，以增加近端肢體的穩定性 \nC.運用重力協助動作，並選擇重量較輕的工具使用 \nD.建議個案使用光滑握柄的器具", "answer": "B", "prof_en": "Occupational Therapist", "subject_en": "Physiological Disability Occupational Therapy"} +{"year": "105_2", "subject": "職能治療學概論", "prof": "職能治療師", "question": "評估時系統誤差（systematic measurement error）較不可能來自下列那一項？ \nA.評估工具之設計 \nB.受試測者之配合程度 \nC.施測者之期待 \nD.評估器材未校正", "answer": "B", "prof_en": "Occupational Therapist", "subject_en": "Introduction to Occupational Therapy"} +{"year": "109_1", "subject": "獸醫公共衛生學", "prof": "獸醫師", "question": "下列何者用以表示臨床疾病在動物族群中的發生機率？\nA.罹病率\nB.侵襲率\nC.死亡率\nD.致死率", "answer": "A", "prof_en": "Veterinarian", "subject_en": "Veterinary Public Health"} +{"year": "101_2", "subject": "獸醫病理學", "prof": "獸醫師", "question": "下列何者會引起肉芽腫性皮膚炎（granulomatous dermatitis）？ \nA.鏈球菌 \nB.痘病毒 \nC.豬丹毒桿菌 \nD.麻瘋分枝桿菌", "answer": "D", "prof_en": "Veterinarian", "subject_en": "Veterinary Pathology"} +{"year": "105_1", "subject": "獸醫病理學", "prof": "獸醫師", "question": "犬貓眼脈絡膜發育不全（choroidal hypoplasia），主要發生原因為： \nA.維生素E缺乏 \nB.脈絡膜與視網膜色素上皮細胞之色素沉積不足 \nC.睫狀小帶（zonule）缺損 \nD.虹膜過度化生", "answer": "B", "prof_en": "Veterinarian", "subject_en": "Veterinary Pathology"} +{"year": "105_1", "subject": "獸醫實驗診斷學", "prof": "獸醫師", "question": "等比重尿（isosthenuria）的尿比重範圍為： \nA.1.001-1.007 \nB.1.008-1.012 \nC.1.015-1.045 \nD.1.046-1.060", "answer": "B", "prof_en": "Veterinarian", "subject_en": "Veterinary Laboratory Diagnosis"} +{"year": "108_2", "subject": "獸醫藥理學", "prof": "獸醫師", "question": "某藥物經口投予的生體可用率（bioavailability）是直腸內投予的50%，下列何項原因的可能性最高？\nA.直腸的局部血流量大，利於藥物吸收\nB.藥物的首渡效應（first-pass effect）很高\nC.藥物進行腸肝再循環（enterohepatic recirculation）的比率很高\nD.藥物脂溶性高、不易形成離子型態", "answer": "B", "prof_en": "Veterinarian", "subject_en": "Veterinary Pharmacology"} +{"year": "102_1", "subject": "獸醫傳染病學", "prof": "獸醫師", "question": "下列何者為傳播靈長類利什曼原蟲（Leishmania spp.）之病媒？ \nA.壁蝨（ticks） \nB.白蛉（Phlebotomus spp.） \nC.采采蠅（tsetse fly） \nD.貓蚤（Ctenocephalides felis）", "answer": "B", "prof_en": "Veterinarian", "subject_en": "Veterinary Infectious Diseases"} +{"year": "106_1", "subject": "獸醫傳染病學", "prof": "獸醫師", "question": "下列有關弓蟲的敘述，何者錯誤？ \nA.屬於一種人畜共通傳染病之病原 \nB.貓科動物為中間宿主 \nC.可以引起母豬的流產 \nD.可引起豬隻中樞神經性症狀", "answer": "B", "prof_en": "Veterinarian", "subject_en": "Veterinary Infectious Diseases"} +{"year": "109_1", "subject": "獸醫公共衛生學", "prof": "獸醫師", "question": "懷孕婦女吃涼拌生菜食物需更注意衛生，因何種疾病可能藉由此途徑感染，嚴重者可導致流死產？\nA.鉤端螺旋體病（Leptospirosis）\nB.李斯特菌症（Listeriosis）\nC.萊姆病（Lyme borreliosis）\nD.第二型豬鏈球菌感染症（Streptococcus suis type 2 infection）", "answer": "B", "prof_en": "Veterinarian", "subject_en": "Veterinary Public Health"} +{"year": "112_2", "subject": "獸醫普通疾病學", "prof": "獸醫師", "question": "有關於母牛發生產後低血鈣症，下列何項敘述最為正確？ \nA.正常牛血鈣濃度平均約為6.3 mg/dL\nB.分娩後兩天完全不榨乳可作為預防或治療\nC.乾乳期給低鈣飼糧可作為預防方法\nD.產前3週餵食高陽離子飼糧可作為預防方法", "answer": "C", "prof_en": "Veterinarian", "subject_en": "Veterinary General Diseases"} +{"year": "109_1", "subject": "獸醫傳染病學", "prof": "獸醫師", "question": "下列有關Corynebacterium kutscheri感染囓齒動物之敘述，何者正確？\nA.會引起囓齒動物的結核病\nB.會感染大鼠，但不會感染小鼠及倉鼠\nC.只會感染肺臟\nD.藏於淋巴結中，造成潛伏感染", "answer": "D", "prof_en": "Veterinarian", "subject_en": "Veterinary Infectious Diseases"} +{"year": "101_2", "subject": "基礎言語科學", "prof": "語言治療師", "question": "聲帶振動可產生不同的發聲模式（phonatory modes），下列何者不是個體可主動掌控發聲模式變化的條件？ \nA. 喉部張力（laryngeal tension） \nB. 向中擠壓的程度（medial compression） \nC. 聲門下壓（subglottal pressure） \nD. 組織彈性度（tissue elasticity）", "answer": "D", "prof_en": "Speech Therapist", "subject_en": "Basic Linguistics"} +{"year": "101_2", "subject": "神經性溝通障礙學", "prof": "語言治療師", "question": "巴金森氏症的言語特質包括下列那一項？ \nA. 重音過度 \nB. 語調過高 \nC. 嗓音起始時間變短 \nD. 鼻音過重", "answer": "D", "prof_en": "Speech Therapist", "subject_en": "Neurological Communication Disorders"} +{"year": "101_2", "subject": "基礎言語科學", "prof": "語言治療師", "question": "關於舌頭位置與母音共振峰頻率（formant frequency）的描述，下列何者正確？ \nA. 舌位前後與第一共振峰頻率有關，舌位高低與第二共振峰頻率有關 \nB. 舌位高低與第一共振峰頻率有關，舌位前後與第二共振峰頻率有關 \nC. 舌位前後與第一共振峰頻率有關，圓唇展唇與第二共振峰頻率有關 \nD. 舌位高低與第一共振峰頻率有關，圓唇展唇與第二共振峰頻率有關", "answer": "B", "prof_en": "Speech Therapist", "subject_en": "Basic Linguistics"} +{"year": "100_2", "subject": "基礎言語科學", "prof": "語言治療師", "question": "老年人會有正常喉部退化的生理變化，其常見的問題為何？ \nA. 任克氏（Reinke’s）水腫 \nB. 聲帶無力打開 \nC. 聲帶鬆弛增長 \n \nD. 喉部軟骨鈣化", "answer": "D", "prof_en": "Speech Therapist", "subject_en": "Basic Linguistics"} +{"year": "100_2", "subject": "基礎言語科學", "prof": "語言治療師", "question": "最能支持呼吸效能的說話姿勢為何？ \nA. 直立站姿 \nB. 挺胸坐姿 \nC. 俯臥趴姿 \nD. 斜躺臥姿", "answer": "A", "prof_en": "Speech Therapist", "subject_en": "Basic Linguistics"} +{"year": "102_2", "subject": "溝通障礙總論", "prof": "語言治療師", "question": "患有聽覺處理異常（auditory processing disorder, APD）的學齡兒童，在尚未被確診前，經常被鑑定為特殊教育類別中的那一類? \nA. 智能障礙 \n \nB. 情緒行為障礙 \nC. 自閉症 \n \nD. 學習障礙", "answer": "D", "prof_en": "Speech Therapist", "subject_en": "Communication Disorders Overview"} +{"year": "107_2", "subject": "嗓音與吞嚥障礙學", "prof": "語言治療師", "question": "關於氣切管（tracheostomy tubes）的敘述何者正確？ \nA. 下呼吸道阻塞時才需要放置氣切管 \nB. 氣切管常放置於聲帶以上之處，以避免傷害喉部 \nC. 咽部水腫阻塞呼吸道是考量氣切的適應症 \nD. 只要氣切管氣囊鬆開病人就可以說出聲音", "answer": "C", "prof_en": "Speech Therapist", "subject_en": "Voice and Swallowing Disorders"} +{"year": "105_2", "subject": "基礎言語科學", "prof": "語言治療師", "question": "雙耳分聽測試（dichotic listening test）可用以測出： \nA. 語音偵測閾值（speech detection threshold） \nB. 氣骨導差距（air-bone gap） \nC. 大腦半球優勢（cerebral dominance） \nD. 詐聾（malingering deafness）", "answer": "C", "prof_en": "Speech Therapist", "subject_en": "Basic Linguistics"} +{"year": "102_1", "subject": "溝通障礙總論", "prof": "語言治療師", "question": "下列何者不是輔助溝通系統版面的呈現方式之一？ \nA. 固定版面式 \nB. 動態版面式 \nC. 混合式 \nD. 隨機式", "answer": "D", "prof_en": "Speech Therapist", "subject_en": "Communication Disorders Overview"} +{"year": "101_2", "subject": "嗓音與吞嚥障礙學", "prof": "語言治療師", "question": "hyold ele. larynx max. larynx elev. larynx close cp open bot retract. bot/ppw con. 1.00.50.0-0.5 1 ml5 mlseconds 57 與電視螢光攝影吞嚥檢查（videofluorographic study of swallowing, VFSS）比較，電視內視鏡（videoendoscopy）會有遮蓋期間主要是： \nA. 軟腭上抬 \nB. 舌骨上抬 \nC. 喉部上抬 \nD. 喉部關閉", "answer": "A", "prof_en": "Speech Therapist", "subject_en": "Voice and Swallowing Disorders"} +{"year": "100_1", "subject": "呼吸器原理及應用", "prof": "呼吸治療師", "question": "根據美國呼吸照護學會（AARC）的臨床操作指引，下列何者不屬於居家侵襲性呼吸器之使用禁忌？ \nA.剛完成氣管切開\nB.病人仍需要侵入性的監測裝置\nC.經濟及人力資源不足\nD.住家距離醫院太遠", "answer": "D", "prof_en": "Respiratory Therapist", "subject_en": "Respiratory Principles and Applications"} +{"year": "104_1", "subject": "呼吸器原理及應用", "prof": "呼吸治療師", "question": "有關容積支持型通氣（volume support）的敘述，下列何者正確？ \nA.不管設定的氣道壓力上限，逐步提高壓力至設定的潮氣容積 \nB.不管設定的氣道壓力上限，直接提供足夠的潮氣容積 \nC.在設定的氣道壓力上限下，直接提供設定的潮氣容積 \nD.在設定的氣道壓力上限下，逐步提高壓力至設定的潮氣容積", "answer": "D", "prof_en": "Respiratory Therapist", "subject_en": "Respiratory Principles and Applications"} +{"year": "101_1", "subject": "心肺基礎醫學", "prof": "呼吸治療師", "question": "量增加 一位原本健康的成人，若因外傷導致延髓（medulla oblongata）以上的腦部損壞，而延髓仍保持完整時，其呼吸動作會變成何種模式？ \nA.無自發性呼吸\nB.有自發性呼吸，但速率及呼吸深度會變得非常不規則\n C.有自發性呼吸，但大部分會停留在吸飽氣之狀態，偶有吐氣動作\nD.有自發性呼吸，但吸氣會明顯加深，吐氣動作則無變化", "answer": "B", "prof_en": "Respiratory Therapist", "subject_en": "Cardiopulmonary Basic Medical Science"} +{"year": "101_2", "subject": "重症呼吸治療學", "prof": "呼吸治療師", "question": "使用呼吸器病人其 FiO2：70%，Hb：10 g/dL，PaO2：60 mm Hg，PaCO2：50 mm Hg，SaO2：90%，pH 7.25，其心輸出量為 4 L/min，則其氧氣供應量（O2 delivery）約為多少？ \nA.300 mL O2 / min \nB.400 mL O2 / min \nC.500 mL O2 / min \nD.600 mL O2 / min", "answer": "C", "prof_en": "Respiratory Therapist", "subject_en": "Intensive Respiratory Therapy"} +{"year": "100_2", "subject": "呼吸疾病學", "prof": "呼吸治療師", "question": "下列關於intrinsic positive end-expiratory pressure的敘述，何者錯誤？ \nA.會減少靜脈血回流\nB.會減少心輸出量\nC.會造成低血壓\nD.可經由增加吸氣時間而減少之", "answer": "D", "prof_en": "Respiratory Therapist", "subject_en": "Respiratory Diseases"} +{"year": "109_2", "subject": "心肺基礎醫學", "prof": "呼吸治療師", "question": "通常用左心室舒張末期壓力（LVEDP）來表示什麼的指標？ \nA.後負荷（afterload）\nB.前負荷（preload）\nC.充血性心衰竭（congestive heart failure）\nD.收縮期結束（the end of the systolic cycle）", "answer": "B", "prof_en": "Respiratory Therapist", "subject_en": "Cardiopulmonary Basic Medical Science"} +{"year": "104_1", "subject": "心肺基礎醫學", "prof": "呼吸治療師", "question": "下列何種藥物有可能造成呼吸性鹼中毒？ \nA.可待因（codeine） \nB.嗎啡（morphine） \nC.安非他命（amphetamine） \nD.碳酸氫鈉（sodium bicarbonate）", "answer": "C", "prof_en": "Respiratory Therapist", "subject_en": "Cardiopulmonary Basic Medical Science"} +{"year": "102_2", "subject": "基礎呼吸治療學", "prof": "呼吸治療師", "question": "在急性呼吸衰竭病患要選用非侵襲性正壓通氣（noninvasive positive pressure ventilation，NPPV）時，發現病患出現下列何種現象時應立即予排除不用 NPPV？ \nA.血壓不穩且下降者 \nB.呼吸輔助肌用力者 \nC.動脈血二氧化碳大於 45 mm Hg 者 \nD.動脈血 pH 值小於 7.35 者", "answer": "A", "prof_en": "Respiratory Therapist", "subject_en": "Basic Respiratory Therapy"} +{"year": "106_1", "subject": "基礎呼吸治療學", "prof": "呼吸治療師", "question": "在實證醫學中，專作證據等級評估以供臨床參考，是下列那一個機構？ \nA.PubMed \nB.eMedicine \nC.Cochrane Library \nD.Ovid Medicine", "answer": "C", "prof_en": "Respiratory Therapist", "subject_en": "Basic Respiratory Therapy"} +{"year": "108_1", "subject": "呼吸疾病學", "prof": "呼吸治療師", "question": "在使⽤⽀氣管擴張劑治療，⽀氣管阻塞有改善後，病⼈的喘鳴（wheezing）的特性會有何種變化？\nA.⾳頻變⾼，期間延⻑（higher pitched, longer duration）\nB.⾳頻變⾼，期間縮短（higher pitched, shorten duration）\nC.⾳頻變低，期間延⻑（lower pitched, longer duration）\nD.⾳頻變低，期間縮短（lower pitched, shorten duration）", "answer": "D", "prof_en": "Respiratory Therapist", "subject_en": "Respiratory Diseases"} +{"year": "107_2", "subject": "心肺疾病與小兒疾病物", "prof": "物理治療師", "question": "求個���進行一次反覆最大重量（1 repetition maximum）訓練即可 關於半邊痙攣（spastic hemiplegia）型腦性麻痺兒童的上肢侷限治療，下列何者正確？ \nA.治療的方法是受損比較嚴重的那隻手戴上治療性手套 \nB.治療的方法是強調受損較嚴重那隻手的大量性訓練 \nC.治療的方法和運用在中風成人個案的方法完全一樣 \nD.治療效果會比雙手強化訓練的效果好", "answer": "B", "prof_en": "Physical Therapist", "subject_en": "Cardiopulmonary and Pediatric Disease Therapy"} +{"year": "105_1", "subject": "骨科疾病物理治療學", "prof": "物理治療師", "question": "執行被動直膝抬腿（straight leg raise）測試時，若將髖關節加上內轉（internal rotation）動作，可以增加髖屈曲（hip flexion）的角度，並減少大腿後方的疼痛感，這代表： \nA.內側膕旁肌（medial hamstrings）太緊\nB.股骨頭（femoral head）外側軟骨磨損\nC.股二頭肌（biceps femoris）太緊\nD.坐骨神經（sciatic nerve）受壓迫", "answer": "A", "prof_en": "Physical Therapist", "subject_en": "Orthopedic Disease Physical Therapy"} +{"year": "109_1", "subject": "骨科疾病物理治療學", "prof": "物理治療師", "question": "有關手部變形與神經傷害之配對，下列何者正確？\nA.猿猴手（ape hand）變形－正中神經傷害\nB.Dupuytren攣縮－尺神經傷害\nC.爪形手指（claw fingers）－橈神經傷害\nD.主教手（Bishop's hand）變形－正中神經傷害", "answer": "A", "prof_en": "Physical Therapist", "subject_en": "Orthopedic Disease Physical Therapy"} +{"year": "103_2", "subject": "物理治療技術學", "prof": "物理治療師", "question": "根據干擾原理，完全的干擾產生於何處？ \nA.兩組直流信號作用的振幅相等處 \nB.兩組交流信號作用的振幅相等處 \nC.兩組直流信號作用的頻率相等處 \nD.兩組交流信號作用的頻率相等處", "answer": "B", "prof_en": "Physical Therapist", "subject_en": "Physical Therapy Techniques"} +{"year": "104_2", "subject": "骨科疾病物理治療學", "prof": "物理治療師", "question": "下列那條肌腱沒有通過腕隧道（carpal tunnel）中？ \nA.屈指淺肌（flexor digitorum superficialis）\nB.屈指深肌（flexor digitorum profundus）\nC.屈拇指長肌（flexor pollicis longus）\n \nD.外展拇指長肌（abductor pollicis longus）", "answer": "D", "prof_en": "Physical Therapist", "subject_en": "Orthopedic Disease Physical Therapy"} +{"year": "107_2", "subject": "骨科疾病物理治療學", "prof": "物理治療師", "question": "有關膝前十字韌帶重建手術的物理治療，下列何者錯誤？ \nA.術前協助其降低發炎腫脹最重要，不宜勉強病人做膝關節完全伸直的關節運動 \nB.術後儘早達到膝關節完全伸直的角度，以預防膝關節內出現纖維化組織 \nC.術後早期即可開始進行誘發股四頭肌與膕旁肌肌肉活性的運動 \nD.術後早期行走訓練時的負重比例，依手術方式不同而有差異，但是運動治療都是以閉鎖式運動為主", "answer": "A", "prof_en": "Physical Therapist", "subject_en": "Orthopedic Disease Physical Therapy"} +{"year": "101_2", "subject": "神經疾病物理治療學", "prof": "物理治療師", "question": "基於注意力有限的假設，我們宜用何種設計來區辨出患者在動作表現之差異？ \nA.正轉移設計（positive transfer） \nB.留存設計（retention design） \nC.逆轉移設計（negative transfer） \nD.雙項任務設計（dual task design）", "answer": "D", "prof_en": "Physical Therapist", "subject_en": "Neurological Disease Physical Therapy"} +{"year": "102_2", "subject": "神經疾病物理治療學", "prof": "物理治療師", "question": "有關初期巴金森氏症患者之步態，下列何者錯誤？ \nA.步長變短 \nB.速度變快 \nC.雙腳支撐期時間增長 \nD.身體旋轉動作減少", "answer": "B", "prof_en": "Physical Therapist", "subject_en": "Neurological Disease Physical Therapy"} +{"year": "102_2", "subject": "物理治療基礎學", "prof": "物理治療師", "question": "下列何者會造成膀胱逼尿肌（detrusor muscle）收縮？ \nA.副交感神經（parasympathetic nerve） \nB.交感神經（sympathetic nerve） \nC.會陰神經（pudendal nerve） \nD.腹下神經（hypogastric nerve）", "answer": "A", "prof_en": "Physical Therapist", "subject_en": "Basic Physical Therapy"} +{"year": "100_2", "subject": "骨科疾病物理治療學", "prof": "物理治療師", "question": "下列有關淺層之部分厚度（superficial partial thickness）燒傷的敘述，那些正確？①傷口表面看到完整的水泡 ②傷口表面看來是白色的 ③不會有水腫（edema） ④病人感覺非常疼痛 \nA.①②\nB.③④\nC.①④\nD.②③", "answer": "C", "prof_en": "Physical Therapist", "subject_en": "Orthopedic Disease Physical Therapy"} +{"year": "102_1", "subject": "藥劑學", "prof": "藥師", "question": "下列何種包覆方法是在一種無水狀��下的操作，適合於含有水氣敏感性藥物之錠片的包覆製程？ \nA.Compression coating \nB.Tangential-spray coating \nC.Top-spray coating \nD.Bottom-spray coating", "answer": "A", "prof_en": "Pharmacist", "subject_en": "Pharmacy"} +{"year": "108_2", "subject": "藥物治療學", "prof": "藥師", "question": "下列何者可能誘發或加重躁症（mania）？①caffeine②pseudoephedrine③corticosteroids④venlafaxine\nA.僅①②\nB.僅①③④\nC.僅②③④\nD.①②③④", "answer": "D", "prof_en": "Pharmacist", "subject_en": "Pharmacotherapy"} +{"year": "101_2", "subject": "調劑學與臨床藥學", "prof": "藥師", "question": "Co-trimoxazole所含之sulfamethoxazole/trimethoprim標示含量比例為何？ \nA.5：1 \nB.1：5 \nC.1：20 \nD.20：1", "answer": "A", "prof_en": "Pharmacist", "subject_en": "Dispensing and Clinical Pharmacy"} +{"year": "110_2", "subject": "藥劑學與生物藥劑學", "prof": "藥師", "question": "下列HPLC所使用之檢測器，其偵測化合物之選擇性由高至低排序，何者正確？①紫外光檢測器（UV） ②電化學檢測器（ECD） ③蒸發光散射檢測器（ELSD） ④折射率檢測器（RID） \nA.②①③④\nB.①②③④\nC.②④①③\nD.①②④③", "answer": "A", "prof_en": "Pharmacist", "subject_en": "Pharmacy and Biopharmaceutics"} +{"year": "111_1", "subject": "藥物治療學", "prof": "藥師", "question": "下列何者不適用於治療B型肝炎？ \nA.lamivudine\nB.adefovir\nC.ribavirin\nD.entecavir", "answer": "C", "prof_en": "Pharmacist", "subject_en": "Pharmacotherapy"} +{"year": "105_1", "subject": "藥物治療學", "prof": "藥師", "question": "下列針對急性心肌梗塞病人之處理何者錯誤？ \nA.若沒有禁忌症，應給與速效劑量的aspirin \nB.在進行心導管之前須停用aspirin避免出血 \nC.若沒有禁忌症，應給與β-blocker及ACEI/ARB \nD.須校正心血管疾病的危險因子，包含血糖及血脂的控制", "answer": "B", "prof_en": "Pharmacist", "subject_en": "Pharmacotherapy"} +{"year": "102_1", "subject": "調劑學與臨床藥學", "prof": "藥師", "question": "有關全靜脈營養輸液（TPN）的敘述，下列何者正確？ \nA.經由鼻胃管給藥的病人適合使用TPN \nB.由周邊靜脈血管給與TPN最多僅能給與2星期 \nC.使用TPN多於7天則須考慮添加微量元素（trace elements） \nD.TPN配方中不一定需要含有脂肪", "answer": "D", "prof_en": "Pharmacist", "subject_en": "Dispensing and Clinical Pharmacy"} +{"year": "110_1", "subject": "藥物治療學", "prof": "藥師", "question": "有關急性腎盂腎炎之敘述，下列何者錯誤？ \nA.可能伴隨有肋椎角壓痛（costovertebral angle tenderness）及噁心、嘔吐、發冷顫等全身性症狀\nB.多屬危及生命的嚴重、複雜性感染，應立即住院接受2～4週的抗生素治療\nC.最常見的病原菌為E. coli，可使用oral fluoroquinolone類抗生素治療\nD.應於治療前採集尿液進行細菌培養及抗藥性檢測", "answer": "B", "prof_en": "Pharmacist", "subject_en": "Pharmacotherapy"} +{"year": "105_1", "subject": "藥物治療學", "prof": "藥師", "question": "下列何種經驗性（empirical）抗生素療法對非典型（atypical）肺炎致病菌無效？ \nA.azithromycin \nB.amoxicillin/clavulanate \nC.doxycycline \nD.moxifloxacin", "answer": "B", "prof_en": "Pharmacist", "subject_en": "Pharmacotherapy"} +{"year": "100_2", "subject": "藥理學與藥物化學", "prof": "藥師", "question": "那一種降壓劑所引起之血管神經性水腫（angioneurotic edema）與 bradykinin 之增加有關？ \nA. Terazosin \nB. Minoxidil \nC. Nifedipine \nD. Enalapril", "answer": "D", "prof_en": "Pharmacist", "subject_en": "Pharmacology and Pharmaceutical Chemistry"} +{"year": "111_2", "subject": "低視力學", "prof": "驗光師", "question": "有關高度近視併發白內障之好發型態，下列何者正確？\nA. 前囊下型和皮質型\nB. 前囊下型和核心型\nC. 皮質型和後囊下型\nD. 核心型和後囊下型", "answer": "D", "prof_en": "Optometrist", "subject_en": "Low Vision"} +{"year": "107_2", "subject": "隱形眼鏡學與配鏡學", "prof": "驗光師", "question": "偏光眼鏡鏡片具有方向性，可降低來自水平表面的反射光強度，而達到消除眩光的功能，此現象是因為入射光在某一角度（布魯斯特角 Brewster's angle）會全部被偏振，則此偏振光（polarized light） 的方向為何？ \nA. 垂直方向 \nB. 水平方向 \nC. 45 度方向 \nD. 135 度方向", "answer": "B", "prof_en": "Optometrist", "subject_en": "Contact Lens and Dispensing"} +{"year": "106_2", "subject": "視光學", "prof": "驗光師", "question": "配戴有散光度數的眼鏡時，如果完全矯正後，受檢者戴上眼鏡有不適應的狀況，下列敘述何者錯誤？ \nA. 減少圓柱透鏡度數，同時增加球面透鏡度數，可以改善調整後視力模糊的情況 \n \nB. 調整圓柱透鏡的角度到接近原來眼鏡的散光角度，可���減輕不適應感覺 \n \nC. 調整圓柱透鏡的角度到接近垂直方向或水平方向，可以減輕不適應感覺 \n \nD. 調整圓柱透鏡的角度，同時增加圓柱透鏡的度數，可以改善調整後視力模糊的情況", "answer": "D", "prof_en": "Optometrist", "subject_en": "Optometry"} +{"year": "111_2", "subject": "視覺光學", "prof": "驗光師", "question": "一位成年人透過老花眼鏡上之 ADD 後可看清楚眼前 33.33 至 100 cm 範圍內之物體，測量其總景深為 1.00 D，此成年人老花眼鏡之 ADD 為何？\nA. 1.00 D\nB. 1.50 D\nC. 2.00 D\nD. 2.50 D", "answer": "B", "prof_en": "Optometrist", "subject_en": "Visual Optics"} +{"year": "112_2", "subject": "視光學", "prof": "驗光師", "question": "下列何者可用來形容斜視（heterotropia），但不適合形容隱斜位（heterophoria）？\nA. 頻率（frequency）\nB. 偏側（laterality）\nC. 量（magnitude）\nD. 方向（direction）", "answer": "A", "prof_en": "Optometrist", "subject_en": "Optometry"} +{"year": "110_2", "subject": "眼球解剖生理學與倫理", "prof": "驗光師", "question": "下列何者不是屬於眼瞼真皮層中的腺體？\nA. 蔡氏腺（glands of Zeis）\nB. 莫氏腺（glands of Moll）\nC. 瞼板腺（meibomian glands）\nD. 淚腺（lacrimal gland）", "answer": "D", "prof_en": "Optometrist", "subject_en": "Eye Anatomy, Physiology and Ethics"} +{"year": "111_2", "subject": "隱形眼鏡學與配鏡學", "prof": "驗光師", "question": "患者加入度為+2.00 DS，使用雙光子片時，雙眼各需加入 1.00∆基底朝外的稜鏡，若要透過改變子片的位置來提供稜鏡量，則應該如何調整？\nA. 右眼子片向鼻側偏移 5 mm，左眼子片向耳側偏移 5 mm\nB. 右眼子片向耳側偏移 5 mm，左眼子片向鼻側偏移 5 mm\nC. 雙眼子片皆向耳側偏移 5 mm\nD. 雙眼子片皆向鼻側偏移 5 mm", "answer": "C", "prof_en": "Optometrist", "subject_en": "Contact Lens and Dispensing"} +{"year": "108_2", "subject": "視光學", "prof": "驗光師", "question": "在交替遮蓋測試（alternating cover test）時，一眼解除遮蓋，該眼球向內移動，則其眼位為何？ \nA. 內斜（eso） \nB. 外斜（exo） \nC. 上斜（hyper） \nD. 下斜（hypo）", "answer": "B", "prof_en": "Optometrist", "subject_en": "Optometry"} +{"year": "108_2", "subject": "視光學", "prof": "驗光師", "question": "選擇測量老花閱讀度數時，驗光參考的重要依據如下：①閱讀字的大小 ②被檢者要求指定的度數 ③工作距離 ④配多焦點或單光鏡片。其重要性由高至低依序為何？ \nA. ①③④②\n \nB. ②①③④\n \nC. ③①④②\n \nD. ④③①②", "answer": "C", "prof_en": "Optometrist", "subject_en": "Optometry"} +{"year": "111_2", "subject": "眼球解剖生理學與倫理", "prof": "驗光師", "question": "有關眼瞼運動的敘述，下列何者錯誤？\nA. 眼瞼閉合由眼輪匝肌（orbicularis oculi muscle）收縮所致\nB. 眼瞼閉合由提上眼瞼肌（levator palpebrae superioris muscle）收縮所致\nC. 眼瞼板（tarsal plate）於眼瞼活動時，維持眼瞼結構穩定\nD. 眼瞼活動除了受制於第七對與第三對腦神經控制，交感神經也有其角色", "answer": "B", "prof_en": "Optometrist", "subject_en": "Eye Anatomy, Physiology and Ethics"} +{"year": "102_2", "subject": "食品衛生與安全", "prof": "營養師", "question": "河豚中所含之毒素，以何部位分布最高？ \nA. 肌肉 \nB. 肝臟 \nC. 卵巢 \nD. 皮膚", "answer": "C", "prof_en": "Dietitian", "subject_en": "Food Hygiene and Safety"} +{"year": "106_1", "subject": "食品衛生與安全", "prof": "營養師", "question": "壬基苯酚（nonylphenol）屬於烷基酚類的一種，烷基酚類對雄性動物生殖系統的影響為： \nA. 與雄性激素受體結合，活化雄性激素的反應 \nB. 增加精蟲數目 \nC. 造成性腺發育不良 \n \nD. 抑制生殖器官腫瘤生成", "answer": "C", "prof_en": "Dietitian", "subject_en": "Food Hygiene and Safety"} +{"year": "101_1", "subject": "生理學與生物化學", "prof": "營養師", "question": "最常用的產前染色體檢查之檢體為： \nA. 胎兒週邊血液 \n \nB. 胎盤絨毛（chorionic villus sample） \nC. 骨髓細胞 \n \nD. 羊水（amniotic fluid）", "answer": "D", "prof_en": "Dietitian", "subject_en": "Physiology and Biochemistry"} +{"year": "107_1", "subject": "團體膳食設計與管理", "prof": "營養師", "question": "下列何者不是供膳人員體檢的必要項目？ \nA. 胸部 X 光 \nB. A\n型肝炎 \nC. B\n型肝炎 \nD. 傷寒", "answer": "C", "prof_en": "Dietitian", "subject_en": "Group Meal Design and Management"} +{"year": "105_1", "subject": "膳食療養學", "prof": "營養師", "question": "若經常復發 nephrotic syndrome 之小兒患者，較容易誘發下列何種疾病？ \nA. 腎臟結石 \n \nB. 早發性動脈粥腫樣硬化症 \nC. 糖尿病 \n \nD. 心衰竭", "answer": "B", "prof_en": "Dietitian", "subject_en": "Diet Therapy"} +{"year": "113", "subject": "食品衛生與安全", "prof": "營養師", "question": "下列何種包裝材質適合使用於微波食品？ \nA.聚乙烯\nB.聚丙烯\nC.聚苯乙烯\nD.美耐皿", "answer": "B", "prof_en": "Dietitian", "subject_en": "Food Hygiene and Safety"} +{"year": "111_1", "subject": "公共衛生營養學", "prof": "營養師", "question": "學校衛生法規定高級中等以下學校，班級數四十班以上者，應至少配置營養師一人，下列何者不是學校營養師職責？\nA. 個案營養照顧\nB. 全校營養指導\nC. 飲食衛生安全督導\nD. 實施學生家長之營養教育", "answer": "D", "prof_en": "Dietitian", "subject_en": "Public Health Nutrition"} +{"year": "108_2", "subject": "公共衛生營養學", "prof": "營養師", "question": "某地區孕婦約有 30%患有缺鐵性貧血，100 位孕婦以新型快速檢驗方法篩檢缺鐵性貧血，結果 28位患者和 3 位健康者呈陽性反應，下列何者正確？ \nA. 特異性 68/100 \nB. 特異性 67/70 \nC. 敏感度 31/100 \nD. 敏感度 30/70", "answer": "B", "prof_en": "Dietitian", "subject_en": "Public Health Nutrition"} +{"year": "103_1", "subject": "營養學", "prof": "營養師", "question": "下列敘述何者錯誤？ \nA. 5 歲半以前肥胖的兒童比 7 歲以後肥胖的兒童，有較高的機率在成年時肥胖 \nB. 研究顯示，看電視時間過長加上活動量低是兒童肥胖的重要危險因子 \nC. 研究顯示，家人規律的一起吃晚餐、晚上睡眠充足、限制看電視（網路）的時間，兒童有較低的肥胖率 \nD. 學童肥胖應以低熱量飲食來減輕體重", "answer": "D", "prof_en": "Dietitian", "subject_en": "Nutrition"} +{"year": "110_1", "subject": "團體膳食設計與管理", "prof": "營養師", "question": "劉先生 82 歲，因中風住醫院復健科病房，其咀嚼和吞嚥有些困難，在飲食設計上，下列何者餐飲組合相對較為適合？\nA. 糖醋里肌、鮑菇菜心、炒莧菜\nB. 蒸肉餅、蔥燒豆腐、炒絲瓜\nC. 滷豬排、三色蛋、炒空心菜\nD. 蒜泥白肉、黃瓜素雞片、炒茄子", "answer": "B", "prof_en": "Dietitian", "subject_en": "Group Meal Design and Management"} +{"year": "101_1", "subject": "基礎醫學", "prof": "醫事放射師", "question": "中老年人出現震顛、肌肉僵直、動作遲緩、步態異常和動作不能等情形，最有可能是下列那種疾病？ \nA.阿茲海默氏病（Alzheimer disease） \nB.帕金森氏病（Parkinson disease） \nC.狂犬病（rabies） \nD.腦震盪（concussion）", "answer": "B", "prof_en": "Radiologic Technologist", "subject_en": "Basic Medical Science"} +{"year": "113", "subject": "放射線器材學", "prof": "醫事放射師", "question": "在快速磁振造影中，若要將一個fast spin-echo sequence改編為multi-echo sequence，最需調整下列何者？ \nA.頻率編碼（frequency encoding）\nB.相位編碼（phase encoding）\nC.切面選擇編碼（slice selection encoding）\nD.射頻激發（RF excitation）", "answer": "B", "prof_en": "Radiologic Technologist", "subject_en": "Radiological Equipment"} +{"year": "104_2", "subject": "核子醫學診療原理與技", "prof": "醫事放射師", "question": "下列何者為肺臟換氣檢查（ventilation scan）中，常用核醫藥物？ \nA.99mTc-HMPAO \nB.99mTc-MAA \nC.133Xe \nD.111In", "answer": "C", "prof_en": "Radiologic Technologist", "subject_en": "Nuclear Medicine Diagnosis Principles and Techniques"} +{"year": "111_2", "subject": "基礎醫學", "prof": "醫事放射師", "question": "黏膜固有層（lamina propria）位於下列那一層？ \nA.漿膜層（serosa）\nB.黏膜層（mucosa）\nC.外肌層（muscularis externa）\nD.黏膜下層（submucosa）", "answer": "B", "prof_en": "Radiologic Technologist", "subject_en": "Basic Medical Science"} +{"year": "108_2", "subject": "放射線治療原理與技術", "prof": "醫事放射師", "question": "電腦刀品質保證作業，每日光子輸出劑量（一致性）與每月光子輸出劑量（準確性），分別為：\nA.小於2%，小於3%\nB.皆小於2%\nC.小於3%，小於2%\nD.皆小於3%", "answer": "B", "prof_en": "Radiologic Technologist", "subject_en": "Radiation Therapy Principles and Techniques"} +{"year": "104_1", "subject": "放射線治療原理與技術", "prof": "醫事放射師", "question": "對於electron arc therapy的照射，在其他照射條件不改變下，若僅從寬照野（大於9.0 cm）改變為較小的寬度照射（小於5.0 cm）。對此改變，下列說明何者錯誤？ \nA.有較低的劑量率 \nB.有較少的X-ray污染 \n C.小照野arc的劑量較低 \nD.對不規則的表面劑量計算，較小的寬度照射，劑量計算較簡單", "answer": "B", "prof_en": "Radiologic Technologist", "subject_en": "Radiation Therapy Principles and Techniques"} +{"year": "106_1", "subject": "醫學物理學與輻射安全", "prof": "醫事放射師", "question": "使用AAPM TG-21方法進行劑量校正時，若已知游離腔腔內體積為0.6 cm3，空氣密度為1.205×10-3 g/cm3，則Ngas（Gy/C）值為何？ \nA.4.70×107 \nB.8.93×107 \nC.8.72×107 \nD.3.15×107", "answer": "A", "prof_en": "Radiologic Technologist", "subject_en": "Medical Physics and Radiation Safety"} +{"year": "100_1", "subject": "醫學物理學與輻射安全", "prof": "醫事放射師", "question": "下列粒子靜止質量的排列順序何者正確？ \nA.質子＞中子＞電子 \nB.質子＞正子＞中子 \nC.中子＞質子＞電子 \nD.中子＞正子＞質子", "answer": "C", "prof_en": "Radiologic Technologist", "subject_en": "Medical Physics and Radiation Safety"} +{"year": "103_1", "subject": "醫學物理學與輻射安全", "prof": "醫事放射師", "question": "下列關於PET儀器中，使用septa ring之敘述何者正確？ \nA.使敏感度增加，解析度變差 \nB.使敏感度下降，解析度變佳 \nC.使用septa ring掃瞄，得到3D scans \nD.不使用septa ring掃瞄，得到2D scans", "answer": "B", "prof_en": "Radiologic Technologist", "subject_en": "Medical Physics and Radiation Safety"} +{"year": "109_1", "subject": "醫學物理學與輻射安全", "prof": "醫事放射師", "question": "下列對近接治療用射源平均光子能量的敘述，何者正確？\nA.60Co > 137Cs > 192Ir > 103Pd\nB.60Co > 192Ir > 103Pd > 137Cs\nC.137Cs> 192Ir > 60Co > 103Pd\nD.192Ir > 103Pd > 60Co > 137Cs", "answer": "A", "prof_en": "Radiologic Technologist", "subject_en": "Medical Physics and Radiation Safety"} +{"year": "110_2", "subject": "精神科與社區衛生護理", "prof": "護理師", "question": "有關現行衛生福利部組織之敘述，下列何者正確？\nA. 國民健康署主要負責發展長期照護體系，提升原住民族與離島地區健康照護品質\nB. 護理及健康照護司主要負責規劃推動生育健康、婦幼健康、癌症、心血管疾病及其他非傳染病防治\nC. 疾病管制署成立之宗旨為建立現代化的防疫體系，免除國人疫病的威脅\nD. 心理及口腔健康司主要負責青少年網路成癮以及齲齒防治與促進口腔衛生", "answer": "C", "prof_en": "Nurse", "subject_en": "Mental Health and Community Health Nursing"} +{"year": "112_1", "subject": "基本護理學", "prof": "護理師", "question": "依據單位內部及外部的環境作適度工作調配，帶領團隊達成共同目標，此領導者運用下列何種領導理論？\nA. 特質理論\nB. 情境理論\nC. 權變理論\nD. 偉人理論", "answer": "C", "prof_en": "Nurse", "subject_en": "Basic Nursing"} +{"year": "111_1", "subject": "精神科與社區衛生護理", "prof": "護理師", "question": "下列那一項指標，最能反映一個國家的經濟負擔狀況？\nA. 依賴指數\nB. 平均餘命\nC. 社會增加率\nD. 孕產婦死亡率", "answer": "A", "prof_en": "Nurse", "subject_en": "Mental Health and Community Health Nursing"} +{"year": "100_1", "subject": "基礎醫學概要", "prof": "護理師", "question": "有關支氣管樹的敘述，下列何者正確？ \nA. 右側的主支氣管管徑較左側粗 \nB. 左右肺各有 3 條二級支氣管 \nC. 左肺的節支氣管有 9 條，右肺有 10 條 \nD. 節支氣管即相當於二級支氣管", "answer": "A", "prof_en": "Nurse", "subject_en": "Overview of Basic Medical Science"} +{"year": "112_1", "subject": "精神科與社區衛生護理", "prof": "護理師", "question": "有關擬定原住民健康政策之敘述，下列何者最適宜？\nA. 強調以改善部落成人健康與工作能力為主\nB. 主要考量疾病特性及預防，不需考量文化與傳統\nC. 上小學後再開始紮根健康意識與健康行為\nD. 人才訓練須融入文化敏感度", "answer": "D", "prof_en": "Nurse", "subject_en": "Mental Health and Community Health Nursing"} +{"year": "107_1", "subject": "精神科與社區衛生護理", "prof": "護理師", "question": "造成細菌性食物中毒之病菌，具有革蘭氏陽性、附著於土壤及動物腸道、及對熱敏感 100℃持續加熱 3～5 分鐘以上無法生存，為下列何者？ \nA. 腸炎弧菌 \nB. 沙門氏菌 \nC. 金黃色葡萄球菌 \nD. 肉毒桿菌", "answer": "D", "prof_en": "Nurse", "subject_en": "Mental Health and Community Health Nursing"} +{"year": "100_1", "subject": "基本護理學概要", "prof": "護理師", "question": "輻射防護的三原則中，不包括下列何者？ \nA. 減少與輻射源接觸的時間 \nB. 使用屏障阻擋輻射 \nC. 操作人員定期健康檢查 \nD. 增加人體與輻射源的距離", "answer": "C", "prof_en": "Nurse", "subject_en": "Overview of Basic Nursing"} +{"year": "100_2", "subject": "內外科護理學概要", "prof": "護理師", "question": "有關青光眼的臨床表徵，下列何者正確？①眼睛疼痛 ②虹彩光圈視覺 ③閃光幻視 ④周邊視野消失 ⑤視野出現浮動的黑點 \nA. ①②③ \nB. ①②④ \nC. ②③④ \nD. ③④⑤", "answer": "B", "prof_en": "Nurse", "subject_en": "Overview of Internal and Surgical Nursing"} +{"year": "101_1", "subject": "產兒科護理學", "prof": "護理師", "question": "情況：丁���士，30 歲，3 年前結婚，避孕半年後即計畫懷孕，但都未如願。因月經已延遲 3 星期未來潮， 而至婦產科門診求診 若丁女士的最後一次月經為 12 月 20 日，以內格萊氏法則（Nägele's rule）推算出其預產期應為明年何時？ \nA. 7 月 17 日 \nB. 7 月 27 日 \nC. 9 月 17 日 \nD. 9 月 27 日", "answer": "D", "prof_en": "Nurse", "subject_en": "Obstetric and Pediatric Nursing"} +{"year": "105_2", "subject": "基本護理學", "prof": "護理師", "question": "關於結腸灌洗（colon irrigation）之敘述，下列何者錯誤？ \nA. 病人採左側臥式 \n \nB. 灌洗筒液面至肛門口距離高於 70 公分 \nC. 溶液溫度為 41~43℃ \nD. 灌入速度約為每分鐘 100~150 c.c.", "answer": "B", "prof_en": "Nurse", "subject_en": "Basic Nursing"} +{"year": "107_1", "subject": "牙醫學(二)", "prof": "牙醫師", "question": "長期使用chloramphenicol抗生素易致何種問題？ \nA.肝傷害（liver damage） \nB.腎傷害（renal impairment） \nC.腸胃傷害（GI disturbance） \nD.惡血質（blood dyscrasia）", "answer": "D", "prof_en": "Dentist", "subject_en": "Dentistry (2)"} +{"year": "106_1", "subject": "牙醫學(三)", "prof": "牙醫師", "question": "正常成人唾液分泌量約為： \nA.1～1.5公升／週 \nB.1～1.5公升／天 \nC.2.5～3.0公升／週 \nD.2.5～3.0公升／天", "answer": "B", "prof_en": "Dentist", "subject_en": "Dentistry (3)"} +{"year": "105_2", "subject": "牙醫學(二)", "prof": "牙醫師", "question": "下列何種病變其開始症狀最常發現在牙齦？ \nA.NK/T細胞淋巴瘤（NK/T cell lymphoma） \nB.白血病（leukemia） \nC.伯奇特氏淋巴瘤（Burkitt's lymphoma） \nD.霍奇金氏淋巴瘤（Hodgkin's lymphoma）", "answer": "B", "prof_en": "Dentist", "subject_en": "Dentistry (2)"} +{"year": "106_2", "subject": "牙醫學(一)", "prof": "牙醫師", "question": "上顎恆側門齒的舌面隆突（cingulum）通常偏向何側？ \nA.近心 \nB.遠心 \nC.正中 \nD.切緣", "answer": "C", "prof_en": "Dentist", "subject_en": "Dentistry (1)"} +{"year": "109_2", "subject": "牙醫學(二)", "prof": "牙醫師", "question": "關於cyclooxygenase（COX）的敘述，下列何者正確？ \nA.共有三種亞型（isoform）\nB.普遍存在於身體各種細胞中包括紅血球、白血球等\nC.主要工作是將細胞膜上的磷脂質（phospholipid）變成花生四烯酸（arachidonic acid）\nD.COX-1 可以抑制血栓素（thromboxane）形成，進而抑制血小板凝集", "answer": "A", "prof_en": "Dentist", "subject_en": "Dentistry (2)"} +{"year": "111_2", "subject": "牙醫學(一)", "prof": "牙醫師", "question": "下列牙齒何者不易由牙冠來區別左側或右側？ \nA.上顎正中乳門齒\nB.下顎正中乳門齒\nC.上顎乳犬齒\nD.下顎乳犬齒", "answer": "B", "prof_en": "Dentist", "subject_en": "Dentistry (1)"} +{"year": "101_1", "subject": "牙醫學(六)", "prof": "牙醫師", "question": "臨床上，在青少年期，可藉下列何種方式將下顏臉高度變長？ \nA.循序拔牙法（serial extraction）\nB.功能性矯正裝置（functional growth modification appliances）\nC.高拉式頭套（high pull headgear）\nD.舌柵欄（tongue crib）", "answer": "B", "prof_en": "Dentist", "subject_en": "Dentistry (6)"} +{"year": "107_1", "subject": "牙醫學(六)", "prof": "牙醫師", "question": "下列何者為下顎角肥大（enlargement of gonial angles）的可能原因？ \nA.因咬肌（masseter muscle）之過度肥大 \nB.因下顎開口肌之過度肥大 \nC.因下顎頦肌（mentalis muscle）之過度肥大 \nD.因下顎顏面表情肌（facial muscles）之過度肥大", "answer": "A", "prof_en": "Dentist", "subject_en": "Dentistry (6)"} +{"year": "100_2", "subject": "牙醫學(五)", "prof": "牙醫師", "question": "在全口義齒排列前牙時，若水平重疊（overjet）已固定，則下列何種垂直重疊（overbite）造成之門齒導引（incisal guidance）最小？ \nA.0毫米\nB.1毫米\nC.2毫米\nD.4毫米", "answer": "A", "prof_en": "Dentist", "subject_en": "Dentistry (5)"} +{"year": "112_2", "subject": "牙醫學(六)", "prof": "牙醫師", "question": "對於智能障礙（intellectual disability）的患者，牙醫師欲進行治療時需注意的事項，下列何者不適當？ \nA.治療中說話緩慢並用簡單字句\nB.一次只給予一個指令\nC.治療時程宜短\nD.病人約診時間宜於門診尾段時間以避免干擾", "answer": "D", "prof_en": "Dentist", "subject_en": "Dentistry (6)"} +{"year": "108_1", "subject": "臨床心理學特論（一）", "prof": "臨床心理師", "question": "Unilateral spatial neglect（USN）症狀與下列何種腦區之病變較無關係？ \nA. Parietal lobe \nB. Frontal lobe \nC. Subcortical lesions \nD. Temporal lobe", "answer": "D", "prof_en": "Clinical Psychologist", "subject_en": "Clinical Psychology Special Topics (1)"} +{"year": "109_1", "subject": "臨床心理學基礎", "prof": "臨床心理師", "question": "幼兒經常只需���些許的經驗就能快速學會一個新詞彙所代表的意義，這個現象稱為：\nA. 命名爆炸（naming explosion）\nB. 快速念名（fast naming）\nC. 快速配對（fast mapping）\nD. 自動念名（automatic naming）", "answer": "C", "prof_en": "Clinical Psychologist", "subject_en": "Basic Clinical Psychology"} +{"year": "106_2", "subject": "臨床心理學特論（一）", "prof": "臨床心理師", "question": "有關 Transient global amnesia 的臨床行為特徵，下列何者錯誤？ \nA. 個案也常發生偏頭痛 \n \nB. 發病時個案會反覆詢問相同的問題 \nC. 較少有 anterograde amnesia \nD. 與 posterior cerebral arteries 缺血有關", "answer": "C", "prof_en": "Clinical Psychologist", "subject_en": "Clinical Psychology Special Topics (1)"} +{"year": "100_2", "subject": "臨床心理學特論（二）", "prof": "臨床心理師", "question": "缺乏自我認同、關係膚淺、衝動控制不好以及無法容忍焦慮等特徵，根據 Kernberg 的觀點，最可能被診斷為下列何種疾病？ \nA. 自戀人格 \nB. 邊緣人格 \nC. 依賴人格 \nD. 逃避人格", "answer": "B", "prof_en": "Clinical Psychologist", "subject_en": "Clinical Psychology Special Topics (2)"} +{"year": "109_1", "subject": "臨床心理學特論（二）", "prof": "臨床心理師", "question": "會直接評估與處理妄想議題的心理治療模式為：\nA. 認知行為治療\nB. 認知修復治療\nC. 個案管理\nD. 社交技巧訓練", "answer": "A", "prof_en": "Clinical Psychologist", "subject_en": "Clinical Psychology Special Topics (2)"} +{"year": "100_2", "subject": "臨床心理學特論（一）", "prof": "臨床心理師", "question": "Fairburn 等人 1991 年比較認知行為治療（CBT）與人際關係治療（IPT）在暴食症上的療效，其在療程結束一年後的追蹤結果是： \nA. CBT 比 IPT 療效好 \n \nB. IPT 比 CBT 療效好 \nC. CBT 與 IPT 療效一樣好 \nD. CBT 和 IPT 都無療效", "answer": "C", "prof_en": "Clinical Psychologist", "subject_en": "Clinical Psychology Special Topics (1)"} +{"year": "104_1", "subject": "臨床心理學特論（二）", "prof": "臨床心理師", "question": "依據 Camara 等人在 2000 年的研究，美國執業心理師大約花多少比例的工作時間在「心理衡鑑」上？ \nA. 20% \nB. 40% \nC. 60% \nD. 80%", "answer": "A", "prof_en": "Clinical Psychologist", "subject_en": "Clinical Psychology Special Topics (2)"} +{"year": "103_2", "subject": "臨床心理學特論（二）", "prof": "臨床心理師", "question": "依照 Petersen 提出對「輕度認知障礙」（Mild Cognitive Impairment, MCI）的診斷流程，如果臨床上遇到一位患者僅有執行功能缺損的抱怨，但沒有明顯記憶力困擾，且沒有伴隨其他認知功能缺損。這位患者可能屬於那一類型的 MCI？ \nA. 單一面向非失憶型 MCI \nB. 多重面向失憶型 MCI \nC. 單一面向失憶型 MCI \n \nD. 多重面向非失憶型 MCI", "answer": "A", "prof_en": "Clinical Psychologist", "subject_en": "Clinical Psychology Special Topics (2)"} +{"year": "104_1", "subject": "臨床心理學特論（三）", "prof": "臨床心理師", "question": "根據 DSM-5 對持續性憂鬱症（persistent depressive disorder）的研究發現，下列何者正確？ \nA. 持續性憂鬱症至少須具備兩項憂鬱症狀，且症狀消失不超過一個月，至少持續兩年 \nB. 五年追蹤研究發現鬱症（major depressive disorder）較持續性憂鬱症更需住院、更易企圖自殺 \nC. 五年追蹤研究發現持續性憂鬱症較鬱症（major depressive disorder）更易有生活功能障礙 \nD. 十年追蹤研究有 32%以上持續性憂鬱症患者會經驗一次重鬱發作", "answer": "C", "prof_en": "Clinical Psychologist", "subject_en": "Clinical Psychology Special Topics (3)"} +{"year": "106_1", "subject": "臨床心理學特論（一）", "prof": "臨床心理師", "question": "依據 Price 等人（2009）的研究，身體症狀（somatic symptom）所涉及的大腦病變區域為①anterior cingulate cortex ②parietal lobes ③occipital lobes ④anterior insula \nA. ①① \nB. ①② \nC. ②③ \nD. ①③", "answer": "D", "prof_en": "Clinical Psychologist", "subject_en": "Clinical Psychology Special Topics (1)"} +{"year": "104_2", "subject": "醫學(一)", "prof": "醫師", "question": "一旦感染下列何種病毒，可以及早利用接種疫苗的方式來預防病毒在體內擴散而發病？ \nA.玻納病毒（Borna disease virus） \nB.狂犬病毒（Rabies virus） \nC.線狀病毒（Filovirus） \nD.馬堡病毒（Marburg virus）", "answer": "B", "prof_en": "Physician", "subject_en": "Medicine (1)"} +{"year": "111_2", "subject": "醫學(五)", "prof": "醫師", "question": "有關主動脈瓣置換手術的適應症，下列何者最不適當？ \nA.有症狀的嚴重主動脈瓣狹窄之病人，可進行主動脈瓣置換手術 \nB.中度主動脈瓣狹窄（moderate aortic stenosis）合併冠狀動脈阻塞需進行繞道手術之病人，可進行主動��瓣置換\n手術 \nC.無症狀的嚴重主動脈瓣狹窄合併左心室收縮功能＜50%之病人，可進行主動脈瓣置換手術 \nD.為預防猝死，在無症狀的嚴重主動脈瓣狹窄之病人，可進行主動脈瓣置換手術", "answer": "D", "prof_en": "Physician", "subject_en": "Medicine (5)"} +{"year": "104_1", "subject": "醫學(三)", "prof": "醫師", "question": "國小學童於學校食用營養午餐後一至六小時，陸續發生多位學童出現噁心、嘔吐及腹瀉之食物中毒群聚事件。鑑別診斷中，除考慮 Staphylococcus aureus 為可能病原外，下列何者亦是最可能病原？ \nA. Bacillus cereus \nB. Campylobacter jejuni \nC. Salmonella spp. \nD. Vibrio parahemolyticus", "answer": "A", "prof_en": "Physician", "subject_en": "Medicine (3)"} +{"year": "106_1", "subject": "醫學(三)", "prof": "醫師", "question": "COPD患者休息狀態時，動脈血已出現缺氧現象，該病患較不可能因COPD而出現下列那一項呼吸生理的障礙？ \nA.第一秒吐氣量（FEV1）低於預期值的50% \nB.分流（shunt）增加 \nC.換氣／灌流失衡（ventilation/perfusion mismatching） \nD.第一秒吐氣量（FEV1）低於預期值的25%時，可能同時伴有動脈血中二氧化碳升高（PaCO2）", "answer": "B", "prof_en": "Physician", "subject_en": "Medicine (3)"} +{"year": "100_1", "subject": "醫學(二)", "prof": "醫師", "question": "下列何者不是胸部脊髓損傷（thoracic spinal cord injury）病患之臨床特徵？ \nA. impaired pinprick sensation below T6 \nB. reduced abdominal reflex \nC. presence of Babinski sign \nD. hyperactive biceps reflex", "answer": "D", "prof_en": "Physician", "subject_en": "Medicine (2)"} +{"year": "106_1", "subject": "醫學(三)", "prof": "醫師", "question": "32歲男性病人，因反覆發作葡萄膜炎（uveitis）從眼科轉診過來；詳細病史，發現其已有一年多常有口腔潰瘍疼痛的病史，且兩下肢也時常出現有壓痛的皮膚紅疹。但無慢性下背痛的病史，下列那一項檢查，可能具診斷的價值？ \nA.pathergy test \n \nB.Schober test \nC.Schirmer’s test \nD.PPD skin test", "answer": "A", "prof_en": "Physician", "subject_en": "Medicine (3)"} +{"year": "111_1", "subject": "醫學(一)", "prof": "醫師", "question": "下列何者經由橫膈（diaphragm）的主動脈裂口（aortic hiatus），穿通胸腔與腹腔？ \nA.胸管（thoracic duct）\nB.食道（esophagus）\nC.內胸動脈（internal thoracic artery）\nD.下膈靜脈（inferior phrenic vein）", "answer": "A", "prof_en": "Physician", "subject_en": "Medicine (1)"} +{"year": "112_2", "subject": "醫學(四)", "prof": "醫師", "question": "有關注意力不足／過動症的病因學與神經學研究，下列敘述何者最適當？ \nA.主要是由環境因子而非基因遺傳所導致的疾病\nB.遺傳率（heritability）大約為15%\nC.腦部造影顯示大多數病患都有明顯的結構異常\nD.前額葉（prefrontal cortex）的功能主要與注意力和衝動控制有關，為注意力不足／過動症常被研究的腦部區", "answer": "D", "prof_en": "Physician", "subject_en": "Medicine (4)"} +{"year": "109_2", "subject": "醫學(一)", "prof": "醫師", "question": "下列有關肺部界面活性劑（surfactant）之敘述，何者錯誤？ \nA.為第二型肺泡細胞（type II alveolar cells）所分泌\nB.其缺乏時，肺泡不易擴張\nC.可增加肺順應性（lung compliance）\nD.可增加肺泡的表面張力（surface tension）", "answer": "D", "prof_en": "Physician", "subject_en": "Medicine (1)"} +{"year": "108_2", "subject": "醫學(五)", "prof": "醫師", "question": "下列有關根除性膀胱切除術（radical cystectomy）的敘述，何者錯誤？\nA.經膀胱內藥物灌注後仍反覆復發的high grade膀胱癌或膀胱原位癌（carcinoma in situ）患者，建議要施行此\n類手術\nB.術前不必停止服用aspirin\nC.腿部深層靜脈血栓可能於術後發生\nD.手術的死亡率約為1～3%", "answer": "B", "prof_en": "Physician", "subject_en": "Medicine (5)"} +{"year": "109_1", "subject": "臨床血清免疫學與臨床", "prof": "醫事檢驗師", "question": "下列何者是抗流感藥物zanamivir（Relenza）及oseltamivir（Tamiflu）的作用對象？\nA.neuraminidase\nB.uncoatase\nC.RNA polymerase\nD.protease", "answer": "A", "prof_en": "Medical Laboratory Scientist", "subject_en": "Clinical Serum Immunology and Clinical"} +{"year": "106_2", "subject": "醫學分子檢驗學與臨床", "prof": "醫事檢驗師", "question": "RET基因的突變與先天性的multiple endocrine neoplasia（MEN）syndromes有關。下列何者是RET基因突變主要分子檢驗的標的？①Exon 5 ②Exon 10 ③Exon 11 ④Exon 16 ⑤Exon 18 \nA.①②③ \nB.②③④ \nC.③④⑤ \nD.①④⑤", "answer": "B", "prof_en": "Medical Laboratory Scientist", "subject_en": "Medical Molecular Testing and Clinical"} +{"year": "105_2", "subject": "臨床血液學與血庫學", "prof": "醫事檢驗師", "question": "有關人類白血球組織抗原（HLA）與臨床輸血關係之敘述，下列何者正確？ \nA.血小板上具有HLA class I和II之抗原，anti-HLA與血小板輸注無效有關 \nB.病人體內anti-HLA與輸血相關移植物反宿主反應（TA-GVHD）有關 \nC.捐血者體內測出anti-HLA可能與輸血相關急性肺損傷（TRALI）有關 \nD.病人體內anti-HLA與輸血後紫斑症（post-transfusion purpura）有關", "answer": "C", "prof_en": "Medical Laboratory Scientist", "subject_en": "Clinical Hematology and Blood Bank"} +{"year": "100_1", "subject": "臨床血液學與血庫學", "prof": "醫事檢驗師", "question": "Hepcidin 的作用是下列何者？ \nA. 運送鐵 \n \nB. 抑制吞噬細胞釋放鐵 \nC. 調節 ferritin 之生成 \n \nD. 調節 transferrin receptor 1 之合成", "answer": "B", "prof_en": "Medical Laboratory Scientist", "subject_en": "Clinical Hematology and Blood Bank"} +{"year": "107_1", "subject": "臨床生理學與病理學", "prof": "醫事檢驗師", "question": "下列何者不是決定軟組織腫瘤惡性度（grading）之主要參數？ \nA.細胞密度（cellularity） \nB.細胞多形性（pleomorphism） \nC.有絲分裂像（mitotic figure） \nD.腫瘤大小（tumor size）", "answer": "D", "prof_en": "Medical Laboratory Scientist", "subject_en": "Clinical Physiology and Pathology"} +{"year": "106_1", "subject": "生物化學與臨床生化學", "prof": "醫事檢驗師", "question": "血清methylmalonic acid可以用來測定下列那一種維生素？ \nA.B1 \n \nB.B2 \nC.B6 \nD.B12", "answer": "D", "prof_en": "Medical Laboratory Scientist", "subject_en": "Biochemistry and Clinical Biochemistry"} +{"year": "101_2", "subject": "微生物學及臨床微生物", "prof": "醫事檢驗師", "question": "下列有關 X 因子（X-factor）及 V 因子（V-factor）之敘述，何項錯誤？ \nA. V 因子比 X 因子耐熱 \nB. NAD（nicotinamide adenine dinucleotide）可提供 V 因子 \nC. Hemin 或 hematin 可提供 X 因子 \nD. 綿羊血 BAP 含有酵素可緩慢分解 V 因子，因此不適合用於分離 V 因子依賴性嗜血桿菌", "answer": "A", "prof_en": "Medical Laboratory Scientist", "subject_en": "Microbiology and Clinical Microbiology"} +{"year": "106_2", "subject": "臨床血液學與血庫學", "prof": "醫事檢驗師", "question": "osmotic fragility test可用於確定診斷下列何種疾病？ \nA.hereditary spherocytosis \nB.thalassemia \nC.polycythemia \nD.paroxysmal nocturnal hemoglobinuria", "answer": "A", "prof_en": "Medical Laboratory Scientist", "subject_en": "Clinical Hematology and Blood Bank"} +{"year": "111_2", "subject": "生物化學與臨床生化學", "prof": "醫事檢驗師", "question": "棕櫚酸（palmitic acid）經過一連串的氧化作用（oxidation）產生乙醯輔酶A（acetyl-CoA），此氧化作用稱為下列何者？ \nA.α-oxidation\nB.β-oxidation\nC.γ-oxidation\nD.ω-oxidation", "answer": "B", "prof_en": "Medical Laboratory Scientist", "subject_en": "Biochemistry and Clinical Biochemistry"} +{"year": "109_1", "subject": "臨床生理學與病理學", "prof": "醫事檢驗師", "question": "心肌細胞的絕對不反應期（absolute refractory period）不會出現在穿膜動作電位（transmembrane actionpotential）的第幾期： \nA.1\nB.2\nC.0\nD.4", "answer": "D", "prof_en": "Medical Laboratory Scientist", "subject_en": "Clinical Physiology and Pathology"} +{"year": "103_2", "subject": "聽覺與平衡系統之創健", "prof": "聽力師", "question": "雙耳不對稱聽損病患，若因為經濟因素考量，只能選用單耳佩戴時，建議選配耳最好是聽損程度接近多少者？ \nA. 40 dB HL \nB. 50 dB HL \nC. 60 dB HL \nD. 70 dB HL", "answer": "C", "prof_en": "Audiologist", "subject_en": "Health of Auditory and Balance Systems"} +{"year": "102_2", "subject": "聽覺輔具原理與實務學", "prof": "聽力師", "question": "關於助聽器內接收器（receiver）的輸出頻率反應曲線在耳掛型與耳道型的敘述，以下何者錯誤？ \nA. 耳內型助聽器的接收器機械共振頻率（mechanical resonance frequency）大約在 2~3 kHz \nB. 耳掛型助聽器的頻率反應曲線圖上，波峰與波谷的數目通常較耳內型多 \nC. 耳掛型助聽器的接收器頻率曲線上，通常在 4 kHz 附近會出現赫爾姆霍茲（Helmholtz）效應所引\n起的波峰 \nD. 為了提升輸出功率，通常耳內型助聽器內接收器的機械共振頻率（mechanical resonance frequency）", "answer": "D", "prof_en": "Audiologist", "subject_en": "Principles and Practice of Hearing Aids"} +{"year": "109_2", "subject": "行為聽力學", "prof": "聽力師", "question": "下列何種音叉測試由氣傳導與骨傳導途徑聽到的音量大小不同，可以知道是傳導性或感音性聽損？\nA. Bing test\nB. Weber test\nC. Schwabach test\nD. Rinne test", "answer": "D", "prof_en": "Audiologist", "subject_en": "Behavioral Audiology"} +{"year": "105_2", "subject": "基礎聽力科學", "prof": "聽力師", "question": "鼓膜與卵圓窗的面積比增益（area advantage）可以獲得更多聲壓的有效轉換，請問這裡所計算的鼓膜面積與卵圓窗面積分別是指： \nA. 鼓膜的全面積與卵圓窗的全面積 \nB. 鼓膜的 1/3 全面積與卵圓窗的全面積 \nC. 鼓膜的 2/3 全面積與卵圓窗的全面積 \nD. 鼓膜的 2/3 全面積與卵圓窗的 1/3 全面積", "answer": "C", "prof_en": "Audiologist", "subject_en": "Basic Audiology"} +{"year": "102_1", "subject": "電生理聽力學", "prof": "聽力師", "question": "20 歲男性，10 多年來純音聽閾呈波動性變化，需要依賴讀唇才能了解對話內容，無法聽懂電話中的語音訊息，噪音中聽力極差，最可能的診斷為何？ \nA. 聽覺處理異常 \nB. 聽神經病變 \nC. 聽神經瘤 \nD. 珍珠瘤", "answer": "B", "prof_en": "Audiologist", "subject_en": "Electrophysiological Audiology"} +{"year": "108_2", "subject": "聽覺輔具原理與實務學", "prof": "聽力師", "question": "關於壓縮起始時間（attack time, AT）與釋放時間（release time, RT），下列敘述何者正確？ \nA. 較長的 AT 可用來保護助聽器使用者免於突發大聲音的傷害 \nB. 較長的 AT 可使助聽器使用者感受到語音音節的抑揚頓挫 \nC. 較短的 RT 會讓語音包絡（envelope）產生失真 \nD. 較長的 RT 可能產生 pumping effect", "answer": "C", "prof_en": "Audiologist", "subject_en": "Principles and Practice of Hearing Aids"} +{"year": "102_2", "subject": "電生理聽力學", "prof": "聽力師", "question": "以 ABR 評估閾值（tABR），其判斷標準為： \nA. 第一波潛時隨音強減弱遞增至波消失前的刺激音強 \nB. 第五波潛時隨音強減弱遞增至波消失前的刺激音強 \nC. 第一波潛時隨音強減弱遞減至波消失前的刺激音強 \nD. 第五波潛時隨音強減弱遞減至波消失前的刺激音強", "answer": "B", "prof_en": "Audiologist", "subject_en": "Electrophysiological Audiology"} +{"year": "102_2", "subject": "基礎聽力科學", "prof": "聽力師", "question": "關於引起 auditory brainstem-evoked responses（ABR）所使用的刺激音，下列何者最適合？ \nA. 250 ms 緩升緩降的複合音（complex sound） \nB. 爆破音（tone burst） \nC. 白噪音 \nD. 語言音素的基頻（fundamental frequency）", "answer": "B", "prof_en": "Audiologist", "subject_en": "Basic Audiology"} +{"year": "100_2", "subject": "聽語溝通障礙學", "prof": "聽力師", "question": "對於聽覺口語法（auditory-verbal approach）的敘述，下列何者錯誤？ \nA. 重視早期鑑定，對於已入學之聽損兒童較不適用 \nB. 上課時必須要有父母或主要照顧者的參與 \nC. 主要提供一對一的教學模式 \nD. 不適合沒有配戴助聽器或人工電子耳之聽損孩童", "answer": "A", "prof_en": "Audiologist", "subject_en": "Hearing and Language Communication Disorders"} +{"year": "102_1", "subject": "聽覺與平衡系統之創健", "prof": "聽力師", "question": "造成習語前聽損最常見的原因，下列何者正確？ \nA. 疾病 \nB. 基因 \nC. 噪音 \nD. 不明原因", "answer": "B", "prof_en": "Audiologist", "subject_en": "Health of Auditory and Balance Systems"} +{"year": "101_1", "subject": "中醫臨床醫學（一）", "prof": "中醫師", "question": "患者因頸部與上背肌肉緊繃，牙關緊閉無法講話，四肢抽搐無力，惡寒較重且有發熱，頭痛無汗數日，就診於中醫，醫師察其舌診為苔薄白，診脈為浮緊脈，治以下列何方最適宜？ \nA. 羌活勝濕湯 \nB. 葛根湯 \nC. 瓜蔞桂枝湯 \nD. 九味羌活湯", "answer": "B", "prof_en": "Traditional Chinese Medicine Practitioner", "subject_en": "Clinical Chinese Medicine (1)"} +{"year": "106_1", "subject": "中醫臨床醫學（三）", "prof": "中醫師", "question": "患者因口腔內突然出現血泡於上腭，呈紫色或暗紅色，泡壁薄，容易潰破者，經診斷後應屬下列何病引起？ \nA. 雪口 \nB. 飛揚喉 \nC. 鵝口瘡 \nD. 口疳", "answer": "B", "prof_en": "Traditional Chinese Medicine Practitioner", "subject_en": "Clinical Chinese Medicine (3)"} +{"year": "107_2", "subject": "中醫臨床醫學（二）", "prof": "中醫師", "question": "65 歲汪先生罹患膀胱癌，近出現血尿就診，症見小便短赤帶血，頭暈，耳鳴，神疲體倦，腰膝痠軟，顴紅潮熱，舌紅，脈細數，治以下列何方最適當？ \nA. 知柏地黃丸 \nB. 小薊飲子 \nC. 無比山藥丸 \nD. 歸脾湯", "answer": "A", "prof_en": "Traditional Chinese Medicine Practitioner", "subject_en": "Clinical Chinese Medicine (2)"} +{"year": "108_2", "subject": "中醫基礎醫學（二）", "prof": "中醫師", "question": "有關《溫病條辨》杏蘇散之敘述，下列何者錯誤？ \nA. 與《醫林改錯》血府逐瘀湯比較，皆以桔梗、枳殼升降氣機、理氣寬胸 \nB. 主治外感涼燥，伴氣機鬱滯、津液輸布不利 \nC. 本方去杏仁，加人參、香附、葛根，即為《太平惠民和劑局方》參蘇飲的組成 \nD. 也可用於外感風寒之輕證", "answer": "C", "prof_en": "Traditional Chinese Medicine Practitioner", "subject_en": "Basic Chinese Medicine (2)"} +{"year": "101_1", "subject": "中醫臨床醫學（二）", "prof": "中醫師", "question": "某 16 歲男性患者來到門診，主訴咽痛二天，伴有咽癢、鼻塞、畏風、微流鼻水、噴嚏連連、小便呈現茶色、腰酸，過去病史有 IgA 腎炎一年，目前並無服用任何藥物，患者另有過敏性鼻炎。診其舌質紅，苔薄白，有齒痕，中有裂紋，脈浮數，尿液檢查 protein(-)，glucose(-)，WBC 10/HPF，RBC>500/HPF，bilirubin +++。在現階段的治療上，下列診斷何者最為適宜？ \nA. 脾肺氣虛 \nB. 氣陰兩虛 \nC. 濕熱鬱滯 \nD. 外感風熱", "answer": "D", "prof_en": "Traditional Chinese Medicine Practitioner", "subject_en": "Clinical Chinese Medicine (2)"} +{"year": "105_1", "subject": "中醫基礎醫學（二）", "prof": "中醫師", "question": "有關《醫學心悟》之半夏白朮天麻湯之敘述，下列何者錯誤？ \nA. 可治眩暈頭痛，痰多胸悶，苔白膩者 \nB. 以半夏燥濕化痰降逆止嘔為主藥 \nC. 以天麻平肝熄風為次藥 \nD. 方中有橘紅、茯苓、生薑、甘草及大棗", "answer": "C", "prof_en": "Traditional Chinese Medicine Practitioner", "subject_en": "Basic Chinese Medicine (2)"} +{"year": "106_2", "subject": "中醫基礎醫學（二）", "prof": "中醫師", "question": "清骨散治療肝腎陰虧，虛火內擾所致之證，方中何藥最能滋陰潛陽、引藥入陰？ \nA. 銀柴胡 \nB. 胡黃連 \nC. 鱉甲 \nD. 地骨皮", "answer": "C", "prof_en": "Traditional Chinese Medicine Practitioner", "subject_en": "Basic Chinese Medicine (2)"} +{"year": "103_1", "subject": "中醫基礎醫學（一）", "prof": "中醫師", "question": "下列關於「手少陰之脈獨無腧」之敘述，何者錯誤？ \nA. 心者五藏六府之大主，精神之所舍；其藏堅固，邪弗能容 \nB. 心者若容邪則心傷，心傷則神去，神去則死矣 \nC. 故諸邪之在於心者，皆在於心之包絡 \nD. 若在「心藏」之外手少陰所循行處有病，則獨取其經於掌後兩筋間", "answer": "D", "prof_en": "Traditional Chinese Medicine Practitioner", "subject_en": "Basic Chinese Medicine (1)"} +{"year": "108_1", "subject": "中醫臨床醫學（四）", "prof": "中醫師", "question": "有關膽經的五俞穴，下列敘述何者錯誤？ \nA. 足竅陰是井（金）穴 \nB. 陽陵泉是合（土）穴 \nC. 足臨泣是俞（木）穴 \nD. 陽輔是經（水）穴", "answer": "D", "prof_en": "Traditional Chinese Medicine Practitioner", "subject_en": "Clinical Chinese Medicine (4)"} +{"year": "109_2", "subject": "中醫臨床醫學（二）", "prof": "中醫師", "question": "21歲女性，初經後不久開始經行少腹冷痛，最近一年症狀加重，牽及腰脊酸楚，經水量少色淡，夾有血塊。舌淡紅，苔白膩，脈沉緊。下列關於此病患的證候分析以何者最宜？\nA. 寒濕阻滯\nB. 氣血虛弱\nC. 氣虛濕困\nD. 脾腎陽虛", "answer": "A", "prof_en": "Traditional Chinese Medicine Practitioner", "subject_en": "Clinical Chinese Medicine (2)"} +{"year": "109_2", "subject": "牙體技術學（二）", "prof": "牙體技術師", "question": "為了感染控制，下列何種消毒步驟最正確？\nA. 印模從患者口中取出後就必須消毒\nB. 灌製模型後再消毒模型\nC. 印模前消毒患者口腔\nD. 用消毒水混合石膏後灌模", "answer": "A", "prof_en": "Dental Technician", "subject_en": "Dental Technology (2)"} +{"year": "110_2", "subject": "牙體技術學（四）", "prof": "牙體技術師", "question": "製作平行模型的敘述，下列何者正確？\nA. 平行模型整體高度之標準規格為 5 公分\nB. 製作平行模型流程複雜，故目前幾乎不採用\nC. 製作平行模型時會以正中口蓋縫線為模型的中心來製作\nD. 製作平行模型時，模型高度須依牙弓大小而異", "answer": "C", "prof_en": "Dental Technician", "subject_en": "Dental Technology (4)"} +{"year": "111_2", "subject": "牙體技術學（二）", "prof": "牙體技術師", "question": "關於鑄造用金屬的敘述，下列何者錯誤？\nA. 合金的使用原則最好不要重複使用\nB. 含銀的合金容易使陶瓷變色\nC. 陶材融合用金合金表面可使用 10～20%稀硫酸去除氧化膜\nD. Type I 金合金其機械性質不佳，僅適用於單純的嵌體（inlay）", "answer": "C", "prof_en": "Dental Technician", "subject_en": "Dental Technology (2)"} +{"year": "108_2", "subject": "牙體技術學（四）", "prof": "牙體技術師", "question": "下列何種狀況不需將牙體技術所招牌撤除？ \nA. 牙體技術所停業時間逾一年以上 \nB. 牙體技術所歇業 \nC. 牙體技術所變更負責牙體技術師 \nD. 牙體技術所經主管機關廢止開業執照", "answer": "C", "prof_en": "Dental Technician", "subject_en": "Dental Technology (4)"} +{"year": "102_1", "subject": "牙體技術學（四）", "prof": "牙體技術師", "question": "依據牙體技術師法之規定，下列何者符合執業登記之名稱？ \nA. 鑲牙補綴所 \nB. 牙體技術所 \nC. 牙科技工所 \nD. 齒模製造所", "answer": "B", "prof_en": "Dental Technician", "subject_en": "Dental Technology (4)"} +{"year": "103_2", "subject": "牙體技術學（一）", "prof": "牙體技術師", "question": "上顎第一大臼齒咬合面的斜嵴（oblique ridge），是由那兩個牙阜的三角嵴所構成？ \nA. 近心頰側牙阜及近心舌側牙阜 \nB. 遠心頰側牙阜及遠心舌側牙阜 \nC. 近心舌側牙阜及遠心頰側牙阜 \nD. 近心頰側牙阜及遠心舌側牙阜", "answer": "C", "prof_en": "Dental Technician", "subject_en": "Dental Technology (1)"} +{"year": "102_1", "subject": "牙體技術學（二）", "prof": "牙體技術師", "question": "全陶瓷使用的燒結瓷，染色劑色素主要是金屬氧化物，下列何種顏色配對錯誤？ \nA. 氧化鈦－白黃色 \nB. 氧化鈷－青色 \nC. 氧化鎳－灰色 \nD. 氧化鐵－白色", "answer": "D", "prof_en": "Dental Technician", "subject_en": "Dental Technology (2)"} +{"year": "102_2", "subject": "牙體技術學（一）", "prof": "牙體技術師", "question": "下列那一項元素的添加，可降低貴金屬合金的熔點？ \nA. 金 \nB. 銅 \nC. 鉑 \nD. 鈀", "answer": "B", "prof_en": "Dental Technician", "subject_en": "Dental Technology (1)"} +{"year": "111_2", "subject": "牙體技術學（一）", "prof": "牙體技術師", "question": "以 B 來命名右上第一乳臼齒的命名法為何？\nA. Universal 系統\nB. Palmer 標記系統\nC. Zsigmondy/Palmer 標記系統\nD. Federation Dentaire Internationale（FDI）系統", "answer": "A", "prof_en": "Dental Technician", "subject_en": "Dental Technology (1)"} +{"year": "102_2", "subject": "牙體技術學（四）", "prof": "牙體技術師", "question": "有關牙齒固位器（tooth positioner）的製作，外形線在離開各齒的齒頸部多少毫米最適當？ \nA. 1 \nB. 3 \nC. 5 \nD. 7", "answer": "B", "prof_en": "Dental Technician", "subject_en": "Dental Technology (4)"} +{"year": "105_1", "subject": "助產學（一）", "prof": "助產師", "question": "有關無痛性子宮收縮的敘述，下列何者正確？ \nA.收縮造成破水現象 \nB.多發生於背部 \nC.不規則性收縮 \nD.子宮頸會變薄和擴張", "answer": "C", "prof_en": "Midwife", "subject_en": "Midwifery (1)"} +{"year": "110_2", "subject": "基礎醫學", "prof": "助產師", "question": "關於陰莖波文樣丘疹（Bowenoid papulosis）的敘述，何者錯誤？ \nA.最常發生在性行為頻繁的成年人\nB.常以多發性病灶表現\nC.大部分病灶會進展為侵襲性癌\nD.組織學上的變化與波文氏病（Bowen disease）相似", "answer": "C", "prof_en": "Midwife", "subject_en": "Basic Medical Science"} +{"year": "108_2", "subject": "各科護理學", "prof": "助產師", "question": "林爺爺因腹痛、嘔吐入院，至今7天未解便，聽診腸蠕動音消失、叩診腹部有鼓音，下列敘述何者錯誤？\nA.可能為腸阻塞\nB.放置鼻胃管以減緩腸胃道壓力\nC.鼓勵多吃蔬菜、水果以促進腸胃蠕動\nD.監測腸蠕動音及排便或排氣狀況", "answer": "C", "prof_en": "Midwife", "subject_en": "Nursing for All Specialties"} +{"year": "105_1", "subject": "助產學（一）", "prof": "助產師", "question": "呼吸技巧可幫助產婦減輕疼痛，其衛教的方式何者正確？ \nA.呼吸技巧的運用是讓產婦集中注意力在子宮收縮及放鬆的意念 \nB.教導產婦腹式呼吸可減輕橫膈對宮底的干擾，減輕宮縮不適 \nC.教導每次收縮開始和結束時深呼吸，可減少二氧化碳和增加氧氣 \nD.呼吸對產婦來說是一種放鬆，故教導產婦當吐氣時開始集中注意力在子宮收縮", "answer": "C", "prof_en": "Midwife", "subject_en": "Midwifery (1)"} +{"year": "103_2", "subject": "助產學（二）", "prof": "助產師", "question": "王先生懷疑他太太可能以前拿過小孩，所以導致不容易懷孕。對於王先生的陳述，下列回應何者最不適當？ \nA.造成不孕的原因很多，要進一步評估與檢查才會比較清楚可能的導因 \nB.不孕症約有25～40%是男性因素 \nC.人工流產的確會造成子宮內膜損傷，進而影響受精卵著床 \nD.不孕症約有10～20%成因不明", "answer": "C", "prof_en": "Midwife", "subject_en": "Midwifery (2)"} +{"year": "104_1", "subject": "助產學（一）", "prof": "助產師", "question": "一般女性，在下列那一時間發生性行為，最容易受孕？ \nA.排卵兩天前 \nB.排卵前一天至排卵當天 \nC.排卵當天至排卵後一天 \nD.排卵兩天後", "answer": "B", "prof_en": "Midwife", "subject_en": "Midwifery (1)"} +{"year": "112_2", "subject": "助產學（一）", "prof": "助產師", "question": "如何建立一個正向的生產環境？①待產與生產可以不用移床，直接在同一個房間完成 ②讓待產婦的先生可以進產房陪伴 ③待產婦在分娩早期時就��予持續使用胎兒監測器，尚未破水也不能下床如廁 ④讓所有的待產婦女在同一間待產室，方便觀察 ⑤提供柔和燈光與沙發的單人待產室，讓待產婦與家屬相處 \nA.①②③\nB.①②⑤\nC.①④⑤\nD.②③④", "answer": "B", "prof_en": "Midwife", "subject_en": "Midwifery (1)"} +{"year": "110_2", "subject": "基礎醫學", "prof": "助產師", "question": "內呼吸（internal respiration）主要發生在下列那個位置？ \nA.支氣管\nB.肺泡管\nC.肺泡微血管\nD.組織微血管", "answer": "D", "prof_en": "Midwife", "subject_en": "Basic Medical Science"} +{"year": "108_2", "subject": "各科護理學", "prof": "助產師", "question": "吳先生與太太育有 2名子女，依據Bossard家庭互動定律，請問家庭成員互動關係有幾種？\nA.4 種\nB.6 種\nC.8 種\nD.10 種", "answer": "B", "prof_en": "Midwife", "subject_en": "Nursing for All Specialties"} +{"year": "104_1", "subject": "助產學（一）", "prof": "助產師", "question": "有關周產期乳房組織之變化，下列敘述何者正確？ \nA.動情素（estrogen）使乳腺管增生，黃體素（progesterone）刺激乳房小葉與乳腺泡發育 \nB.懷孕第 12 週，乳腺泡會製造一種內含豐富蛋白質及免疫球蛋白，稱為初乳 \nC.產後因動情素（estrogen）及黃體素（progesterone）下降，促使腦下垂體後葉分泌泌乳\n素（prolactin），刺激乳腺分泌乳汁 \nD.乳房的脂肪組織可決定乳房的大小和乳汁分泌的多寡", "answer": "A", "prof_en": "Midwife", "subject_en": "Midwifery (1)"} +{"year": "103_1", "subject": "個案評估與心理衡鑑", "prof": "諮商心理師", "question": "Prochaska 和 DiClemente（1984, 1992）認為個案改變歷程有五個階段，其中「探索個案的行為模式，評估個案的優點、資源和弱點」是下列那一階段的個案改變歷程？ \nA. 前考慮期 \nB. 考慮期 \nC. 行動期 \nD. 維持期", "answer": "B", "prof_en": "Counseling Psychologist", "subject_en": "Case Assessment and Psychological Evaluation"} +{"year": "108_2", "subject": "諮商與心理治療理論", "prof": "諮商心理師", "question": "依據現實治療的擬定計畫，下列敘述何者最為妥適？ \nA. 請媽媽提醒個案每天要做一小時運動 \nB. 下週開始，個案每天要做運動 \nC. 今天開始，個案每天晚上七點到八點要做運動 D. 個案有做運動的動機時，再開始行動", "answer": "C", "prof_en": "Counseling Psychologist", "subject_en": "Counseling and Psychotherapy Theories"} +{"year": "100_1", "subject": "諮商與心理治療理論", "prof": "諮商心理師", "question": "家庭系統治療的諸多理論取向對於家庭中待處理的問題，有不同的看法。下列敘述何者錯誤？ \nA. 多世代家庭治療關注不同世代家庭成員所傳遞的家庭價值 \nB. 聯合家庭治療關注家庭成員間互動關係和不良的溝通模式 \nC. 結構家庭治療關注家庭結構內的人際界限和刻板互動模式 \nD. 策略家庭治療關注家庭成員所顯現的問題症狀和解決策略", "answer": "A", "prof_en": "Counseling Psychologist", "subject_en": "Counseling and Psychotherapy Theories"} +{"year": "109_2", "subject": "諮商的心理學基礎", "prof": "諮商心理師", "question": "人本心理學家關切寂寞問題，對於寂寞的敘述下列何者正確？\nA. 在心理學定義上，所謂的寂寞是指個體孤立、沒有朋友\nB. 年紀越長越需要較多朋友才能不感到寂寞\nC. 導致長期寂寞的原因之一是對社會互動的負面預期\nD. 個體的社交技巧良窳與寂寞感並無關連", "answer": "C", "prof_en": "Counseling Psychologist", "subject_en": "Psychological Foundations of Counseling"} +{"year": "107_2", "subject": "諮商與心理治療理論", "prof": "諮商心理師", "question": "存在主義治療取向的諮商心理師，通常會將當事人的憂鬱症狀視為是下列何者？ \nA. 是當事人選擇以憂鬱來滿足其需求 \nB. 是一種外在環境壓迫的結果 \nC. 是重大心理創傷經驗所致 \nD. 是個人期望或行動受阻後的意志消沈", "answer": "D", "prof_en": "Counseling Psychologist", "subject_en": "Counseling and Psychotherapy Theories"} +{"year": "101_2", "subject": "諮商與心理治療理論", "prof": "諮商心理師", "question": "在現實治療的「計劃與承諾」階段中提到的「3C」是指下列何者？ \nA. Controllable、Consistent、Confident \nB. Controllable、Committed、Continuous \nC. Controllable、Committed、Confident \nD. Controllable、Continuous、Consistent", "answer": "B", "prof_en": "Counseling Psychologist", "subject_en": "Counseling and Psychotherapy Theories"} +{"year": "109_2", "subject": "個案評估與心理衡鑑", "prof": "諮商心理師", "question": "根據 Holland 的理論，下列那一組碼的一致性（consistency）程度最高？\nA. RI\nB. SC\nC. EA\nD. IE", "answer": "A", "prof_en": "Counseling Psychologist", "subject_en": "Case Assessment and Psychological Evaluation"} +{"year": "105_2", "subject": "心理健康與變態心理學", "prof": "諮商心理師", "question": "依據 DSM-5，邊緣性人格障礙症個案的人際關係特徵是在那「兩極端之間變換」？ \nA. 對客體的趨近化與逃避 \nB. 對客體的內射化與投射 \nC. 對客體的依賴化與抗拒 \nD. 對客體的理想化與輕貶", "answer": "D", "prof_en": "Counseling Psychologist", "subject_en": "Mental Health and Abnormal Psychology"} +{"year": "102_2", "subject": "團體諮商與心理治療", "prof": "諮商心理師", "question": "在最後一次團體結束後，成員興致高昂地邀請帶領者一起到對面咖啡館聚餐去慶功；若你身為帶領者且想拒絕此邀約，那一個做法是恰當的？ \nA. 明確告知成員倫理規範後斷然拒絕 \nB. 點出大家情感的連結度高並提到進行追蹤聚會的可能性 \nC. 表示自己的精神將永遠與大家同在 \nD. 溫暖而堅定地重申倫理守則後，委婉地以事務繁忙為由而向大家道別", "answer": "B", "prof_en": "Counseling Psychologist", "subject_en": "Group Counseling and Psychotherapy"} +{"year": "107_2", "subject": "諮商的心理學基礎", "prof": "諮商心理師", "question": "潛在發展區（Zone of Proximal Development）是由下列那一位學者所提出的概念？ \nA. Piaget \nB. Freud \nC. Chomsky \nD. Vygotsky", "answer": "D", "prof_en": "Counseling Psychologist", "subject_en": "Psychological Foundations of Counseling"} +{"year": "112_2", "subject": "健康社會行為學", "prof": "公共衛生師", "question": "某健康促進專家在規劃菸害防制計畫時，將影響吸菸行為的因素歸納為對菸害的知識、對戒菸的態度及對肺癌的自覺罹患性。這樣的歸納可能會有下列何種情況產生？\nA. 過度推論造成原子謬誤\nB. 僅著重個人層次的因素造成受害者責備\nC. 將肺癌視為慢性病造成疾病轉型\nD. 推動戒菸但無法降低吸菸盛行率", "answer": "B", "prof_en": "Public Health Specialist", "subject_en": "Health Social Behavior"} +{"year": "112_2", "subject": "流行病學", "prof": "公共衛生師", "question": "為了調查某些具有敏感性的健康議題（例如物質濫用）的盛行率，捉放法（capture-recapture）是一種可利用的研究設計。這種方法的前題假設是？\nA. 必須隨機抽樣\nB. 個案被不同監測系統觀察到的機率是獨立的\nC. 低盛行率（罕見疾病）\nD. 個案之間聚集性高", "answer": "B", "prof_en": "Public Health Specialist", "subject_en": "Epidemiology"} +{"year": "111_2", "subject": "健康社會行為學", "prof": "公共衛生師", "question": "傳染病防治法明定防治傳染病之相關單位包含衛生福利部之外的其他部會，此種作法為健康促進五大行動綱領中的何者？\nA. 強化職場行動力\nB. 營造無感染之環境\nC. 重新導向健康服務\nD. 建立健康的公共政策", "answer": "D", "prof_en": "Public Health Specialist", "subject_en": "Health Social Behavior"} +{"year": "112_2", "subject": "健康社會行為學", "prof": "公共衛生師", "question": "為了提升民眾的健康識能，下列何者可能不是有效的方法？\nA. 製作多國語言的衛教單張\nB. 贈送來醫院打疫苗的民眾小禮物\nC. 教導出院病人自我照顧技能\nD. 播放政府提供照顧長者相關資源的影片", "answer": "B", "prof_en": "Public Health Specialist", "subject_en": "Health Social Behavior"} +{"year": "111_2", "subject": "流行病學", "prof": "公共衛生師", "question": "下列那一個指標最適合用於描述農藥使用與巴金森氏病的相關性，而此資料取自於一項社區型問卷調查的數據，此研究為招募有興趣的社區民眾參與並以自填式的方式完成問卷內容？\nA. 盛行率比（prevalence ratio）\nB. 危險差異（risk difference）\nC. 危險比（risk ratio）\nD. 風險比（hazard ratio）", "answer": "A", "prof_en": "Public Health Specialist", "subject_en": "Epidemiology"} +{"year": "111_2", "subject": "生物統計學", "prof": "公共衛生師", "question": "一項探討醫學檢驗值與胰臟癌關係的病例對照研究，研究過程中收集了飯前血糖、飯後血糖、糖化血色素及總膽固醇，若想要了解有或沒有胰臟癌之相關醫學檢驗值互相校正後，何項相關醫學檢驗值較有顯著意義，下列何種統計方法最合適？\nA. 簡單線性迴歸\nB. 複線性迴歸\nC. 簡單羅吉斯迴歸\nD. 複羅吉斯迴歸", "answer": "D", "prof_en": "Public Health Specialist", "subject_en": "Biostatistics"} +{"year": "112_2", "subject": "流行病學", "prof": "公共衛生師", "question": "在一項病例對照研究中，以下那項關於對照組的選擇是正確的？\nA. 對照組應該是具有結果事件的個體\nB. 對照組應該根據人口學特徵與病例組進行配對\nC. 對照組應該從與病例組相同來源的人群中選擇\nD. 對照組的暴露率應低於病例組", "answer": "C", "prof_en": "Public Health Specialist", "subject_en": "Epidemiology"} +{"year": "111_2", "subject": "健康社會行為學", "prof": "公共衛生師", "question": "在跨理論模式（Transtheoretical Model, TTM）裡，「改變階段（stage of change）」用別種較為健康的選項替代不健康的行為，屬於何種「改變階段」？\nA. 反制約（counter-conditioning）\nB. 自我解放（self-liberation）\nC. 刺激控制（stimulus control）\nD. 社會解放（social liberation）", "answer": "A", "prof_en": "Public Health Specialist", "subject_en": "Health Social Behavior"} +{"year": "111_2", "subject": "環境與職業衛生", "prof": "公共衛生師", "question": "下列何者不是良好的風險特徵描述應符合之原則？\nA. 透明度\nB. 清晰度\nC. 時效性\nD. 合理性", "answer": "C", "prof_en": "Public Health Specialist", "subject_en": "Environmental and Occupational Health"} +{"year": "111_2", "subject": "生物統計學", "prof": "公共衛生師", "question": "針對統計檢定力（statistical power, 1-β）的敘述，下列何者較正確？\nA. 當虛無假設為真的，卻推翻虛無假設的機率\nB. 當虛無假設是真的，卻沒有推翻虛無假設的機率\nC. 當對立假設是真的，卻推翻虛無假設的機率\nD. 當對立假設是真的，卻沒有推翻虛無假設的機率", "answer": "C", "prof_en": "Public Health Specialist", "subject_en": "Biostatistics"}